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Abstract 
Endometriosis is a common gynaecological condition, defined by the presence of 
endometrial-like glands and stroma at sites outside the uterine cavity, often causing pain and 
infertility. There are different kinds of endometriotic lesions, of which peritoneal lesions 
(superficial lesions on pelvic peritoneal surfaces) are the most common. Peritoneal 
endometriotic lesions have a range of appearances, which are related to lesion development, 
starting out as red lesions and progressing to become black and then white scarred.  
 
Endometriosis is an inflammatory condition in which the immune system is thought to play a 
fundamental role in the establishment and progression of disease. Within peritoneal 
endometriotic lesions there is evidence of increased immune cell recruitment and activation, 
however immune cell densities vary greatly. Although the role of the immune system in 
endometriosis is well established, it is still unclear how the lesion immune environment 
relates to peritoneal endometriotic lesion stages of development. Therefore, the main aim of 
this research project was to investigate the development of peritoneal endometriotic lesions 
by characterising their immune environment according to macroscopic appearances.  
 
Peritoneal endometriotic lesions were prospectively collected (total n=32; red n=12, black 
n=13 and white n=7). Immunohistochemical staining was performed to identify DC-Sign+ 
immature and DC-Lamp+ mature dendritic cells; CD4+ helper, CD8+ cytotoxic and Foxp3+ 
regulatory T cells; CD20+ B cells and CD68+ macrophages. Immune cell densities in and 
 iv  
around peritoneal endometriotic lesion samples were quantified with MetaMorph image 
analysis software.  
 
All studied immune cell populations were present both in stroma and surrounding tissue of 
peritoneal endometriotic lesions. While CD8+ cytotoxic T cells, Foxp3+ regulatory T cells 
and CD68+ macrophages were significantly increased in density in lesion stroma compared 
to surrounding tissue; DC-Sign+ immature dendritic cells and CD20+ B cells were 
significantly increased in density in tissue surrounding peritoneal endometriotic lesions. 
Additionally, there were a number of correlations observed between the densities of different 
immune cell populations in both stromal and surrounding tissue, indicating relationships and 
interactions between cell types. However, the density of immune cell populations in and 
around peritoneal endometriotic lesions was not correlated with the stage of lesion 
development (lesion appearances).  
 
The recruitment of immune cells to tissue within and around peritoneal endometriotic lesions 
is likely an attempt to attack the lesion. However, their released products may in fact promote 
processes such as angiogenesis and fibrosis and thereby promote lesion growth and 
persistence. Immune-targeted treatment approaches show potential efficacy for 
endometriosis. This study supports the high variability and complexity of endometriosis. The 
findings from this thesis have implications for understanding of endometriosis pathogenesis, 
particularly peritoneal lesion development, and also potentially for development of novel 
treatment approaches. 
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Chapter 1 
Endometriosis 
1.1 Introduction 
Endometriosis is a common gynaecological disorder defined by the presence of endometrial-
like tissue outside the uterine cavity (Senturk and Arici, 1999). The most common symptoms 
of this disease are pelvic pain and infertility. The exact prevalence of endometriosis in the 
general population is not clear, however, in women of reproductive age, it is estimated to 
range between 10 and 15% (Lebovic et al., 2001). Although the majority of women with 
endometriosis are of childbearing age, reports have also described infrequent cases in pre-
menarchal girls and postmenopausal women (Cramer and Missmer, 2002, Sasson and Taylor, 
2009). 
 
Endometriotic lesions can be distinguished as three distinct types: peritoneal, deep infiltrating 
and ovarian (Amer, 2008, Giudice, 2010). As it is illustrated in Figure 1.1, endometriosis is 
primarily found on the pelvic peritoneum, ovaries, and rectovaginal septum, and in rare cases 
on the diaphragm, pleura, and pericardium (Netter, 1954). 
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Figure 1.1 Anatomical locations of areas that can be affected by endometriosis, usually 
within the pelvic cavity. Right upper quadrant illustrates a histology stain of the lining of an 
ovarian endometriotic cyst highlighting endometrial-like glands and stroma (Netter, 1954). 
 
1.2 Pathogenesis  
The earliest identification of ectopic endometrial-like tissue was in 1860 by Carl Rokitansky 
(Rokitansky, 1860). Since then, various theories have been proposed to explain the 
pathogenesis and aetiology of endometriosis. However, the exact pathogenesis of 
endometriosis is still not completely understood. In fact, different types of endometriosis may 
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have different origins, therefore it may not be possible to explain all types and sites of 
endometriosis with only one theory (Giudice and Kao, 2004, Amer, 2008). 
 
1.2.1 Implantation Theory 
The implantation theory, proposed by Sampson (1927b) states that endometrial tissue shed 
during menstruation passes through the fallopian tubes and can attach to and proliferate at 
ectopic sites in the peritoneal cavity. Sampson’s implantation theory is generally considered 
to be the most widely accepted theory of endometriosis pathogenesis (Fauser et al., 2011). 
There is a range of evidence in support of the theory, such as the phenomenon of retrograde 
menstruation occurring in most women with patent fallopian tubes (Halme et al., 1984, Liu 
and Hitchcock, 1986), viability of shed menstrual fragments (Koks et al., 1997, Seli et al., 
2003), common anatomic distribution of endometriotic lesions matching with sites accessible 
by retrograde menstruation (Jenkins et al., 1986) and increased exposure to menstruation 
leading to increased likelihood of endometriosis (Scott and TeLinde, 1950, D'Hooghe et al., 
2006). 
 
1.2.2 Coelomic Metaplasia 
Although the implantation theory is well known, the coelomic metaplasia theory for 
endometriosis is also quite widely held. This theory suggests that endometriotic lesions arise 
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from transformation or mutations occurring in peritoneal mesothelium or ovarian epithelium 
(Matsuura et al., 1999, Seli et al., 2003). 
 
The induction theory is an extension of coelomic metaplasia which postulates that menstrual 
endometrium produces certain factors with the ability to induce metaplasia of the peritoneal 
mesothelium into endometriosis (Levander and Normann, 1955). Von Recklinghausen 
(1896) and Russell (1899) similarly proposed the embryonic rests theory suggesting that 
when cell rests of müllerian origin are stimulated, they may differentiate into endometriosis. 
 
1.2.3 Lymphatic and Vascular Spread  
The lymphatic and vascular metastasis theory of endometriosis suggests that the lymphatic 
and vascular circulation disseminate endometrial cells at menstruation (Halban, 1924, 
Sampson, 1927a). Shed endometrium enters lymphatic and blood vessels and then can 
metastatically implant and invade the peritoneum at distant sites to form endometriotic 
lesions (Javert, 1949). The rare cases of endometriosis found in locations such as the pelvic 
lymph nodes, pleura, lungs or brain may be explained by lymphatic and vascular metastasis 
of endometrium (Javert, 1949, Mechsner et al., 2010). 
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1.2.4 Composite Theories 
Endometriosis is not fully explained by any one single theory defined above, therefore, the 
composite theory of endometriosis proposed by Javert (1951) brings together the theories of 
implantation, vascular and lymphatic spread and direct extension of endometrial tissue 
through the myometrium to understand the histogenesis of endometriosis and also to explain 
different types of endometriosis. Similarly, Nisolle and Donnez (1997) proposed that there is 
an association between the location and type of endometriotic lesion. The implantation 
theory explains peritoneal endometriosis while ovarian and deep infiltrating endometriosis 
can be explained by coelomic metaplasia (Nisolle and Donnez, 1997). 
  
1.3 Eutopic Endometrial Anomalies 
There is accumulating evidence suggesting fundamental differences between the eutopic 
endometrium from women with and those without endometriosis. These biochemical 
differences include various anomalies in proliferation and apoptosis, immune components, 
adhesion molecules, proteolytic enzymes and inhibitors, steroid and cytokine production and 
responsiveness, angiogenesis, lymphangiogenesis, neurogenesis and gene expression and 
protein production. These endometrial differences may play an important role in the 
pathogenesis of endometriosis. 
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1.3.1 Proliferation and Apoptosis 
Proliferation is increased in the eutopic endometrium of women with endometriosis 
compared to endometrium of women without endometriosis (Wingfield et al., 1995, Seo et 
al., 2004, Burlev et al., 2006). However, some authors found no significant differences in 
endometrial cell proliferation between women with and those without endometriosis 
(Jurgensen et al., 1996). There is an increase in the expression of proteolytic markers such as 
Ki67 and epidermal growth factor, telomerase and telomerase length and transforming 
growth factor- beta (Bourlev et al., 2006, Sokolov et al., 2005, Park et al., 2009). 
 
Apoptosis is decreased in eutopic endometrium of women with endometriosis compared to 
endometrium of women without the disease. Apoptosis is a distinct mechanism, which plays 
a central role in the elimination of cells from tissues without provoking an inflammatory 
response. Studies have shown the increased expression of anti-apoptotic markers such as B-
cell lymphoma/leukemia-2; Bcl-2 and FasL proteins in eutopic endometrium of women with 
endometriosis (Gebel et al., 1998, Meresman et al., 2000, Dmowski et al., 2001, 
Szymanowski, 2007, Agic et al., 2009). Increased endometrial proliferation and decreased 
apoptosis implies that the number of viable shed endometrial cells entering the peritoneal 
cavity is greater in women who develop endometriosis. 
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1.3.2 Immune Components 
There are alterations in both densities and function of a number of immune cell components 
in women with endometriosis compared to women without endometriosis (summarised in 
Table 1.1). It is suggested that immune dysfunction contributes to implantation of 
endometrial fragments and progression of endometriosis. 
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Table 1.1 Alterations in endometrial immune cell populations in women with endometriosis. 
Cell Type Density Function References 
Dendritic Cells 
(DCs) 
↑ immature DCs in the 
proliferative phase  
 
↓ mature DCs in the 
proliferative phase 
Unknown (Schulke et al., 2009) 
T Cells ↓ CD8+cells  
 
↑ CD4+, γδ-T cells and 
Tregs in secretory phase 
↓Anti-
inflammatory 
action 
(Dmowski et al., 1994, Antsiferova 
et al., 2005, Berbic et al., 2010) 
Macrophages ↑ İn proliferative & 
secretory phases 
↓ phagocytosis (Berbic et al., 2009) 
Natural Killer 
Cells (NKs) 
↓ in the mid-secretory 
phase 
↓ cytotoxicity (Oosterlynck et al., 1992) 
 
Alterations in these cells may be involved in pain generation and the pathogenesis of 
endometriosis. The hypothesised role of the immune system is to clear shed and refluxed 
endometrial tissue and to protect the peritoneal cavity from adhesion and invasion of this 
tissue, therefore the dysregulated response of the immune system may permit viable 
endometrial fragments to enter peritoneal cavity and ectopic lesions to develop and survive. 
 
1.3.3 Cell Adhesion Molecules 
The expression of cell adhesion molecules is altered in eutopic endometrium of women with 
endometriosis compared to women without endometriosis. Cell adhesion molecules (CAMs) 
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are transmembrane receptors that facilitate intercellular binding and cellular interaction with 
the extracellular matrix (ECM). The establishment of cell-to-cell connections is required by 
endometrial cells to implant at ectopic sites (Wingfield et al., 1995). In the eutopic 
endometrium of women with endometriosis, the expression of L1 cell adhesion molecule and 
intercellular adhesion molecule-1 (ICAM-1) is increased compared to controls (Ota et al., 
1996, Viganò et al., 2000, Youssry et al., 2008). This is thought to be associated with the 
development of endometriosis due to the ability of these cells to promote cell adhesion at 
ectopic sites. 
 
1.3.4 Proteases and Their Inhibitors 
In eutopic endometrium of women with endometriosis, the proteases such as matrix 
metallaproteases (MMPs) and their inhibitors such as tissue inhibitor of metalloproteinase 
(TIMPs) are involved in invasion of endometrial cells to the peritoneum and extracellular 
matrix remodelling (Sillem et al., 1998, Salamonsen et al., 2000). MMP-2 (degrades type IV 
collagen) and MMP-9 (involved in vascular growth and possible role in tumour metastasis) 
are increased, while the expression of their tissue inhibitors which are TIMP-2 and TIMP-1 
respectively is decreased in the eutopic endometrium of women with endometriosis 
compared to controls (Chung et al., 2002, Collette et al., 2004). Increased proteolytic activity 
of proteases involved in extracellular matrix remodelling in the eutopic endometrium of 
women with endometriosis explains the invasive properties of viable endometrial cells at 
ectopic sites.  
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1.3.5 Steroid Production and Responsiveness 
There is a decrease in steroid production and responsiveness in eutopic endometrium in 
women with endometriosis. Since endometriosis is defined as a hormone-dependent disorder, 
the mitogenic action of oestrogen in endometriosis leads to endometriotic lesion development 
whereas; progesterone antagonises the mitogenic effects of oestrogen. Eutopic endometrium 
from women with endometriosis has been found to contain high levels of aromatase, which 
converts androstenedione and testosterone to oestrone (E1) and oestradiol (E2) in various 
tissues including the ovary and placenta, however normally it is not present in the 
endometrium. (Nisolle et al., 1994, Noble et al., 1997, Winer et al., 2002). The oestrogen and 
progesterone receptor status of eutopic endometrium from women with and without 
endometriosis does not vary (Chamie et al., 2011), hence the ability to produce oestrogen in 
eutopic endometrium from women with endometriosis may contribute to promotion of their 
growth in ectopic locations. Progesterone is the main stimulator of steroid enzymes and plays 
a protective role to balance the actions of oestradiol (E2). The eutopic endometrium of 
women with endometriosis is partially resistant to the action of progesterone, since there is a 
decrease in the expression of progesterone receptor-B (PR-B) (Overton, 2007, Chamie et al., 
2011). This leads to impaired secretory transformation, decreased apoptosis and an increase 
in proliferation of endometrial cells in the peritoneal cavity (Overton, 2007)  
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1.3.6 Angiogenesis 
Higher expression of angiogenic factors has been observed in eutopic endometrium of 
women with endometriosis compared to women without endometriosis (Oosterlynck et al., 
1993b, Donnez et al., 1998, Mahnke et al., 2000, Kim et al., 2001, Taylor et al., 2002, 
Hayrabedyan and Kyurkchiev, 2005, Bourlev et al., 2006, Hur et al., 2006). The primary 
angiogenic growth factor in the endometrium is considered to be vascular endothelial growth 
factor-A (VEGF-A), with its receptors VEGFR-1, VEGFR-2, and neuropilin-1 (NRP-1). The 
expression of potent angiogenic factors VEGF-A, angiopoietin-1 (Ang-1), and Ang-2, and 
their receptors VEGFR-2 and Tie2 was increased in the eutopic endometrium of women with 
endometriosis compared to women without endometriosis (Figure 1.2) (Donnez et al., 1998, 
Khan et al., 2003, Takehara et al., 2004, Bourlev et al., 2006, Hur et al., 2006, Gilabert-
Estelles et al., 2007).  
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Figure 1.2 Expression of VEGF-A in eutopic endometrial tissue during the proliferative 
phase. VEGF-A immunoreactivity is weaker in the gland of eutopic endometrium of women 
without (A) than with (B) endometriosis (magnification 400x) (Takehara et al., 2004). 
 
Although angiogenic activity is clearly increased in eutopic endometrium of women with 
endometriosis (Tan et al., 2002, Khan et al., 2003, Bourlev et al., 2006, Hur et al., 2006), the 
total uterine blood vessel density is not different between women with and without 
endometriosis (Hey-Cunningham et al., 2010). Importantly, however, density of newly 
forming blood vessels is increased in eutopic endometrium of women with endometriosis. 
Over-expression of these angiogenic factors in the eutopic endometrium allows shed 
endometrial fragments to attract a blood supply once they reach the peritoneum, ensuring 
their survival. 
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1.3.7 Lymphangiogenesis 
In addition to the increased angiogenesis, it is becoming more apparent that there are some 
changes in local lymphangiogenesis (lymphatic growth) in eutopic endometrium of women 
with endometriosis. However, little is known regarding lymphangiogenesis in the 
endometrium of women with and without endometriosis. 
 
There is an increase in the expression of a large range of growth factors, which also play a 
role in angiogenesis such as angiopoietins, fibroblast growth factor and hepatocyte growth 
factor and a decrease in IGF-1, IGF-2 and VEGF-C expression (Sbracia et al., 1997, 
Takehara et al., 2004). The evidence of altered lymphangiogenesis in eutopic endometrium 
of women with endometriosis is supported by the finding of locally increased lymphatic 
micro-vessel density in these women. The lymphatic vessel density within the basal-layer 
endometrium in women with endometriosis during the menstrual cycle is increased in 
comparison to women without the disease (Figure 1.3) (Hey-Cunningham et al., 2010).  
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Figure 1.3 Comparison of mean density of lymphatic micro-vessels in the basal layer of the 
endometrium in women with and without endometriosis during the menstrual cycle. The 
lymphatic micro-vessels density is increased in eutopic endometrium of women with 
endometriosis compared to women without endometriosis during the proliferative and 
secretory phases (P= proliferative phase, S =secretory phase, M =menstrual phase; * p<0.05) 
(Hey-Cunningham et al., 2010). 
 
The increased expression of lymphangiogenic factors and density of lymphatic vessels are 
associated with the theory of lymphatic spread of endometriosis which is the dissemination 
of the fragments of endometrial tissue into the lymphatic circulation at menstruation and 
forming endometriotic lesions (Sampson, 1927a, Javert, 1949).   
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1.3.8 Neurogenesis 
In eutopic endometrium of women with endometriosis, there are some alterations in 
neurogenesis, which is the process of nerve fibre development within tissues, occurring in 
endometrium and endometriotic lesions.  
 
The expression of neurotrophins, their receptors and other neuronally active molecules is 
increased in eutopic endometrium of women with endometriosis compared to women without 
the disease. Specifically, expression of NGF and its receptors TrkA and p75 is increased, 
particularly in the functional layer of the endometrium (Tokushige et al., 2008). Additionally, 
some of the important angiogenic and lymphangiogenic factors and receptors are also 
neuronally active. The expression of these parameters is known to be mostly increased in the 
eutopic endometrium from women with endometriosis compared to control endometrium.  
For example, VEGF-A, which is increased in eutopic endometrium from women with 
endometriosis, has neurotrophic qualities (Sondell et al., 1999, Sondell et al., 2000, Tucker 
and Mearow, 2008).  Other eutopic endometrial disturbances in endometriosis related to 
neurogenesis include increased densities of neuroendocrine and immune cells that produce 
neurotrophins. 
 
Furthermore, the eutopic endometrium from women with endometriosis contains small, 
unmyelinated nerve fibres in the functional layer which are most likely sensory C and 
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autonomic nerve fibres (Figure 1.4) (Tokushige et al., 2006a, Al-Jefout et al., 2007, Al-Jefout 
et al., 2009, Bokor et al., 2009, Tokushige et al., 2007). The nerve fibre densities in basal 
endometrium of women with endometriosis and myometrium are also significantly increased 
compared to women without the disease (Figure 1.4) (Tokushige et al., 2006a). The presence 
of nerve fibres and expression of NGF implies that the eutopic endometrium may be involved 
in pain generation and contribute to various pain symptoms in women with endometriosis 
(Zhang, 2009, Fraser, 2010a).  
 
A variety of anomalies in proliferation and apoptosis, immune components, adhesion 
molecules, proteolytic enzymes and inhibitors, steroid and cytokine production and 
responsiveness, and angiogenesis, lymphangiogenesis and neurogenesis occur in eutopic 
endometrium from women with endometriosis. Although some of the data in the literature 
mandate further investigation, these differences appear to contribute the pathogenesis of 
endometriosis and development of endometriotic lesions. 
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Figure 1.4 Density of nerve fibres in the functional and basal layers of the endometrium 
from woman with and without endometriosis. (A) Endometrium from the functional layer of 
a woman with endometriosis stained for PGP9.5 (magnification×400) indicating multiple 
small nerve fibres. (B) Endometrium from the functional layer of a woman without 
endometriosis stained for PGP9.5 (magnification×400) showing no nerve fibres identified. 
(C) Endometrium from the basal layer of a woman with endometriosis stained for PGP9.5 
(magnification ×200) showing thick nerve fibre trunks stained red. (D) Endometrium from 
the basal layer of a woman without endometriosis stained with PGP9.5 (magnification×200) 
showing small nerve fibres (Tokushige et al., 2006a). 
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1.4 Symptoms 
The main presenting symptoms of endometriosis are pain and infertility (Fraser, 2010a). 
 
1.4.1 Pelvic Pain 
The most common presenting symptom of endometriosis is pelvic pain, which can include 
dysmenorrhoea (pain during menstruation), dyspareunia (pain on sexual intercourse), 
dyschezia (bowel motion pain), dysuria (pain on urination), mid-cycle pelvic pain or in 
extreme cases, pain during all times of the menstrual cycle (Mahmood et al., 1991, Mounsey 
et al., 2006, Fraser, 2008). The prevalence of pelvic pain amongst women with endometriosis 
is estimated to be between 40 to 90% (Murphy, 2002). Studies indicate that 90% of women 
suffer from dysmenorrhoea, 42% from deep dyspareunia and 39% from non-menstrual pelvic 
pain (Jamieson and Steege, 1996, Eskenazi and Warner, 1997, Zondervan et al., 1999, 
Cramer and Missmer, 2002, Schindler, 2004, Mounsey et al., 2006, Vercellini et al., 2007). 
Endometriosis pain has an enormous social and psychological impact on the lives of women 
across several domains such as productivity at work, income and relationships with partners 
and family (Denny, 2004, Dancet et al., 2012). 
 
Numerous researchers have found that there is no significant association between 
documented symptoms of endometriosis and the extent of disease upon surgical examination 
(Vercellini, 1996, Hurd, 1998, Fauconnier et al., 2002, Fauconnier and Chapron, 2005). 
Currently, pain generation mechanisms and pain perception in women with endometriosis are 
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incompletely understood. However, there is evidence that nociceptive, inflammatory, or 
neuropathic mechanisms contribute to endometriosis-associated pelvic pain. It is suggested 
that the inconsistencies of the relationships of the extent of disease upon surgical 
examination and the presence or severity of pain are likely due to variable roles of different 
pain mechanisms in endometriosis (Howard, 2009). 
 
1.4.2 Infertility 
The second most common presenting complaint of women with endometriosis is infertility. 
Infertility is defined by the failure to achieve a successful pregnancy after 12 months or more 
of timed unprotected intercourse or therapeutic donor insemination (Practice Committee of 
American Society for Reproductive Medicine, 2008). The estimated prevalence of infertility 
in women diagnosed with endometriosis is between 30 to 50% (Kistner, 1979, Muse, 1988, 
Giudice et al., 2002, Ozkan et al., 2008). 
 
The biologic mechanisms, which may be responsible for reduced fertility in endometriosis, 
remain poorly understood. However, a number of factors have been proposed which may 
explain the link between endometriosis and infertility. These mechanisms include aberrant 
folliculogenesis (Toya et al., 2000), ovulatory dysfunction (Donnez and Thomas, 1982, 
Cahill et al., 1997), sperm phagocytosis (Oral et al., 1996, Pillai et al., 1998), decreased 
fertilisation and altered tubal motility (Ayers, 1982, Wardle et al., 1985), implantation 
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defects (Arici et al., 1996), immunological factors (Lachapelle et al., 1996) and poor-quality 
embryonic development (Garrido et al., 2000). 
 
1.4.3 Other Associated Symptoms 
Other symptoms described by woman with endometriosis include menstrual bleeding and 
gastrointestinal disturbances. Uterine or menstrual bleeding disturbances reported by women 
suffering from endometriosis include premenstrual spotting, heavy menstrual bleeding, inter-
menstrual bleeding and prolonged menstruation (beyond eight days) (Jansen, 1993, 
Vercellini et al., 1997, Ballard et al., 2008, Fraser, 2008). Gastrointestinal symptoms include 
painful abdominal bloating, pain and discomfort on bowel movements, diarrhoea, 
constipation and in rare cases, cyclical rectal bleeding (Muse, 1988, Fraser, 2008, Seaman, 
2008, Luscombe, 2009). These gastrointestinal symptoms may or may not be associated with 
endometriotic lesions involving the bowel (Muse, 1988).  
 
1.5 Diagnosis 
1.5.1 Surgical Diagnosis 
The diagnosis of endometriosis via direct surgical visualisation of the pelvic cavity is the 
current “gold standard” to identify the presence of endometriotic lesions (Kennedy et al., 
2005, Banerjee et al., 2006). Surgical diagnosis can be done via laparoscopy (keyhole 
surgery in which operations in the abdomen are performed through small incisions and 
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insertion of a camera and other instruments) or laparotomy (an open operation requiring a 
larger cut in the skin) (Hershlag and Markovitz, 2005, Anna-Sofia et al., 2013). 
Histopathological confirmation of biopsied tissues to microscopically identify endometrial-
like glands and stroma should also be performed as the visualisation of peritoneal lesions 
alone has limited accuracy (Wood et al., 2002, Winkel, 2003, Fernando et al., 2013, 
Dunselman et al., 2014). The recognition of the wide range of endometriotic lesion types 
(peritoneal, ovarian and deep infiltrating) and colours (clear, red, black and white) is 
important to accurately diagnose endometriosis (Jansen and Russell, 1986, Albee et al., 
2008). There is an undeniable delay, which is approximately six to 10 years in diagnosis of 
endometriosis, which is associated with the diverse range and non-specific nature of 
symptoms presented by women suffering from endometriosis (Kuohung et al., 2002, Ballard 
et al., 2006, Sinaii et al., 2008).  
 
1.5.2 Imaging 
Imaging techniques currently used in diagnosis of endometriosis are ultrasound and magnetic 
resonance imaging (MRI). Imaging has limited efficacy in diagnosing endometriosis as it 
lacks adequate resolution to identify adhesions or superficial peritoneal implants (Schenken, 
1996, Wellbery, 1999). Endometriomas, bladder lesions, and deep nodules such as those in 
the rectovaginal septum can be diagnosed by transvaginal ultrasound. MRI is of value in 
identifying the presence and the extent of deeply infiltrating lesions and it may also help in 
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detecting bowel and ureteric involvement (Umaria and Olliff, 2001, Kinkel et al., 2006, 
Mounsey et al., 2006). 
 
1.6 Classification 
A number of attempts have been made to categorise endometriosis by “stages” of disease 
severity (Cullen, 1920, Acosta et al., 1973). In 1979, the American Fertility Society (AFS) 
released a classification of endometriosis which was amended in 1985 and again revised in 
1996 and is now known as the American Society for Reproductive Medicine (ASRM) 
classification (ASRM, 1997). This classification system of endometriosis is used to 
determine the disease stage (ranging from I, indicating minimal disease, to IV, indicating 
severe disease) on the basis of the type, location, appearance, and depth of invasion of lesions 
and the extent of disease and adhesions (ASRM, 1997, Giudice, 2010). 
 
Although the ASRM endometriosis classification is widely used, it does not predict fertility 
or pregnancy rates following treatment (Palmisano et al., 1993, Guzick et al., 1997) 
recurrence of dysmenorrhoea symptoms or recurrence of disease (Vercellini, 1996). 
Recently, the endometriosis fertility index (EFI) was proposed by Adamson and Pasta (2010) 
to predict non-assisted-pregnancy rates after surgical procedures in women with a surgical 
diagnosis of endometriosis. It combines ASRM scores with other information such as a “least 
function score” (determines the level of dysfunction of the fallopian tube, fimbria and ovary), 
age, years of infertility and prior pregnancies, to provide a numeric score from 0 (lowest 
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probability of fertility) to 10 (highest probability of fertility) (Adamson and Pasta, 2010). 
Whether the different appearance/age/stage of endometriosis is related to the development of 
endometriosis is still unclear, this will be better understood at the end of this study. 
 
1.7 Treatment 
1.7.1 Surgical 
Endometriosis can be treated pharmacologically or surgically. Common surgical treatments 
include laparoscopy or laparotomy during which endometriotic lesions, cysts, nodules and 
adhesions may be excised (cut out) or diathermied (burnt out). In some severe cases, surgical 
treatment may also involve colorectal excision or hysterectomy (removal of the uterus). With 
hysterectomy, one or both of the ovaries and fallopian tubes may also be removed. The 
generally preferred approach to excise lesions and restore anatomy is laparoscopic surgery as 
it is less invasive (Catalano, 1996). However, a highly skilled and experienced endoscopic 
surgeon is required for the laparoscopic excision of endometriotic lesions. 
 
Surgical therapeutic procedures for endometriosis are effective in significantly reducing pain 
in about 65% of women with severe disease (Sutton et al., 1997, Banerjee et al., 2006) and 
improving fertility outcomes for 18%, particularly in women with minimal to mild 
endometriosis (Marcoux et al., 1997, Adamson and Pasta, 2010, Pahlajani and Falcone, 
2010). However, there is recurrence of pain symptoms and requirement for further surgery in 
20 to 50% of women following conservative surgery (the removal of as many endometrial 
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implants and cysts as possible without causing surgical scarring and subsequent adhesions) 
(Vercellini et al., 2006, Guo, 2009, Vercellini et al., 2009). 
 
1.7.2 Medical 
Medical management of endometriosis usually involves the use of analgesics for pain relief 
and/or hormonal suppression of endometriotic lesion activity. 
 
Analgesics 
Analgesic therapies are used to manage various pain symptoms in endometriosis. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) in conjunction with intermittent stronger 
analgesic alternatives such as ibuprofen, codeine and tramadol are first choice for 
management of pain in endometriosis. In extreme pain, stronger analgesics such as 
oxycodone, intramuscular injections of pethidine or morphine may be recommended for 
acute use (Fraser, 2008, Ferrero et al., 2010). 
 
Hormone Therapy 
Various hormonal treatments have been demonstrated to reduce the severity of endometriosis 
pain symptoms safely and efficaciously by suppressing the growth of endometrial cells and 
endometriotic lesions (Table 1.2). Hormone therapies may be used as a treatment in mild 
endometriosis or as an added or combined therapy prior to, or after surgery, especially in 
moderate to severe forms of endometriosis. Use of the oral contraceptive pill is suitable as an 
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initial approach for medical treatment. Progestogens offer the most highly effective 
suppression with minimal side effects (Fraser, 2008, Fraser, 2010b). Highly effective 
hormonal suppression is also provided by gonadotrophin-releasing hormone (GnRH) 
analogues and danazol (Fraser, 2008, Vercellini et al., 2008, Brown et al., 2010). 
Additionally, selective oestrogen receptor modulators (Stratton et al., 2008), progesterone 
receptor modulators (Chwalisz et al., 2005) and aromatase inhibitors (Takayama et al., 1998) 
are alternative approaches for which good therapeutic outcomes have been reported. 
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Table 1.2 Hormonal treatments for endometriosis. 
Medication Indications Comment 
Combined OCPs Pain relief Common usage in primary care 
Danazol (Danocrine) Pain relief Significant androgenic side effects 
Depot MDPA (Depo-Provera) Pain relief Common usage in primary care 
Gestrinone Pain relief  Hot flashes 
Gonadotropin – releasing hormone analogues (e.g., 
goserelin [Zoladex], leuprolide [Lupron], triptorelin 
[Trelstar Depot]) 
Pain relief Expensive; significant side effects 
(hypoestrogenic symptoms) 
Levonorgestrel intrauterine system (Mirena) Pain relief after 
surgery 
Can be placed easily in primary 
care setting 
MDPA (Provera) Pain relief Common usage in primary care 
Nafarelin (synarel) Pain relief Expensive; significant side effects 
MDPA = medroxyprogesterone acetate; OCPs = oral contraceptive pills. Adapted from 
(Mounsey et al., 2006). 
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Chapter 2 
Peritoneal Endometriotic Lesions 
2.1 Introduction 
Endometriotic lesions can be primarily defined as peritoneal, ovarian and deep infiltrating 
endometriosis (DIE) (Nisolle and Donnez, 1997, Donnez et al., 2003). 
 
2.1.1 Peritoneal Endometriosis 
Peritoneal endometriosis is simply superficial lesions on peritoneal surfaces. The peritoneum 
is a membrane lining the interior of the abdominal cavity and surrounding its organs. 
These lesions are most commonly found on the pelvic side walls, the uterosacral ligaments 
(Giudice, 2010) and will be covered in detail in the remainder of this chapter. 
 
2.1.2 Ovarian Endometriosis 
Ovarian endometriotic lesions, as the name suggests, is endometriosis on the ovaries. There 
is superficial endometriosis on the ovary and endometrioma or ‘chocolate’ cyst. Superficial 
ovarian endometriosis occurs when the lesion penetration is less than four mm on the surface 
of the ovaries. However, the ‘chocolate cyst’ is an accumulation of a thick brown fluid 
caused by old cyclical “menstrual” bleeding (Figure 2.1) and it can grow to more than 10 cm 
in diameter (Redwine, 1987, Nisolle and Donnez, 1997, Fraser, 2008). Chocolate cysts may 
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be a progression of superficial peritoneal endometriosis with localised scarring, invagination 
of the ovarian cortex and formation of a pseudo-cyst (Brosens et al., 1993, Brosens, 1997). 
 
 
Figure 2.1 Laparoscopic appearance of a chocolate cyst (Fraser, 2008). 
 
2.1.3 Deep-infiltrating Endometriosis  
Another form of endometriotic lesion phenotype is DIE, defined as endometriotic lesions that 
penetrate greater than 5 mm below the peritoneal surface (Figure 2.2) (Koninckx and Martin, 
1992, Chamie et al., 2011). Between 5% and 12% of women with endometriosis will have 
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DIE. The most frequent locations of DIE are the uterosacral ligaments, pouch of Douglas 
(cul-de-sac), rectum and bladder (Chapron et al., 2002, Koh et al., 2012). Smooth muscle 
cells and endometrial glands aggregation leads DIE lesions to form nodules that are fibrous 
and “adenomatous” (Donnez et al., 1995). These nodules can invade the muscularis wall of 
the rectum or other pelvic organs (Koninckx and Martin, 1992). DIE can be severe and 
destroy the posterior cul-de-sac with extensive adhesions (Sampson, 1922).   
 
 
Figure 2.2 Laparoscopic appearance of deep infiltrating endometriosis (Chamie et al., 2011). 
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2.2 Lesion Establishment 
According to the retrograde menstruation theory, fragments of endometrium refluxed through 
the fallopian tubes into the peritoneal cavity then attach to and grow on peritoneal surfaces 
(Sampson, 1927b). Shed endometrial cells were first found to be able to create endometriotic 
lesions in 1950 with inversion of the uterus and diversion of menstrual flow into the 
peritoneal cavity in monkeys, where 50% of the animals developed endometriosis (Scott and 
TeLinde, 1950). Similar outcomes are described in baboons with development of 
endometriosis after injection of menstrual endometrium into the retroperitoneal space 
(D'Hooghe et al., 1995, D’Hooghe et al., 2001a, D'Hooghe et al., 2009) and in women with 
formation of endometriotic lesions after injection of menstrual effluent into abdominal fat 
(Ridley and Edwards, 1959). These findings demonstrated that viable endometrial cells in 
menstrual effluent are able to develop into endometriotic lesions. 
 
In the establishment of peritoneal endometriotic lesions, five critical steps have been 
postulated: attachment of endometrial cells to the peritoneal surface, invasion of these cells 
into the mesothelium, endometrial cellular proliferation, recruitment of inflammatory cells 
and angiogenesis (Oosterlynck et al., 1993b, Sharpe‐ Timms, 2001, Witz et al., 2002, Taylor 
et al., 2002, Ulukus et al., 2006). 
 
Cell attachment is thought to be mediated by integrins at the peritoneal surface and 
inflammatory cytokines such as IL-8, which foster endometrial adhesion to mesothelial cells 
 31 
 
(Brooks et al., 1996, Brooks et al., 1997). Findings suggest that increased metalloproteinase 
activity in and around endometriotic lesions may facilitate endometrial cell invasion of the 
extracellular matrix and growth of lesions (Bruner et al., 1997, Brooks et al., 1997).  
 
After the endometrial tissue adheres to the peritoneum and invades the mesothelium, 
proliferation of endometrial cells and establishment of a blood supply are necessary. 
Persistence of lesions is supported with the local macrophage, lymphocyte and mesothelial 
cell production of inflammatory cytokines and growth factors (such as interleukins [IL-1, IL-
6, IL-8], TNF-α and RANTES) with proliferative and angiogenic enhancing properties 
(Giudice, 1994, Cohen et al., 1996, Arici, 2002). Eventually, establishment of new blood 
vessels occur involving the secretion of number of angiogenic factors including VEGF, 
angiogenin, fibroblastic growth factor (FGF), hepatocyte growth factor (HGF), transforming 
growth factors (TGF) to support survival and growth of lesions (Donnez et al., 1996, 
McLaren, 2000, Olive, 2005). Peritoneal fluid immune cells, mainly macrophages, secrete 
many of these angiogenic growth factors (McLaren et al., 1996a, Gazvani and Templeton, 
2002, Lin et al., 2006). 
 
2.2.1 Lesion Appearances 
Peritoneal endometriotic lesions appear in a range of macroscopic appearances, which reflect 
different stages in development (Figure 2.3) (Ueki, 1991, Overton, 2007). Serial 
laparoscopies and correlation of lesion appearance and women’s age have shown the 
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development of endometriosis from clear to pigmented lesions of different types (Jansen and 
Russell, 1986, Redwine, 1987). Clear vesicles and red lesions represent the early stages. Red 
lesions are rich with blood vessels which is a main reason for them to be considered the most 
active peritoneal lesion type (Bloom, 1978). The lesions undergo cycles of partial shedding 
and regrowth, inducing an inflammatory reaction and scarification process that encloses 
them. The enclosed lesion becomes “black” because of the build-up haemosiderin from 
repeated “menstrual” breakdown. In some cases, the inflammatory process and subsequent 
fibrosis totally devascularise the lesion, and white plaques of old collagen are all that remain, 
giving a white appearance (Dan, 1990). White opacifications are considered latent stages of 
endometriotic lesions; they probably are inactive and could be quiescent for a long time 
(Jansen and Russel, 1987, Nisolle and Donnez, 1997).  
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A)  
B)  
C)  
Figure 2.3 Laparoscopic appearances of peritoneal endometriotic lesions; (A) red lesion, (B) 
black lesions and (C) white lesion (Overton, 2007). 
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2.2.2 Peritoneal Fluid and its Roles in Lesion Development 
Studies have demonstrated functional changes in several immunological and related 
components of the peritoneal fluid of women with endometriosis (Oral et al., 1996, Ho et al., 
1997b, Senturk and Arici, 1999, Gazvani and Templeton, 2002). Women with endometriosis 
also have a greater peritoneal fluid volume than fertile controls, patients with tubal disease, 
or those with unexplained infertility (Syrop and Halme, 1987, Oral et al., 1996). Peritoneal 
fluid contains cellular and soluble constituents, including macrophages, lymphocytes, natural 
killer cells, prostaglandins, cytokines and growth factors. Studies also demonstrated that the 
number of peritoneal fluid immune cells significantly increased in women with 
endometriosis, implying that these cells may be chemotactically attracted to the peritoneal 
cavity in response to the disease, or their increased presence could represent the primary 
abnormality (Harada et al., 2001, Gazvani and Templeton, 2002, Bedaiwy and Falcone, 
2003). 
 
Peritoneal fluid macrophages, in addition to being increased in number, are more activated in 
endometriosis (Halme J et al., 1983, Oral et al., 1996, Ho et al., 1997b, Gazvani and 
Templeton, 2002). Their released products such as cytokines, prostaglandins (PGs), 
complement components and hydrolytic enzymes regulate and alter the function of 
neighbouring immune and tissue cells (Khan et al., 2004a). Peritoneal fluid macrophages 
play important roles in modulating the growth and inflammatory behaviour of endometriotic 
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lesions by stimulating implantation and proliferation of misplaced, and possibly altered, 
endometrial cells (Dmowski et al., 1994). 
 
Approximately 30 to 50% of peritoneal fluid cells are lymphocytes (Oosterlynck et al., 1992) 
and their total number is higher in women with endometriosis (Badawy et al., 1984, 
Gallinelli et al., 2004). Increased numbers of CD4+ and CD8+ T cells have been reported in 
the peritoneal fluid of women with endometriosis with the proportion of CD4+ T cells lower 
than CD8+ T cells 40% and 69% respectively (Hill et al., 1988). In addition to increased 
numbers, CD4:CD8 (T-helper to T-suppressor) ratio was noted to be increased in peritoneal 
fluid in endometriosis (Steele et al., 1984, Badawy et al., 1987, Witz et al., 1994, Dmowski et 
al., 1994, Szyllo et al., 2003, Gallinelli et al., 2004). There is also an alteration in anti-
inflammatory cytokine production by T cells in the peritoneal fluid of women with 
endometriosis. There is a decrease in Th1 cytokine production; IL-2, IL-12, interferon (IFN)-
γ and TNF-α, whereas Th2 (helper T cells type 2) cytokine production; IL-4, IL-5, IL-6, IL-
9, IL-10 and IL-13 were increased in the peritoneal fluid (Giudice and Kao, 2004) which 
potentially promote endometriotic lesion growth, and pathogenesis through the activating cell 
mediated immunity in the peritoneal cavity. Decreased cytotoxicity and altered cytokine 
production by T cells may promote survival of shed fragments and endometriotic lesion 
development (Halis and Arici, 2004). Besides the alterations of T cell functions, many recent 
findings have shown alterations in B-cell function in endometriosis patients as evidenced by 
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abnormal antigen-antibody reaction and increased B-cell function (Bedaiwy and Falcone, 
2003). 
 
The number of peritoneal fluid NK cells is unchanged in women with endometriosis 
(Oosterlynck et al., 1991). However, there is a significant decrease in cytotoxicity of these 
cells in peritoneal fluid in endometriosis (Oosterlynck et al., 1992, Wilson et al., 1994, Ho et 
al., 1995, Bedaiwy and Falcone, 2003). This is thought to facilitate survival of refluxed 
endometrial cells at ectopic sites (Koninckx et al., 1998, Harada et al., 2001). Locally 
decreased NK-mediated cytotoxicity in peritoneal fluid might be implicated in pathogenesis 
of endometriosis by failure to clear refluxed endometrial cells and allowing their proliferation 
and subsequent formation as lesions. This is thought to be associated with the concentration 
of soluble ICAM-1 (sICAM-1), which is present in the peritoneal fluid and thought to 
originate from ectopic endometrial stromal cells and peritoneal mesothelial cells (Somigliana 
et al., 1996). Soluble ICAM-1 is able to bind leukocytes, inhibiting leukocyte – epithelial cell 
adhesion and scavenger function (Becker et al., 1993). It has been shown to be associated 
with evasion of the immune system, suggesting that this may also allow endometriotic lesion 
progression (Becker et al., 1991). Thus, shedding of ICAM-1 may be a mechanism by which 
ectopic endometrial cells can escape immune surveillance and may account for the reduced 
NK cell activity observed in women with endometriosis.  
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There is evidence that the expression of prostaglandin concentrations is increased in the 
peritoneal fluid of women with endometriosis (Oral et al., 1996, Oral and Arici, 1996). 
Additionally, it has been shown that significantly more prostaglandins (especially 
prostaglandin E2 and prostaglandin F2a) are released by peritoneal macrophages from 
women with endometriosis in comparison to that of macrophages from women without the 
disease (Karck et al., 1996). Prostaglandins are also involved in the regulation of the 
production and function of cytokines, and they have been implicated in endometrial cell 
proliferation (Orlicky et al., 1986, Graham et al., 1994, Hickey et al., 2014). Additionally, 
prostaglandins and specifically prostaglandin E2 stimulate activity of aromatase, which 
promotes the growth of endometriotic lesions via local oestrogen production (Giudice and 
Kao, 2004, Velasco et al., 2006). Therefore the elevated concentrations of prostaglandins in 
peritoneal fluid may play an important role in the development and persistence of peritoneal 
endometriotic lesions. 
 
Cytokines and growth factors are mainly produced by macrophages in the peritoneal cavity 
in response to a variety of inflammatory stimuli but lymphocytes, endometriotic lesions and 
mesothelial cells of the peritoneum also release a variety of cytokines (Harada et al., 2001). 
The concentration of cytokines and growth factors such as TNF-α, interleukins such as IL-6 
and IL-1 and RANTES (Regulated on Activation, Normal T-Cell Expressed and Secreted) is 
elevated in peritoneal fluid of women with endometriosis (Khorram et al., 1993, Koyama et 
al., 1993, Ortiz et al., 1996, Harada et al., 1997, Ho et al., 1997b). Other cytokines have been 
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identified including IL-4 (Hsu et al., 1997), IL-5 (Koyama et al., 1993), IL-8 (Iwabe et al., 
1998), (Bedaiwy et al., 2002), IL-10 (Ho et al., 1997a), IL- 12 (Mazzeo et al., 1998, Bedaiwy 
et al., 2002), IL-13 (McLaren et al., 1997), interferon-γ 10, monocyte chemotactic protein-1 
(MCP-1) (Arici et al., 1997), macrophage colony stimulating factor (MCSF) (Fukaya et al., 
1994) and transforming growth factor (TGF)-α (Oosterlynck et al., 1994). All these cytokines 
found increased in the peritoneal fluid of women with endometriosis compared to without are 
believed to facilitate implantation and progression of displaced endometrial cell in the 
peritoneum. 
As a conclusion, peritoneal fluid may have an important role in peritoneal endometriotic 
lesion development and persistence through its components, which can promote 
inflammation, adhesion and proliferation of endometrial cells in the peritoneal cavity. 
 
2.2.3 The Role of the Peritoneum in Lesion Establishment  
There is increasing evidence that the pelvic peritoneal mesothelium may make important 
contributions to the development and progression of peritoneal endometriotic lesions (Witz et 
al., 1999, Giudice and Kao, 2004, Stegeman et al., 2013, Jin, 2014). It has been found that 
endometriotic lesions are associated with peritoneal cell-cell disruption, which allow for sites 
of adhesion and invasion for endometrial cells (Witz et al., 2002, Nair et al., 2008, 
DeSancho, 2014).  
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Mesothelial cells lining the pelvis could be damaged after exposure to menstrual effluent and 
these results in an altered morphology leading to gaps between the cells and loss of tight 
junctions (Dunselman et al., 2001). Studies found that attachment and invasion of menstrual 
cells were described only to damaged areas in peritoneum (Witz et al., 2002). Additionally, 
presence of mesothelial layer prevents endometrial cells going into the invasion chambers 
(Nair et al., 2008). This was supported with another study demonstrated that human 
peritoneal mesothelial cells from women without endometriosis resist invasion, whereas 
those from women with endometriosis cannot resist invasion. Therefore, loss of mesothelial 
monolayer or adhesion between the mesothelial cell monolayer in peritoneum may facilitate 
invasion of attached ectopic endometrial cells, implying that the peritoneal mesothelium may 
play an essential role in development of endometriotic lesions. 
 
2.3 Structure and Function of Peritoneal Endometriotic Lesions 
In this section, structure and function of peritoneal endometriotic lesions will be discussed in 
terms of immune cell populations, blood vessels, lymphatic vessels and nerve fibres.  
 
2.3.1 Immune Cell Populations 
It has been repeatedly shown that there are changes in immune cell populations in peritoneal 
endometriotic lesions compared to eutopic endometrium, including T and B cells, DC, NK 
cells and macrophages. 
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Dendritic cells (DCs) are a heterogeneous population of antigen presenting cells involved in 
the initiation and modulation of immune responses (Banchereau and Steinman, 1998). While 
the density of CD1a+ immature DCs was higher in endometriotic lesions than the eutopic 
endometrium, significantly lower numbers (very few or none) of CD83+ mature DCs were 
detected in lesions (Schulke et al., 2009). Additionally, CD1a DCs were most abundant at the 
lesion side and as the distance from lesion increased, their density in the peritoneum 
progressively decreased (Schulke et al., 2009). CD1a and CD83 DC populations were not 
detected at all in normal peritoneum of women without endometriosis (Schulke et al., 2009). 
Thus, DCs might be recruited to lesions in order to initiate an immune response against the 
invasive abnormal tissue.  
 
T cells are a family of lymphocytes which are essential for the establishment and 
maintenance of immune responses, primarily through the secretion of cytokines and directly 
binding and destructing foreign antigens (Piccinni, 2005). CD8+ T cells are cytotoxic killer 
cells which directly destroy abnormal cells, CD4+ T cells are helper cells which transmit 
signals from antigen presenting cells to stimulate the immune system (Andersen et al., 2006, 
Waisman and Becher, 2014) and FoxP3+ T cells are regulatory T cells which control and 
suppress a range of immune responses (Fehervari and Sakaguchi, 2004). The density of 
activated cytotoxic T cells and helper T cells is higher in endometriotic lesions than in the 
eutopic endometrium, regardless of the phase of the menstrual cycle (Witz et al., 1994, Oral 
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et al., 1996, Jones et al., 1998, Paul Dmowski and Braun, 2004, Seeley et al., 2005, 
Ganewatta et al., 2010). Additionally, FoxP3+ regulatory T cells are detected in the stroma of 
some peritoneal endometriotic lesions and a great variation in the density of these cells was 
observed between lesions (Figure 2.4) (Berbic et al., 2010). 
 
B cells are also lymphocytes and a component of the adaptive immune response, which act to 
synthesise antibodies against antigens following activation (Batista 2008). The population of 
activated B cells in the endometriotic lesions was found to be significantly higher than in the 
eutopic endometrium, although no differences were detected in inactivated B-cells or other 
B-cell subsets (Antsiferova et al. 2005; Dmowski et al. 1994). These altered immune 
conditions might suggest that B cells are involved in the development of endometriosis and 
endometriotic lesions; however, it is important to consider that T cells are regulators of B cell 
maturation, and these changes might be a consequence of increased T cell populations and 
activity (Fagarasan and Honjo 2000). 
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Figure 2.4 The variation in the density of FoxP3+ regulatory T cells within peritoneal 
endometriotic lesions (Berbic et al., 2010). 
 
Density of macrophages was found to be increased and show great variations in peritoneal 
endometriotic lesions (and interestingly also in unaffected peritoneum) from women with 
endometriosis compared to normal peritoneum from women without endometriosis (Table 
2.1) (Oosterlynck et al., 1993a, Khan et al., 2004a, Khan et al., 2004b, Berbic et al., 2009, 
Tran et al., 2009). The accumulation of activated macrophages and their products may have 
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important roles in the development of endometriotic tissues. IL-6 and TNF-a both elevated in 
peritoneal endometriotic lesions in comparison with eutopic endometrium (Sokolov et al., 
2005, Birt et al., 2013) and released by activated peritoneal macrophages, can promote 
aromatase activity in endometriotic stromal cells and increase the production of oestrogen, a 
key hormone for the growth of lesions (Velasco et al., 2006). Macrophages are also capable 
of producing a number of angiogenic factors; including fibroblast growth factor, angiogenin 
and vascular endothelial growth factor (VEGF) (Sunderkötter et al., 1994, McLaren et al., 
1996b); with the capacity to stimulate formation of new blood vessels in the implanting 
endometriotic tissue (Lin et al., 2006). The expression of FGF and VEGF are up-regulated in 
peritoneal endometriotic lesions in comparison with eutopic endometrium (McLaren, 2000, 
Hayrabedyan and Kyurkchiev, 2005). Macrophages show significantly less phagocytic 
activity in endometriotic lesions than macrophages in normal peritoneum (Dmowski et al., 
1998). Therefore, these cells may play roles in the growth and development of endometriotic 
lesions. 
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Table 2.1 The variations between the densities of macrophages with the mean number (per 
mm2) in peritoneal endometriotic lesions. Group I, normal peritoneum from women without 
endometriosis; Group II peritoneal lesions from women with endometriosis; Group III 
unaffected peritoneum from women with endometriosis. Adapted from (Tran et al., 2009). 
 N Minimum Maximum Mean SD 
Group I        18 0 11 1.4 3.6 
Group II 24 3.7 275.7 67.7 67.9 
Group III 14 3.7 99.3 32.8 31.4 
P value           P<0.001 between Groups I and II 
                        P<0.001 between Groups I and III  
                        P=0.12 between Groups II and III 
 
Natural killer (NK) cells are the effector cells of the innate immune system, which usually 
recognise and destroy abnormal cells via killer inhibitory and killer activating receptors that 
inhibit or direct cytotoxic activity, respectively (Maeda et al., 2002, Vivier et al., 2008). 
Although a statistically significant increase in NK cell numbers were found in lesions 
compared to normal peritoneum by a recent study (Ganewatta et al., 2010), not much is 
known about NK cells in peritoneal endometriotic lesions. 
 
Immune cell activation results in release of a cascade of cytokines from various cells (Iwabe 
et al., 2002). Cytokines can be pro- or anti-inflammatory, which recruit different cell types to 
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the site of inflammation (Iwabe et al., 2002). Cytokine secretion is altered in women with 
endometriosis in the endometrium, peritoneal lesions, peritoneal fluid and peripheral blood 
compared to women without the disease. Table 2.2 summarises the expression and roles of 
key cytokines in endometriotic lesions. Pro-inflammatory cytokines from endometriotic 
lesions and associated immune cells contribute to the enhanced inflammatory reaction 
associated with endometriosis that promotes the survival of these lesions instead of leading to 
their demise (Senturk and Arici, 1999, Lebovic et al., 2001). 
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Table 2.2 Important cytokines and their possible roles and levels in endometriotic lesions 
compared to eutopic endometrium.  
Cytokine Produced by Function/s Levels Possible Roles References 
Interleukin-1 
(IL-1) 
Macrophages Pro-inflammatory; 
induces 
angiogenesis and 
expression of 
adhesion molecule 
↑ Promotes blood 
supply to lesions 
and endometrial 
cell-peritoneal 
adhesion  
(Bedaiwy et al., 
2002, Voronov et 
al., 2003, Hudelist 
et al., 2005) 
Interleukin-1β  
(IL-1β) 
Monocytes Stimulate 
interleukin-6 
secretion 
↑ Facilitates neo-
vascularisation of 
lesions 
(Wu and Ho, 2003) 
Interleukin-4 
(IL-4) 
T helper 2, 
natural killer 
and mast cells  
Regulates Th2 cell 
proliferation by 
induces Growth 
factor independent-
1 
↑ Stimulates 
proliferation of 
endometriotic 
stromal cells, 
facilitates lesion 
establishment  
(Antsiferova et al., 
2005, Zhu et al., 
2002) 
Interleukin-6 
(IL-6) 
T cells, 
macrophages 
and 
endometriotic 
lesions 
themselves 
↑ production of 
Endo-1 protein, 
mediate VEGF 
expression, possibly 
facilitate in neo-
vascularisation 
↑ ↑ lesion 
establishment 
through 
involvement in 
impaired 
immunity 
(Wu and Ho, 2003, 
Ulukus et al., 2006) 
Interleukin-8 
(IL-8) 
Macrophages 
and 
endometriotic 
lesions 
themselves 
Potent growth and 
differentiation 
factor for activated 
B cells  
↑ Endometrial cell-
peritoneal 
adhesion, 
improves blood 
supply and 
proliferation 
within lesions  
(Burkman, 1991, 
Rafet Gazvani et al., 
1998, Harada et al., 
2001) 
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In summary, the increases in immune cell densities in the stroma of peritoneal endometriotic 
lesions may suggest targeting of the immune response at the core of lesions in an attempt to 
inhibit further development. Changes in immune cell populations and their released products 
in endometriosis appear to increase angiogenesis, growth of lesions, inflammatory cell 
recruitment, adhesions and oestrogen production. These changes may result in a failure of the 
immune system to clear peritoneal endometriotic lesions and instead enhance their 
development and persistence.  
 
2.3.2 Blood Vessels 
A number of studies have shown that the density of blood vessels and other angiogenic 
parameters are increased within peritoneal endometriotic lesions compared to normal 
Monocyte 
Chemotactic 
Protein-1 
(MCP-1) 
Macrophages 
and endothelial 
cells  
 
Chemo-attractant, 
pro inflammatory 
and activating factor 
for monocytes  
↑ Recruitment and 
activation of 
peritoneal 
macrophages  
(Jolicoeur et al., 
1998, Kalu et al., 
2007) 
Tumour 
Necrosis 
Factor-α (TNF-
α) 
Platelets, 
activated 
lymphocytes 
and 
macrophages 
Induce interleukin-8 
expression 
↑ Promotes 
endometriotic 
stromal cell 
proliferation and 
angiogenesis 
(Oosterlynck et al., 
1993b, Iwabe et al., 
2000, Harada et al., 
2001, Bedaiwy and 
Falcone, 2003) 
Vascular 
endothelial 
growth factor 
(VEGF) 
Mainly 
macrophages 
and many 
leukocytes 
Promotes 
angiogenesis 
↑ Improves 
vascularization of 
lesions 
(Sokolov et al., 
2005, Pupo-
Nogueira et al., 
2007) 
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peritoneum, and that they show variations between different types of lesions (Figure 2.5) 
(Donnez et al., 1998, Tan et al., 2002, Bourlev et al., 2006, Reichelt et al., 2012). 
Endometriotic lesions have a greater micro-blood vessel density compared to normal 
endometrium (Young et al., 2013). Furthermore, peritoneal endometriotic lesions have higher 
blood vessel density compared to ovarian endometriosis, whereas DIE lesions have the 
highest blood vessel density of any lesion type (Tan et al., 2002, Machado et al., 2008). 
Interestingly, the amount of vascularisation in and around endometriotic lesions correlates 
with the mitotic activity within the lesion (Nisolle et al., 1993).  
 
Figure 2.5 Red flare lesion with extensive vascularisation surrounding peritoneal 
endometriosis (Overton, 2007). 
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Several angiogenic growth factors; such as VEGF-A, endoglin, epidermal growth factor 
(EGF), transforming growth factor-α (TGF-α), fibroblast growth factor (FGF), platelet 
endothelial cell adhesion molecule (PECAM) and integrin-αvβ3 and their receptors VEGFR-
1 and VEGFR-2; are increased in expression in endometriotic lesions compared to normal 
endometrium (Healy et al., 1998, Kim et al., 2001, Van Langendonckt et al., 2004, Print et 
al., 2004, Bourlev et al., 2006, Pupo-Nogueira et al., 2007). 
 
Red lesions have higher expression of VEGF-A, its VEGFR-2 receptor (Nisolle et al., 1993, 
Bourlev et al., 2006) and other angiogenic cytokine levels compared to older black or white 
scarred lesions (Donnez et al., 1998, Tan et al., 2002); and express lower levels of 
angiogenesis inhibitors such as thrombospondin protein 1 (TSP-1) (Tan et al., 2002). This 
suggests more active angiogenic processes in red lesions (Nisolle et al., 1993). Red, black 
and white endometriotic lesions have different mitotic activity, which appears to correlate 
with the content of VEGF in the peritoneal fluid (Khan et al., 2004b).  
 
2.3.3 Lymphatic Vessels 
A few studies have recently demonstrated high lymphatic vessel density and expression of 
lymphatic growth factors in peritoneal endometriotic lesions. Lymphatic vessel density is 
increased in the stroma of peritoneal endometriotic lesions compared to the surrounding sub-
peritoneal tissue but not statistically significantly different to normal peritoneum (Hey-
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Cunningham et al., 2011). On the other hand, density of lymphatic vessels in DIE is 
significantly higher than corresponding healthy tissues (Keichel et al., 2011). Lymphatic 
micro-vessels play an important role in immune surveillance and increased stromal lymphatic 
vessel density parallels immune cell distribution, which is also increased in the stroma of 
endometriotic lesions (as reviewed above in section 2.3.1). The increases in immune cell and 
lymphatic vessel densities in the stroma of peritoneal endometriotic lesions may suggest 
targeting of the immune response at the core of lesions in an attempt to inhibit further 
development. 
 
Expression of a range of lymphangiogenic growth factors and their receptors are also 
increased in endometriotic lesions compared to normal peritoneum and eutopic endometrium 
from women with and without endometriosis. Expression of VEGF-C and VEGF-D are 
elevated in peritoneal endometriotic lesions (Figure 2.6) (Takehara et al., 2004, Reichelt et 
al., 2012) and VEGF-A and VEGF-C in ovarian endometriosis (Takehara et al., 2004). In 
addition, other growth factors known to promote lymphangiogenesis, such as IGF-1 and IGF-
2, are increased in endometriotic lesions (Khan et al., 2003, Milingos et al., 2006, Milingos et 
al., 2011).  
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Figure 2.6 The variations of lymphatic vessel density with standard error bars in peritoneal 
endometriotic lesion stroma (A) and surrounding (B) throughout the menstrual cycle. Data 
are represented as mean ± SEM (P= proliferative phase, S= secretory phase, M= menstrual 
phase) (Hey-Cunningham et al., 2011). 
 
In summary, studies demonstrate that lymphatic vessels are present in peritoneal 
endometriotic lesions and that this may be induced by lymphangiogenic growth factors 
expressed by lesions. Although little is currently known about the roles of lymphatic vessels 
or lymphangiogenesis in the establishment and progression of endometriotic lesions, they 
most probably support local maintenance as well as dissemination of endometriotic cells. 
This would occur in close interaction with immunological factors in the peritoneal cavity. 
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2.3.4 Nerve Fibres 
Several researches have demonstrated the presence of nerve fibres in endometriotic lesions 
(Anaf et al., 2000, Tulandi et al., 2001, Tamburro et al., 2003, Berkley et al., 2004, 
Tokushige et al., 2006b, Mechsner et al., 2007). Significantly more nerve fibres are present in 
peritoneal endometriotic lesions compared to normal peritoneum (Tokushige et al., 2006b, 
Mechsner et al., 2007). Furthermore, the density shows great variation with the mean 
densities of 16.3 ± 10.0 within peritoneal endometriotic lesions (Figure 2.7) (Tokushige et 
al., 2006b). Nerve fibre density is also increased in ovarian endometrioma compared to 
ovarian cortex from women with ovarian endometriosis and those without endometriosis 
(Tokushige et al., 2010, Zhang et al., 2010). Furthermore, it also has been shown that there is 
a great variation in density of nerve fibres between peritoneal endometriotic lesions. 
Additionally, DIE lesions have substantially greater density of nerve fibres than peritoneal 
lesions (Wang et al., 2009a). A mixture of sensory A-δ, sensory C, adrenergic and 
cholinergic fibres is found in peritoneal lesions (Tokushige et al., 2006a). These nerve fibres 
are pain conducting and the presence of functional nerve fibres in peritoneal lesions suggests 
a critical role in pain processing and perception, although exact pathways remain unclear. 
 
Researchers have also shown that a wide range of neurotrophins (NGF and NT-3), their 
receptors (TrkA and p75) and other neuronally active molecules are present in endometriotic 
glands and stroma of peritoneal lesions, as well as ovarian and DIE lesions (Anaf et al., 2002, 
Tokushige et al., 2006a, Mechsner et al., 2007, Odagiri et al., 2009, Wang et al., 2009a, 
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Wang et al., 2009b, Tokushige et al., 2010). In addition, there is evidence that recruited 
immune cell sub-populations in peritoneal lesions contribute to increased local neurotrophic 
factors (Torcia et al., 1996, Kerschensteiner et al., 1999, Noga et al., 2007). In particular, 
more nerve fibres were found in lesions with increased numbers of activated macrophages 
(which are likely secreting neuroattractant cytokines and providing a suitable environment 
for nerve in-growth in lesions; Figure 2.7) (Anaf et al., 2006, Kalu et al., 2007, Berbic et al., 
2009, Hassa et al., 2009, Tran et al., 2009). 
 
 
Figure 2.7 The correlation between macrophage and nerve fibre densities in peritoneal 
endometriotic lesions, showing variation in both densities (Tran et al., 2009). 
 54 
 
 
In summary, immune cells, blood vessels, lymphatic vessels and nerve fibres play a range of 
important roles in the structure and function of peritoneal endometriotic lesions. 
Additionally, it is apparent that there is variation in immune cell density, lymphatic vessels, 
blood vessels and nerve fibres within peritoneal endometriotic lesions. The reasons for and 
the implications of this are currently largely unclear. However, the variation is likely to be 
associated with the age or stage of lesion development (red, black, white peritoneal 
endometriotic lesions), as is the case for angiogenic parameters. Improved understanding of 
how lesion appearance (which correlates with lesion age or stage of development) exactly 
relates to the microscopic structure and function of lesions is required. 
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Chapter 3 
Aims and Hypotheses 
 
3.1 Introduction 
Previous studies have shown that densities of immune cell populations are increased within 
peritoneal endometriotic lesions in comparison to the surrounding peritoneum and normal 
peritoneum. Additionally, the immune cells have shown great variations in density between 
lesions. While these observations are considered to be important for endometriotic lesion 
development, exactly how these cells relate to lesion appearance, age or stage of 
development is currently unclear.  
 
3.2 Primary Hypothesis 
It is hypothesised that the variations in immune cell environment in and around 
endometriotic lesions are associated with the stage of lesion development. 
 
3.3 Secondary Hypotheses 
Following from primary hypothesis, it is specifically hypothesised that: 
 The density of immune cell populations is higher in the stroma of peritoneal 
endometriotic lesions compared to the surrounding tissue. 
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 The density of immune cell populations is higher in red lesions (early stage of 
development), implying that the immune response in these lesions is more active, 
compared to black and white lesions (later stages of development). 
 Black lesions have higher density of immune cell populations than white lesions 
(earlier versus later stages of development, respectively). 
 
3.4 Aims 
To test the hypotheses stated above, the main aim of this research project was to investigate 
the development of peritoneal endometriotic lesions by characterising their immune 
environment by their macroscopic appearance.  
 
The specific aims of this study were to determine the density and distribution of immune cell 
populations; specifically, dendritic cells, T cells, B cells and macrophages; in and around red, 
black and white peritoneal endometriotic lesions. 
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Chapter 4 
Methodology 
4.1 Ethics Approval 
This study has been approved by the Ethics Review Committee (Royal Prince Alfred 
Hospital Zone) of the Sydney Local Health District (protocol number: X11-0270 & 
HREC/II/RPAH/419). 
 
4.2 Participant Recruitment and Sample Collection 
Participants were prospectively recruited from gynaecology operating theatres at Royal 
Prince Alfred Hospital (n=32; mean age=31.5, age range=20-45). The study included 
participants who were non-pregnant, required laparoscopic excision of endometriosis, of a 
reproductive age or pre-menopausal and regularly menstruating, understood the conditions of 
the study and gave informed consent. Women who were pregnant or post-menopausal or 
unable to consent to involvement were excluded from this study. Women who provided 
informed consent were asked to provide information regarding their symptoms; 
gynaecological, obstetric and, past medical history including autoimmune disorders; family 
history of endometriosis, and current medications. 
 
Collection of peritoneal endometriotic lesion samples involved wide laparoscopic excision 
with minimal use of diathermy. Appearance of lesions prior to excision was categorised 
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during the procedure by surgeons as red, black or white and laparoscopic pictures captured 
before the excision.  
 
4.3 Sample Processing 
 
4.3.1 Fixation 
Tissue samples were fixed in 10% neutral-buffered formalin to preserve tissue components 
and morphology as close to its natural state as possible (Boenisch, 2001). After the tissue 
samples were fixed, they were dehydrated by alcohol, cleared of dehydrating agents using 
xylene and infiltrated with paraffin wax to replace xylene according to a standardised 
protocol. Paraffin embedding provides structural support and allows sectioning for 
visualisation (Boenisch, 2001, Miller et al., 2001). 
 
4.3.2 Sectioning 
Paraffin embedded tissue samples were cooled to -5°C on a cold plate (Leica EG1150 C, 
Leica Microsystems Nussloch GmbH, Germany; Figure 4.1 (A)) before cutting as it 
improves sectioning. Cooled tissue blocks were cut at 4μm on a manually operated rotary 
microtome (Leica RM 2135, Leica Microsystems Nussloch GmbH, Germany; Figure 4.1 
(B)). Cut sections were mounted on glass slides (IHC Microscope Slides, FLEX; Dako, 
Denmark) and dried in an oven at 60°C for 60 minutes. 
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A)   
 
B)  
Figure 4.1 (A) Leica EG1150 C cold plate and (B) manually operated microtome used for 
cutting tissue sections. Source: leica.microsystems.com 
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4.3.3 Deparaffinisation and Rehydration 
Dried slides were allowed to cool after removal from the oven. Xylol is an organic solvent 
capable of dissolving wax, therefore slides were deparaffinised with xylol twice for five 
minutes each and rehydrated with decreasing concentrations of alcohols for two minutes each 
(100% alcohol twice, 95% alcohol and 70% alcohol) and placed into slow running tap water 
for two minutes. 
 
4.3.4 Haematoxylin and Eosin Staining (H&E) 
Haematoxylin and eosin (H&E) staining was performed for all samples to assess tissue 
morphology and locate the lesion within the tissue block. Deparaffinised and rehydrated 
slides were H&E stained using the following protocol:  
1. Harris Haematoxylin       4 mins 
2. Rinse well in tap water      1 min 
3. Differentiate in acid alcohol and stop action by washing quickly in running tap water 
4. Blue in Scott’s Bluing Solution     30 secs - 1min 
5. Rinse in tap water (examine microscopically) 
6. Wash well in tap water      1 min 
7. 70% alcohol        1 min 
8. Counterstain with Alcohol Eosin     15 - 60 secs 
9. 95% alcohol        1 min 
10. 100% alcohol        1 min 
11. 100% alcohol        1 min 
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12. Xylene         2 mins 
13. Xylene         2 mins 
14. Coverslip with Ultramount (Fronine Pty Ltd, Riverstone, Australia). 
 
4.4 Immunohistochemistry Concept and Protocol 
4.4.1 Antigen Retrieval  
Antigen retrieval is a method to unmask antigens which have been heavily modified by 
fixation and/or paraffin processing. Cross-links between proteins formed during fixation are 
broken down and some of the antigen denaturation caused by fixation and paraffin 
processing is reversed with this method (Miller et al., 2001, Ramos-Vara, 2005). Antigen 
retrieval can be performed by proteolytic digestion or heat treatment in a buffer solution 
(heat-induced antigen/epitope retrieval, HIER) (Ramos-Vara, 2005). 
 
In this study, HIER was performed on tissue sections prior to immunohistochemical (IHC) 
staining. HIER involved immersing tissue slides in a preheated buffer solution prepared by 
diluting 4 mLs of Antigen Target Solution pH 9 (x50 concentrate; Dako, Glostrup, Denmark) 
in 196 mLs distilled water. The working solution was preheated in a water bath to 95-99°C. 
Slides were immersed in the preheated solution and incubated for 20 minutes at 95-99°C. 
Retrieved sections were cooled to room temperature in a cold-water bath, rinsed in water and 
incubated in TRIS buffer for 10 minutes to break the surface tension prior to staining.  
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4.4.2 Antibodies 
Antibodies belong to a group of proteins called immunoglobulins (Ig). There are five major 
classes of immunoglobulin: IgG, IgA, IgM, IgD, and IgE. Each immunoglobulin structure is 
composed of four identical chains including two heavy (that determine the class and subclass 
of the molecule) and two light chains (that found as kappa or lambda types differ across the 
different classes). The Y shaped antibody has a specific recognition site on its light chains 
that reacts with a site on antigen called epitope (Buchwalow and Ebrary, 2010). The 
antibody-antigen binding complex is commonly used in IHC. Figure 4.2 below represents 
this specific binding interaction. 
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Figure 4.2 The antibody-antigen binding interaction.  
 
Antibodies used in this project were monoclonal primary antibodies, which are the product of 
an individual clone of plasma cells. Monoclonal antibodies bind to a single epitope on the 
antigen and currently, are exclusively produced in mice (Boenisch, 2001). Antibodies used in 
this research are detailed in Table 4.1.  
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Table 4.1 Antibodies used in this study. 
Antibody Stains Species Dilution Supplier 
DC-Lamp Mature dendritic cells Monoclonal mouse 
(clone 1010E1.01) 
1:50 with 
Amp Link 
Dendritics, Lyon, 
France 
DC-Sign Immature dendritic cells Monoclonal mouse 
(clone 102E11.06) 
1:100 
 
Dendritics, Lyon, 
France 
CD4 Effector T cells Monoclonal mouse 
(clone 4B12) 
1:60 with 
Amp Link 
Dako, Glostrup, 
Denmark 
CD8 Cytotoxic T cells Monoclonal mouse 
(clone C8/144B) 
1:100 Dako, Glostrup, 
Denmark 
FoxP3 Regulatory T cells Monoclonal mouse 
(clone 236A/E7) 
1:50 with 
Amp Link 
Abcam, 
Cambridge, UK 
CD20 B cells  Monoclonal mouse 
(clone JCB117) 
1:400 
 
Dako, Glostrup, 
Denmark 
CD68 Macrophages Monoclonal mouse 
(clone PG-M1) 
1:300 Dako, Glostrup, 
Denmark 
 
4.4.3 Amplifier 
EnVision FLEX+ Mouse (LINKER) (Dako, Glostrup, Denmark) was used as an amplifying 
agent as required. Initial staining with some antibodies including DC-Lamp, CD4 and FoxP3 
gave weak, unsatisfactory results even at high concentrations and the use of the amplifier 
gave four-five fold increases in signal.  
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4.4.4 Detection System 
EnVision+ Dual Link System-HRP (Dako, Glostrup, Denmark) was used as the detection 
system. This system is based on a horseradish peroxidise (HRP) labelled polymer, which is 
conjugated with secondary antibodies directed against mouse. The reagent contains goat 
secondary antibodies with anti-mouse Ig specificity coupled with peroxidise-labelled 
polymers in Tris-HCl buffer with stabilising protein and anti-microbial agents. It is a signal 
enhancing detection system. 
 
4.4.5 Visualisation 
Liquid Diaminobenzidine+ (DAB+) Substrate Chromagen (Dako, Denmark) was used as the 
visualisation system. This is a high-sensitivity DAB system suitable for use in peroxidase-
based IHC. DAB forms a brown end-product at the site of the target antigen upon oxidation. 
A DAB working solution was prepared by adding one drop (20 μL) of DAB Chromagen per 
1 mL of substrate buffer according to the volume required. Since it has a carcinogenic effect, 
DAB+ was prepared with caution and disposed of in a safe way. 
 
4.4.6 Autostainer 
An automated slide processing system, Dako Autostainer Plus Universal Staining System 
(Dako, Glostrup, Denmark), was used for IHC staining in this study (Figure 4.3). The 
Autostainer is made up of a slide processor, dedicated desktop computer, printer and a 
labelling system. A maximum of 48 slides can be processed in one run and the reagent, 
dispense volume and dispense location were individually programmed for each slide. The 
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drop zones for each slide were also selected individually according to the tissue location to 
ensure full coverage with a dispense volume total of 200 μL (two dispense locations of 100 
μL).   
 
 
Figure 4.3 Dako Autostainer Plus Universal Staining System (Dako, Glostrup, Denmark). Source: 
www.dako.com.au 
 
4.4.7 Wash Buffer 
Wash buffers remove non-specifically bound proteins in specimens to reduce or eliminate 
background. The buffer was prepared by diluting Wash Buffer concentrate (10x; Dako, 
Denmark), a Tris-buffered saline solution containing Tween 20 with pH 7.6 (+ 0.1), in 
deionised water. Buffer rinse steps, which are a buffer wash and air blow cycle, were 
programmed on the Autostainer between each reagent step. 
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4.4.8  Blocking 
Blocking steps eliminate and reduce non-specific background staining which is a result of 
positive staining that is not due to antigen-antibody binding (Gao et al., 2008). Dual 
Endogenous Enzyme Block (DEEB; Dako, Glostrup, Denmark) inhibits the activity of 
endogenous peroxidise, pseudoperoxidase and alkaline phosphatase, which are frequently 
observed in IHC procedures resulting in non-specific staining. The presence of endogenous 
peroxidase and alkaline phosphatase can obscure specific staining of the target antigen (Gao 
et al., 2008). Following an initial buffer wash to ensure reagent spread, the Autostainer was 
programmed with a 10 minute DEEB blocking step. 
 
4.4.9 Protocol 
The following protocol was performed for tissue staining on the Autostainer: 
1. Wash buffer rinse  
2. DEEB block        10 mins 
3. Wash buffer rinse 
4. Primary antibody       30 mins  
5. Wash buffer rinse 
6. EnVision FLEX+ Mouse (LINKER) (as required)   15 mins 
7. Wash buffer rinse 
8. EnVision+ Dual Link System-HRP     30 mins  
9. Wash buffer rinse  
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10. Wash buffer rinse  
11. DAB+         10 mins 
12. Wash buffer rinse 
 
4.4.10 Counterstaining and Cover-Slipping 
The protocol for counterstaining and cover-slipping of IHC stained slides was as follows:  
1. Rinse with deionised water  
2. Tap water        30 secs 
3. One quick dip in Mayers Haematoxylin 
4. Rinse in running tap water until water runs clear 
5. Blue in hot tap water       15 secs 
6. 70% alcohol        2 mins 
7. 95% alcohol        2 mins 
8. 100% alcohol        2 mins 
9. 100% alcohol        2 mins 
10. Xylol         3 mins 
11. Xylol         3 mins 
12. Coverslip in Ultramount (Fronine Pty Ltd, Riverstone, Australia). 
 
4.5 Quantification of Immune Cell Populations 
All stained slides were observed using an Olympus BX51 microscope (Olympus, Tokyo 
Japan). All peritoneal endometriotic lesion areas were captured under x10 magnification 
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objective using an Olympus DP70 digital camera (Olympus, Tokyo Japan). Quantification of 
positive cells was performed using MetaMorph software (Molecular Devices, Downington, 
PA, USA). 
 
4.5.1 Regions 
Immune cell populations were examined in endometriotic stroma of peritoneal lesions as well 
as in the tissues immediately surrounding lesions. Three different regions were drawn around 
each peritoneal endometriotic lesion area: (1) immediately inside the glandular epithelium 
(gland region), (2) at the edge of the endometriotic stroma (stroma region) and (3) 250 µm 
from the edge of the stroma (surrounding region). An example of the lesion regions is shown 
in Figure 4.4. 
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Figure 4.4 Region areas in a captured peritoneal endometriotic lesion (CD4 effector T cell 
staining; image captured under 10x magnification). 
 
4.5.2 Thresholding and Measurement 
Thresholds were manually created for each marker using the ‘Set Colour Threshold’ function 
of MetaMorph. This was done using the ‘Set by Example’ option and clicking on positive 
(brown) pixels until all shades of brown staining were included in the threshold. Thresholds 
were tested on multiple images (at least five) for every marker to ensure all positive cells 
were included within the threshold before being finalised. An example of thresholding with 
MetaMorph is shown in Figure 4.5. 
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Figure 4.5 Thresholding of CD8+ cytotoxic T cells in and around a peritoneal endometriotic 
lesion area with the ‘Set Colour Threshold’ function in MetaMorph. Positive pixels included 
within the threshold are indicated with a red overlay.  
 
After thresholding was performed, the next step was setting up scoring parameters (setting 
the ‘State’) for every marker based on morphometric characteristics (size). This was done in 
the ‘Integrated Morphometry Analysis’ (IMA) function from the MetaMorph tool-bar (Figure 
4.6). Minimum and maximum size limits (in pixels) were determined for each cell type based 
on positively stained cell morphology. 
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Figure 4.6 Measurement of CD8+ cytotoxic T cells in and around a peritoneal endometriotic 
lesion area with the ‘Integrated Morphometry Analysis’ function in MetaMorph. Within the 
regions, the green overlay indicates the positive cells detected by the threshold and within the 
size limits for the cell type which are therefore measured. 
 
4.5.3 Data Processing 
All MetaMorph measurements were directly logged to Microsoft® Excel. For each image, 
the number of positive cells and region area measurements were obtained. Raw 
measurements included all counts and area within entire regions (including smaller regions 
contained within) so exact measurements for endometriotic stroma only and surrounding 
tissue only were obtained by subtracting smaller embedded region measurements. Stromal 
tissue cell counts and region areas were calculated by subtracting gland region measurements 
from stroma region measurements. Similarly, surrounding tissue cell counts and region areas 
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were calculated by subtracting stroma region measurements from surrounding region 
measurements.  
 
Area measurements from MetaMorph were provided in pixels, so were converted to mm with 
the following formula (derived as 250 µm = 450 pixels):  
Area mm2 = Pixel area 
3240000 
 
Measurements for different areas of samples (images) were summed to give the total positive 
cell counts and mm2 area per lesion sample (for both stroma and surrounding). The density 
per mm2 of immune cell populations in the stroma and surrounding regions was calculated by 
the following: 
Density per mm2 = Positive cell count 
Area mm2 
 
4.6 Statistical Analyses 
Statistical analyses were performed using IBM Statistical Package for the Social Sciences 
(SPSS) version 21.0 software. One-Sample Kolmogorov-Smirnov test was used to determine 
distribution of variables. To compare marker densities in stromal versus surrounding tissue, 
either paired sample t tests or the non-parametric equivalent, the Wilcoxon Signed Ranks 
Test (z score) were performed. To compare marker densities between lesion types (red, black 
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or white) within either stromal or surrounding tissue either one-way analysis of variance 
(ANOVA with contrasts for pairwise comparisons, or for non-normally distributed data, the 
Kruskal-Wallis chi-square test, with Mann-Whitney U z tests for pairwise comparisons, were 
used. Correlations between marker densities within either stromal or surrounding tissue were 
examined using either the Pearson’s correlation coefficient if both variables were normally 
distributed or the Spearman’s correlation coefficient (rs) if data were skewed. Statistics were 
considered to be statistically significant with P-values of less than 0.05. 
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Chapter 5 
Results 
 
5.1 Density of Immune Cell Populations in and around Peritoneal 
Endometriotic Lesions  
Immune cell populations were present in and around peritoneal endometriotic lesions, with 
variations in numbers and distribution. Representative images of staining are provided for all 
dendritic cell (Figure 5.1), T cell (Figure 5.2), B cell (Figure 5.3) and macrophage (Figure 
5.4) populations. The staining on negative controls was always negative (Figure 5.5). 
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A)  B)  
C)  D)  
Figure 5.1 Immunohistochemical staining for dendritic cell populations in and around 
peritoneal endometriotic lesions. DC-Sign+ immature dendritic cells at 100x magnification 
(A) and 400x magnification (B); and DC-Lamp+ mature dendritic cells at 100x magnification 
(C) and 400x magnification (D) stained brown with DAB+ chromagen. 
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A)  B)   
C)  D)  
E)  F)  
Figure 5.2 Immunohistochemical staining for T cell populations in and around peritoneal 
endometriotic lesions. CD4+ effector T cells at 100x magnification (A) and 400x 
magnification (B); CD8+ cytotoxic T cells at 100x magnification (C) and 400x magnification 
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(D); and FoxP3+ regulatory T cells at 100x magnification (E) and 400x magnification (F) 
stained brown with DAB+ chromagen.  
 
A)  B)  
Figure 5.3 Immunohistochemical staining for CD20+ B cells at 100x magnification (A) and 
400x magnification (B) in and around peritoneal endometriotic lesions, stained brown with 
DAB+ chromagen. 
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A)  B)  
Figure 5.4 Immunohistochemical staining for CD68+ macrophage populations at 100x 
magnification (A) and 400x magnification (B) in and around peritoneal endometriotic 
lesions, stained brown with DAB+ chromagen. 
 
A)  B)  
Figure 5.5 A representative image of negative control at 100x magnification (A) and 400x 
magnification (B). 
 
5.1.1 Lesion Stroma Compared to Surrounding Tissue  
In peritoneal endometriotic lesions, densities of immune cell populations showed significant 
variations between stromal and surrounding tissues (Figure 5.6). 
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A)  B)  
C)  D)  
E)  F)  
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G)  
Figure 5.6 Graphs showing variations in the densities per mm2 of DC-Sign+ immature 
dendritic cells (A), DC-Lamp+ mature dendritic cells (B), CD4+ effector T cells (C), CD8+ 
cytotoxic T cells (D), Foxp3+ regulotory T cells (E), CD20+ B cells (F) and CD68+ 
macrophages (G) showing variations in the densities of populations between stroma and 
surrounding tissue of peritoneal endometriotic lesions. The solid line in the box plots 
represent the median density, the length of the box denotes the interquartale range (IQR; 25th  
to 75th centiles) and the wiskers indicate the minimum and the maximum values of the data 
that are not outliers. The circles represent outliers 1.5-3 IQRs from the end of the box. The 
asterisk represents an extreme outliner defined as a value >3 IQRs from the end of the box. In 
bar chart, data represent the mean ± SD density per mm2. 
 
Dendritic cells 
Density of DC-Sign+ dendritic cells was significantly lower in lesion stroma compared to 
surrounding tissue (p<0.001, Mann Whitney U z=3.903, Figure 5.6 [A]), while there was no 
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statistically significant difference for DC-Lamp+ dendritic cells between stromal and 
surrounding tissue. 
 
T cells 
Density of CD8+ and FoxP3+ T cells were significantly higher in stromal compared to 
surrounding tissue of peritoneal endometriotic lesions (p=0.014, df=31, t=2.60, Figure 5.6 
[D] and p=0.035, U z=2.213, Figure 5.6 [E]; respectively). However, there was no 
statistically significant difference in CD4+ T cell density between lesion stroma and 
surrounding tissue. There were CD4+ and CD8+ T cell aggregates in the tissue surrounding 
peritoneal endometriotic samples for 9 of the 32 samples. These aggregates ranged in size 
range from 40 µm diameter to 100x300 µm in size (Figure 5.7). 
 
A)  B)  
Figure 5.7 Examples of CD4+ (A) and CD8+ (B) T cell aggregates in the tissue surrounding 
peritoneal endometriotic lesions. 
 
 83 
 
B cells 
CD20+ B cells showed significantly higher density in surrounding tissue in comparison to 
lesion stroma (p=0.033, U z=2.129, Figure 5.6 F). There were CD20+ B cell aggregates in 
tissue surrounding lesions for 9 of 32 lesion samples (same samples with CD4+ and CD8+ T 
cell aggregates), ranging in size between 40 µm diameter to 100x300 µm in size (Figure 5.8). 
 
 
Figure 5.8 Example of a CD20+ B cell aggregate in surrounding tissue of a peritoneal 
endometriotic lesion. 
 
Macrophages 
Stromal density of CD68+ macrophages was significantly higher than the surrounding 
density (p=0.012, U z-2.499, Figure 5.6 [G]). 
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5.1.2 Lesion Appearance  
There was no correlation observed between participant age and lesion type. None of the 
immune cell populations studied differed significantly in density between the three lesion 
types (red, black and white) either in the stroma or surrounding tissue (Figures 5.9 and 5.10). 
 
A)  B)  
C)  D)  
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E)  F)  
G)  
Figure 5.9 The densities of immune cell populations in stroma of peritoneal endometriotic 
lesions for red, black and white lesion appearances. DC-Sign+ immature dendritic cells (A), 
DC-Lamp+ mature dendritic cells (B), CD4+ effector T cells (C), CD8+ cytotoxic T cells 
(D), Foxp3+ regulotory T cells (E), CD20+ B cells (F) and CD68+ macrophages (G). Data 
represent the mean ± SD densities per mm2. 
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A)  B)  
C)  D)  
E)  F)  
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G)  
Figure 5.10 The densities of immune cell populations in tissue surrounding peritoneal 
endometriotic lesions for red, black and white appearances. DC-Sign+ immature dendritic 
cells (A), DC-Lamp+ mature dendritic cells (B), CD4+ effector T cells (C), CD8+ cytotoxic 
T cells (D), Foxp3+ regulotory T cells (E), CD20+ B cells (F) and CD68+ macrophages (G). 
Data represent the mean ± SD densities per mm2. 
 
5.2 Correlations between the Densities of Immune Cell Populations  
 
Stroma 
In stromal tissue of peritoneal endometriotic lesions, statistically significant positive 
correlations were observed between CD4+ and CD8+ T cell densities (p<0.001, Spearman’s 
rho rs=0.647; Figure 5.11 [A]) and between CD4+ T cell and CD68+ macrophage densities 
(p=0.029, rs=0.386; Figure 5.11 [B]). There was a strong trend for positive correlation 
between DC-Sign+ dendritic cell and CD4+ T cell densities (p=0.050, rs=0.349; Figure 5.11 
[C]). 
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A)  B)  
C)  
Figure 5.11 The correlations between the densities of different immune cell populations in 
the stroma of peritoneal endometriotic lesions. CD8+ cytotoxic T cells with CD4+ effector T 
cells (A) and CD68+ macrophages with CD4+ effector T cells (B), DC-Sign+ dendritic cells 
with CD4+ effector T cells (C).  
 
Surrounding 
In tissue surrounding peritoneal endometriotic lesions, there were 11 different positive 
correlations between immune cell population densities (Figure 5.12). There was correlation 
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between the densities of DC-Sign+ dendritic cells with CD4+ T cells (p<0.001, rs=0.608, 
Figure 5.12 [A]); and CD20+ B cells (p=0.003, rs=0.508; Figure 5.12 [B]) and DC-Sign+ 
dendritic cells with CD68+ macrophages (p=0.002, rs=0.522; Figure 5.12 [C]) DC-Lamp+ 
dendritic cells with both CD4+ T cells (p=0.001, rs=0.543, Figure 5.12 [D]) and CD68+ 
macrophages (p=0.037, rs=0.371; Figure 5.12 [E]). Density of CD4+T cells was correlated 
with all other studied cell populations (CD8+ T cells p=0.008, rs=0.463, Figure 5.12 [F]; 
Foxp3+ p=0.045, rs=0.357, Figure 5.12 [G]; CD20+ p=0.037, rs=0.370, Figure 5.12 [H]; and 
CD68+ p<0.001, rs=0.704, Figure 5.12 [I]). There was correlation between the densities of 
CD8+ T cells with both CD20+ B cells (p=0.002, rs=0.527, Figure 5.12 [J] and CD68+ 
macrophages (p=0.30, r=0.384, Figure 5.12 [K]). 
 
A)  B)  
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C) D)  
E)  F)  
G)  H)  
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I)  J)  
K)  
Figure 5.12 The positive correlations between the densities of different immune cell 
populations in tissue surrounding peritoneal endometriotic lesions. DC-Sign+ immature 
dendritic cells correlated with CD4+ T cells (A), DC-Sign+ immature dendritic cells with 
CD20+ B cells (B), DC-Sign+ immature dendritic cells with CD68+ macrophages (C), DC-
Lamp+ mature dendritic cells with CD4+ effector cells (D), DC-Lamp+ mature dendritic 
cells with CD68+ macrophages (E), CD4+ effector T cells with CD8+ cytotoxic (F), CD4+ 
effector T cells with Foxp3+ regulatory T cells (G), CD4+ effector T cells with CD20+ B 
cells (H), CD4+ effector cells with CD68+ macrophages (I), CD8+ cytotoxic T cells with 
CD20+ B cells (J) and CD8+ cytotoxic T cells with CD68+ macrophages (K).   
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Chapter 6 
Discussion 
 
6.1  Introduction 
This study has observed the presence of all studied immune cell populations; including 
dendritic cells, T cells, B cells and macrophages; in and around peritoneal endometriotic 
lesions. Some of these cell populations have been examined in endometriotic lesions for the 
first time in this study. It has been demonstrated that while CD8+ cytotoxic T cells, Foxp3+ 
regulatory T cells and CD68+ macrophages were significantly higher in density within lesion 
stroma; DC-Sign+ immature dendritic cells, CD4+ helper T cells and CD20+ B cells were 
significantly increased in density in tissue surrounding peritoneal endometriotic lesions. 
Additionally, this study has for the first time shown correlations between different immune 
cell population densities in lesion stroma and surrounding tissue, which suggest functional 
interactions in terms of peritoneal lesion pathogenesis. Due to the great variations in immune 
cell densities in peritoneal endometriotic lesions, it was initially hypothesised that densities 
of immune cell populations correlate with stage of lesion development. Subsequent results 
from this study found no relationship between lesion appearance and immune environment.  
 
Evidence from this thesis indicates immune cell populations present have a range of possible 
roles in and around peritoneal endometriotic lesions. The recruitment of immune cells to 
tissue within and around peritoneal endometriotic lesions, likely in an attempt to attack the 
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lesion but their released products may in fact promote processes such as angiogenesis and 
fibrosis and thereby promote lesion growth and persistence. The results suggest that the 
numbers and function of immune cells are altered at some point in endometriosis to allow 
further lesion growth and persistence through their released products. In addition, functional 
interactions between different immune cell populations might suggest cooperation between 
these cells in order to promote the development of lesions. 
 
6.2  Immune Environment within Peritoneal Endometriotic Lesions 
This study has shown that all the immune cell populations studied were present in the stroma 
of peritoneal endometriotic lesions. These cells include dendritic cells, T cells, B cells and 
macrophages. CD8+ T cells, Foxp3+ T cells and CD68+ macrophages were significantly 
higher in density within lesions compared to the surrounding tissue. In addition, there was a 
correlation between the densities of some of these immune cell types, indicating possible 
functional relationships and interactions within lesion stroma. These cells may be recruited to 
stroma in an attempt to clear the lesion, however, actually promote the growth and 
persistence of peritoneal endometriotic lesions through their released products. 
 
For the first time, this study has shown the presence of DC-Sign+ immature and DC-Lamp+ 
mature dendritic cells in the stroma of peritoneal endometriotic lesions. These dendritic cells 
were observed at low density and they were not present in all lesion sections. A previous 
study has also confirmed the presence of CD1a+ immature and CD83+ mature dendritic cells 
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in peritoneal endometriotic lesions and that these cells were not detected at all in normal 
peritoneum of women without endometriosis (Schulke et al., 2009). DC-SIGN+ cells 
regulate adhesion processes, such as DC trafficking and T-cell synapse formation, as well as 
antigen capture (Geijtenbeek et al., 2000, Teunis et al., 2002). DC-LAMP+ cells function in 
the processing and presentation of antigens by transferring of peptide-MHC class II 
molecules to the surface of DC (de Saint-Vis et al., 1998). Thus, dendritic cells might be 
recruited to endometriotic lesions in order to initiate an immune response and subsequent 
clearance of ectopic antigens. However, these cells may influence other leucocyte 
populations through their released cytokines and chemokines (such as IL-6, IL-10, IL-12, 
TNF-α, RANTES and MCP-1), which also promote lesion growth (Nagorsen et al., 2004). 
Supporting this, immature dendritic cells were found to infiltrate peritoneal lesions and to 
encourage angiogenesis and lesion growth a murine model (Fainaru et al., 2008).  
 
Alterations in DC populations may directly contribute aberrant T cell function in women 
with endometriosis (Schulke et al., 2009). Similarly, a positive correlation was observed 
between DC-Sign+ immature dendritic cells and CD4+ helper T cell densities in the stroma 
of peritoneal endometriotic lesions. This might be because of the fact that DC-Sign+ cells 
present antigens to CD4+ T cells to initiate an immune response (Garcia-Vallejo et al., 2013). 
CD4+ T cells produce Th1 and Th2 cytokines (such as IL-2, IL-12, interferon-γ and TNF-α; 
and IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13; respectively), which potentially promote 
endometriotic lesion growth in endometriosis. Interestingly, decreased Th1 and increased 
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Th2 cytokine levels; indicating a switch to the Th2 immune response which implies 
endometriosis pathogenesis through the activating cell mediated immunity in the peritoneal 
cavity, were observed in the peritoneal fluid of women with endometriosis (Giudice and Kao, 
2004). Therefore correlated DC-Sign+ and CD4+ populations in peritoneal endometriotic 
lesions potentially promote endometriotic lesion growth and pathogenesis by secretion of 
cytokines and growth factors (Halis and Arici, 2004). Even though DC-Sign+ cells initially 
might be attacking the lesion stroma to inhibit lesion growth, their altered cytokine 
production and by activated T cells may actually promote survival of shed fragments and 
endometriotic lesion development. 
 
This study has shown increased density of CD8+ cytotoxic T cells in stroma of lesions 
compared to surrounding tissue. This study has also detected a relationship (positive 
correlation) between CD8+ and CD4+ T cell densities in lesion stroma. It has been 
previously found that both CD8+ and CD4+ T cells are increased, and the CD4:CD8 ratio 
decreased in peritoneal endometriotic lesions (compared to normal peritoneum and eutopic 
endometrium) and the peritoneal fluid of women with endometriosis (Witz et al., 1994, Oral 
et al., 1996, Jones et al., 1998, Paul Dmowski and Braun, 2004, Seeley et al., 2005, 
Ganewatta et al., 2010). CD8+ T cells are cytotoxic killer cells, which directly destroy 
abnormal cells, while CD4+ are helper T cells, which transmit signals from antigen 
presenting cells to stimulate the immune system (Andersen et al., 2006, Waisman and 
Becher, 2014). There is evidence that activated CD8+ T cells can stimulate CD4+ T cells by 
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direct interaction and that CD4+ cells help in primary responses by CD8+ T cells (Castellino 
and Germain, 2006). Therefore, CD8+ T cells and functional interactions of CD8+ T cells 
with CD4+ T cells might support endometriotic lesion growth (although these cells are likely 
recruited to lesion stroma to attack the abnormal cells and inhibit the lesion growth).  
 
The current study found increased density of FoxP3+ regulatory T cells in the stroma of 
peritoneal endometriotic lesions compared to surrounding tissue, similar to a previous study 
(Berbic et al., 2010). FoxP3+ regulatory T cells control and suppress a range of immune 
responses (Fehervari and Sakaguchi, 2004), including T cell, dendritic cell, B cell, 
macrophage and natural killer cell proliferation and cytokine release (Thornton, 2005, 
Sakaguchi et al., 2008, Giatromanolaki et al., 2008, Nandakumar et al., 2009). Therefore, 
Foxp3+ T cells might be recruited to lesion stroma in an attempt to control the locally 
recruited immune cells and inflammation. 
 
This study has for the first time shown higher density of macrophages within the stroma of 
peritoneal endometriotic lesions in comparison to the surrounding tissue. Previous studies 
have shown an increase in the numbers of macrophages in peritoneal endometriotic lesions 
compared to normal peritoneum and eutopic endometrium (Oosterlynck et al., 1993a, Khan 
et al., 2004a, Khan et al., 2004b, Berbic et al., 2009, Tran et al., 2009). Since macrophages 
generally act as scavengers of the body, they are thought to be recruited to endometriotic 
lesions to phagocytose the ectopic tissue. However, they can secrete cytokines and growth 
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factors such as IL-6, IL-8, IL-10 and TNF-α; and a number of angiogenic factors, including 
fibroblast growth factor, angiogenin and VEGF (Sunderkötter et al., 1994, McLaren et al., 
1996b); which stimulate the growth and persistence of endometriotic lesions (Iwabe et al., 
2000, Sokolov et al., 2005, Velasco et al., 2006, Birt et al., 2013, Lin et al., 2006).  
 
A positive correlation was detected between the density of CD68+ macrophages and CD4+ T 
cells in this study. T helper cells help activate macrophages at the sites of infection and both 
T helper cells and macrophages are known to produce a range of cytokines and growth 
factors which facilitate the development of endometriotic lesions in endometriosis (Telser, 
2002, Lin et al., 2006). Therefore, the increased numbers of macrophages and the positive 
correlation with CD4+ T cells within stroma may stimulate the growth of peritoneal 
endometriotic lesions.  
 
In conclusion, this study suggests that immune cells are recruited to the stroma in an attempt 
to clear peritoneal endometriotic lesions. However, their presence may in fact promote lesion 
growth due to the factors they are known to produce. Other factors are also involved in 
endometriotic lesion pathogenesis, including the surrounding sub-peritoneal tissue.  
 
6.3  Immune Environment around Peritoneal Endometriotic Lesions 
This study also examined the presence of all studied immune cells in the sub-peritoneal tissue 
immediately surrounding peritoneal endometriotic lesions. Many of these particular cell 
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types had not specifically been studied around peritoneal endometriotic lesions previously, 
including dendritic cells, CD4+ T cells, B cells and macrophages. The densities of DC-Sign+ 
immature dendritic cells, CD4+ helper T cells and CD20+ B cell populations were higher in 
the tissue surrounding peritoneal endometriotic lesions compared to lesion stroma. The 
densities of a number of immune cell populations in the surrounding tissue were also 
significantly correlated with each other, suggesting local interactions between these cells. 
Another interesting observation of the study was the immune cell aggregates, containing 
CD4+ and CD8+ T cells and CD20+ B cells, in the tissue surrounding lesions in around a 
third of samples. These immune cells might promote tissue fibrosis and lesion persistence 
through their released products in surrounding tissue, even though they may initially 
recruited the area to suppress the lesion growth. 
 
There is evidence that peritoneal endometriotic lesions are surrounded by thickened fibrotic 
areas made up smooth muscle metaplasia which is innervated and quite different compared to 
normal peritoneum (Anaf et al., 2000, Konno et al., 2003, Giudice and Kao, 2004, Odagiri et 
al., 2009). During the development and progression of endometriotic lesions, tissue fibrosis 
may lead to scarring, altered tissue function and contribute to chronic pain (Nisolle and 
Donnez, 1997, Matsuzaki et al., 1999). Inflammatory cells such as macrophages, fibroblasts 
and lymphocytes have an important role in generating fibrotic tissue via production of 
fibrogenic cytokines (Kisseleva and Brenner, 2008, Higashi-Kuwata et al., 2009, Prokop et 
al., 2011). 
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DC-Sign+ and DC-Lamp+ dendritic cells were observed for the first time in the tissue 
surrounding peritoneal endometriotic lesions. Additionally, the density of DC-Sign+ 
immature dendritic cells was higher in surrounding tissue compared to lesion stroma. 
Conversely, a previous study showed increased numbers of CD1a+ immature dendritic cells 
in stroma of peritoneal endometriotic lesions compared to surrounding tissue (Schulke et al., 
2009). These apparently differing results may be because of the markers used. DC-Sign+ 
immature dendritic cells mediate MHC-II dependent antigen presentation pathways, have 
adhesion receptors and play important roles in inflammation and T cell activation (Teunis et 
al., 2002, Zhou et al., 2006). By contrast, CD1a is a cell surface glycoprotein that is 
structurally related to the MHC molecules and mediates MHC-independent antigen 
presentation pathways (Krenács et al., 1993). This study has also detected the presence of 
DC-Lamp+ dendritic cells in low numbers in lesion surrounding tissue. These cells may be 
important in tissue surrounding peritoneal endometriotic lesions to recognise and target 
ectopic “endometrial” cells and initiate appropriate immunological responses. 
 
Positive correlations were observed between the densities of DC-Sign+ dendritic cells with 
CD4+ T cells (similar to stroma) and also both DC-Sign+ and DC-Lamp+ dendritic cells 
with CD68+ macrophages in lesion surrounding tissue. Macrophages appear to be able 
mediate the inflammatory potential of dendritic cells (Pulendran et al., 2007) and 
additionally, interactions of these cells can promote an acute cytokine response (Zhang et al., 
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2001). Therefore, since their released products are known to promote lesion growth and 
persistence, these functionally related cells in lesion surrounding tissue may contribute to the 
development of peritoneal endometriotic lesions. 
 
This study has for the first time found increased CD4+ T cell density in surrounding tissue 
compared to stroma of peritoneal endometriotic lesions. Through chemotaxis, CD4+ T cells 
are recruited to sites of inflammation where they promote secretion of fibrogenic cytokines 
(for example, TGF-β1, PDGF, IL-1, IL-4, IL-5, IL-10, and IL-13) (Kisseleva and Brenner, 
2008, Wynn, 2004) and can activate fibroblasts to produce collagen (Wynn, 2004), ultimately 
resulting in tissue scarring. CD4+ T cell density was correlated with Foxp3+ regulatory T 
cell density but given Foxp3 is be expressed in a sub-set of CD4+ T cells (Hori et al., 2003), 
this correlation is unsurprising. In addition, there were correlations between the densities of 
both CD4+ and CD8+ T cells with CD68+ macrophages. Macrophages are activated by 
CD4+ T cell-derived cytokines to release mediators that induce the proliferation of 
fibroblasts and the synthesis of collagen (Wynn, 2004, Laskin et al., 2011). In addition, an 
increase in the number of activated macrophages has been observed in fibrotic diseases 
(Higashi-Kuwata et al., 2009, Prokop et al., 2011) indicating that these cells themselves are a 
potential source of fibrogenic cytokines. Therefore, these cells with functional correlations 
might contribute to the development of fibrotic tissue surrounding peritoneal endometriotic 
lesions.  
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For the first time, this study has detected an increase in the density of CD20+ B cells in 
surrounding tissue of peritoneal endometriotic lesions compared to lesion stroma. Since B 
cells enhance T cell activity in immune responses (Nelson, 2010), promote the survival and 
proliferation of activated CD8+ T cells (Deola et al., 2008), and function together with CD8+ 
T cells to promote the survival of tumours (Qin et al., 1998); increased density of CD20+ B 
cells might be associated with increased numbers of T cells (with the capacity to produce 
fibrogenic cytokines) in lesion surrounding tissue. Supporting this, correlations between the 
densities of CD20+ B cells with CD4+ and CD8+ T cell densities were observed in lesion 
surrounding tissue. There was also a correlation between CD20+ B cell and DC-Sign+ 
immature dendritic cell densities in lesion surrounding tissue. It has previously been shown 
that dendritic cells signal to naive B cells to initiate antigen-specific antibody responses 
(Wykes and Macpherson, 2000). Therefore, increased numbers of CD20+ B cells in 
surrounding tissue might reflect specific immune responses against the adjacent lesions but 
ultimately promote fibrosis and the persistence of peritoneal endometriotic lesions along with 
T cells. 
 
This study has for the first time detected lymphoid aggregates in tissue surrounding 
peritoneal endometriotic lesions. The aggregates were observed to contain CD4+ and CD8+ 
T cells and CD20+ B cells. Previous studies have shown T and B cell aggregates in uterine 
endometrium, and that these aggregates were small or absent during the early proliferative 
phase, significantly larger at mid cycle and during the secretory phase but absent in post-
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menopausal women (Yeaman et al., 1997, Marshall and Jones, 1988). Therefore, it was 
suggested that the development of endometrial aggregates is hormonally influenced and that 
they develop during the menstrual cycle largely by trafficking of cells to the endometrium 
(Yeaman et al., 1997). At this stage what immune cell aggregates are doing in the tissue 
surrounding peritoneal endometriotic lesions is unclear; however, they might be trafficking to 
the tissue surrounding lesion in attempt to attack the adjacent lesions, but promote fibrosis 
and persistence of peritoneal endometriotic lesions via their released products. 
 
In conclusion, immune cell populations present in tissue surrounding peritoneal 
endometriotic lesions, some with higher density than within the lesion stroma, likely 
contribute to lesion persistence and function. Although these cells may initially be recruited 
to attack the adjacent lesions, their released fibrogenic products promote tissue fibrosis and 
scarring and may ultimately facilitate lesion persistence.  
 
6.4  Immune Environment in Different Lesion Appearances 
Contrary to what was hypothesised, none of the immune cell populations studied differed 
significantly in density between the three peritoneal endometriotic lesion appearances (red, 
black and white) either in the stroma or surrounding tissue. As outlined in the literature 
review, different macroscopic appearances of lesions reflect different stages in development 
(Jansen and Russell, 1986, Redwine, 1987). Red lesions represent early stages, followed by 
black and then white peritoneal endometriotic lesion appearances due to progressive scarring 
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(Bloom, 1978, Dan, 1990). Previous studies have shown great variations in the densities of 
immune cell populations in peritoneal endometriotic lesions, as has the current study. It was 
hypothesised that these variations might be related to the stage of the lesion development, 
with higher density in red lesions than black and white lesions and higher density in black 
lesions compared to white lesions. 
 
While lesion appearances were not found to be linked to immune cell densities in and around 
lesions, great variations in density were observed between lesion samples. At this stage, it is 
unknown what these variations in immune environment are due to. Other possible reasons for 
these variations include individual differences, menstrual cycle phase effects and impact of 
hormonal treatment. It was examined whether there was a correlation between participant age 
and immune cell densities (data not reported) but there was no evidence that age was linked 
to variations in densities.  
 
Immune related parameters vary between individuals. Many individual-related factors are 
known to effect immune cell populations within the body, including stress and depression. 
Psychological stress has been associated with suppressed cellular immune function in some, 
but not all, individuals; and CD8+ cytotoxic T cells were found to be increased in circulation, 
after exposure to stress (Manuck et al., 1991). Previous studies have also suggested that 
depression is associated with immune changes such as increased release of peripheral 
cytokines (Hodes et al., 2014). Currently, there is also accumulating evidence suggesting that 
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genetic variants are associated with how the innate immune response and cytokines vary 
across individuals (Lee et al., 2014, Ferraro et al., 2014). These factors likely contribute to 
and may explain the immune variations between lesions. 
 
Menstrual cycle phase could also account for the immune variations observed. Endometrial 
leukocytes are known to undergo significant changes through the menstrual cycle and have 
important roles in menstruation, endometrial remodelling, implantation and decidualisation 
(Salamonsen and Lathbury, 2000, Salamonsen et al., 2002). While endometriotic lesions do 
not show exactly the same cyclical changes as the eutopic endometrium, they are hormonally 
responsive (Berbic et al., 2010, Schulke et al., 2009). There is no strong evidence for major 
changes in immune cell densities within endometriotic lesions during the cycle; however, 
there may be subtle cyclical changes in immune cell populations such as CD1a+ immature 
dendritic cells (Schulke et al., 2009). At this stage, it cannot be excluded that the menstrual 
cycle phase of women included in this study may be associated with the variations in lesion 
immune cell populations. This was not considered in analyses, as accurate menstrual cycle 
dating was not available for all participants. Participants were asked about their last 
menstrual period (LMP) date but LMP self-reports are known to be unreliable because of 
errors of recall and inaccuracies for determining menstrual cycle phase (Waller et al., 2000, 
Wegienka and Baird, 2005, Wideman et al., 2013). Unfortunately endometrium and/or blood 
samples were not available for all participants to confirm cycle dating, as their collection is 
not part of routine endometriosis surgery at Royal Prince Alfred Hospital. 
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Furthermore, hormonal treatment could be another contributor to variations of density of 
immune cells in peritoneal endometriotic lesions. Initially it was planned that only women 
not on hormonal treatment be eligible for inclusion in the study; however, in order to be able 
to recruit sufficient numbers within the limited time frame, a small sub-group of participants 
on oral contraception was included. Hormonal treatment is commonly used for management 
of endometriosis-associated symptoms (Crosignani et al., 2006). Very few participants were 
on hormonal treatment in this study (oral contraception pill n= 4; 2 red, 1 black and 1 white 
lesion). It is unknown whether or how oral contraceptive pills affect the immune system, 
however the 4 samples from participants on oral contraception did not show any obvious 
differences in immune cell densities in and around lesions compared to the rest of the cohort.  
 
It is also possible that sample number limitations meant that the study was not able to 
demonstrate links between lesion appearance and immune environment in and around 
peritoneal endometriosis lesions. Due to time limitations in this prospective study, only a 
moderate number of samples were able to be collected. Initially, the total number of samples 
recruited was 61 but then some of the samples were excluded because of reasons such as 
combined colour appearances or lesion unable to be located within the paraffin tissue block. 
Even though statistical analysis has shown no significant relationships between lesion 
appearance and the density of immune cell populations, there appear to be some patterns in 
lesions of different appearances. For example, density of a range of populations such as DC-
Sign+, CD4+ and CD8+ cells appeared to be higher in white lesions. It may be that with 
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greater sample numbers, significant differences between lesion appearances would be 
demonstrated.  
 
6.5  Summary and Perspective 
Altered immune responses in endometriosis are thought to play fundamental roles in 
establishment and progression of peritoneal lesions. The findings from this thesis have 
implications for understanding of endometriosis pathogenesis, particularly peritoneal lesion 
development, and also potentially for future treatment approaches. The presence of all 
studied immune cell populations and increased densities of these cells in around peritoneal 
endometriotic lesions suggest that they may be recruited to lesion sites in an attempt to attack 
the ‘foreign’ ectopic tissue. However, through their released products, specifically cytokines 
and growth factors, they may in fact support lesion development and persistence. This may 
particularly be via promotion of fibrosis by immune cells in tissue surrounding peritoneal 
lesions, which this study has considered for largely the first time.  
 
While there was high variation in studied cell densities between samples, there did not appear 
to be a relationship between the densities of immune cell populations in and around 
peritoneal endometriotic lesions and lesion appearances (stage of development). In fact, 
endometriosis is known to be a complex and highly variable disease in terms of the age of 
symptom onset, the delay to diagnosis, types of symptoms, the anatomical sites of ectopic 
lesions and response to treatment (Olive et al., 2004, Fraser, 2010a). This study further 
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supports complexity and variability in endometriosis. Thus, although exactly how these cells 
promote lesion growth and why there are variations between the densities of immune cells 
are still unclear, this study has provided clues for better understanding of the immune 
environment in and around peritoneal endometriotic lesions.  
 
Individualised treatment approaches may provide more effective management of 
endometriosis due to the complexity and high variability of the disease (Olive et al., 2004). 
Current management for endometriosis generally includes medical (analgesic and hormonal 
suppression) and/or surgical approaches (Fraser, 2008). Individualised treatment for 
endometriosis should be tailored according to the desired treatment outcome, whether it is 
relief of pain, improvement of fertility, or the prevention of recurrence (Özkan and Arici, 
2009).  
 
Some current medical modalities for endometriosis may have immune-related effects, with 
danazol and GnRH-analogues suggested to suppress the ability of peritoneal immune cells to 
secrete inflammatory cytokines, regulating endometriotic lesion growth and establishment 
(Nothnick, 2001). Further to this, the current study provides a better understanding of the 
immune environment in and around peritoneal endometriotic lesions and may contribute to 
the basis for development of immune-targeted treatment options. For instance, treatments 
based on anti-cytokine antibodies or cytokine-receptor antagonists such as TNF-α inhibitors, 
angiogenesis inhibitors and matrix metalloproteinase inhibitors, which may be effective by 
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targeting specific immune cells altered in peritoneal endometriosis (Olive et al., 2004, 
Bedaiwy and Falcone, 2004). One such example is human TNF binding protein-I which 
inhibits the production of TNF-α by macrophages and has been shown to significantly reduce 
endometriosis in a baboons model (D’Hooghe et al., 2001b).  
 
While this study has provided new insights into the immune environment in and around 
peritoneal endometriosis lesions, the work does have some challenges and limitations in 
terms of sample collection and technical components. Firstly, as discussed in section 6.4, 
there was difficulty recruiting the desired numbers of suitable participants within the time 
frame. Obtaining suitable samples, which were lesions of only one appearance, was another 
difficulty as lesions can also have mixed appearances such as red-black and black-white or 
even red-black-white (Redwine, 1987, Dan, 1990). 
 
Another challenge was demonstrating natural killer (NK) cells in peritoneal endometriotic 
lesions. Initially, the study included characterisation of 8 different immune cells, including 
NK cells. However, even though extensive optimisation was performed; such as use of 
different antibodies (CD56 [clone 123C3] and CD57 [clone TB01], Dako, Glostrup, 
Denmark), different retrieval methods (pH 6 and pH 9, retrieval time 20-30 minutes) and a 
range of dilutions (between 1:50 and 1:400, with and without the addition of an amplifying 
link); unfortunately staining was unsatisfactory with strong detection of nerve fibres but very 
weak labelling of NK cells. This staining pattern is known to be associated with NK cell 
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markers (Giuliani et al., 2014). Thus, staining for NK cells had to be abandoned because of 
the limited time for this study. 
 
6.6  Conclusions 
In response to the hypotheses and aims, the specific conclusions of this study are: 
 Variations in immune cell environment in and around peritoneal endometriotic 
lesions are not associated with lesion appearance (the stage of lesion development) 
o There are no statistically significant differences between immune cell 
densities in and around peritoneal endometriotic lesions of red compared to 
black compared to white appearances. 
 The densities of CD8+ T cells, Foxp3+ T cells and CD68+ macrophages are 
significantly higher in the stroma of peritoneal endometriotic lesions compared to the 
surrounding tissue (p=0.014, df=31, t=2.60, p=0.035, U z=2.213, p=0.012, U z-2.499, 
respectively). 
 The densities of DC-Sign dendritic cells and CD20+ B cells are significantly higher 
in the tissue surrounding peritoneal endometriotic lesions compared to the stroma 
(p<0.001, U z=3.903, p=0.033, U z=2.129, respectively). 
 The density of CD4+ T cells was increased in the tissue surrounding peritoneal 
endometriotic lesions compared to stroma, however there was no statistically 
significant difference. 
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6.7  Future Directions 
The results obtained in this study provide interesting insights into the immune environment 
in and around peritoneal endometriotic lesions. However, there are many aspects of lesion 
development and immunology that are not yet understood. Key questions that should be 
addressed in future studies of immune involvement in peritoneal endometriotic lesion 
establishment include the following: 
 Further investigating immune cell densities in and around peritoneal endometriotic 
lesions in a larger cohort of well characterised participants and samples, documenting 
factors such as  
o lesion appearance and location 
o the phase of the menstrual cycle (by eutopic endometrial dating) 
o endometriosis history (including symptoms and previous surgeries) 
o hormonal and other treatment status 
o personal situation including current stress, depression.  
 Functional studies of individual immune cell populations in and around peritoneal 
endometriotic lesions, including production of fibrotic and other cytokines. 
 Investigating the functional interactions between different immune cell populations in 
stroma and tissue surrounding peritoneal endometriotic lesions to understand their 
cooperation in promoting lesion growth.  
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 Determining if the peritoneal lesion stroma and fibrotic surrounding tissue themselves 
release cytokines and growth factors to aid lesion progression and how these factors 
interact with the recruited immune cells. 
 Examination of immune environment in and around other lesion types (ovarian and 
deep infiltrating). 
 Using in vitro and animal models to develop more specific and appropriate immune 
based treatment approaches.  
  
 112 
 
References 
 
ACOSTA, A. A., BUTTRAM, J. V. C., BESCH, P. K., MALINAK, L. R., FRANKLIN, R. 
R. & VANDERHEYDEN, J. D. 1973. A proposed classification of pelvic endometriosis. 
Obstetrics and Gynecology, 42, 19-25. 
ADAMSON, G. D. & PASTA, D. J. 2010. Endometriosis fertility index: The new, validated 
endometriosis staging system. Fertility and Sterility, 94, 1609-1615. 
AGIC, A., DJALALI, S., DIEDRICH, K. & HORNUNG, D. 2009. Apoptosis in 
endometriosis. Gynecologic and Obstetric Investigation, 68, 217-223. 
AL-JEFOUT, M., ANDREADIS, N., TOKUSHIGE, N., MARKHAM, R. & FRASER, I. 
2007. A pilot study to evaluate the relative efficacy of endometrial biopsy and full curettage 
in making a diagnosis of endometriosis by the detection of endometrial nerve fibers. 
American Journal of Obstetrics and Gynecology, 197, 578.e1-578.e4. 
AL-JEFOUT, M., DEZARNAULDS, G., COOPER, M., TOKUSHIGE, N., LUSCOMBE, G. 
M., MARKHAM, R. & FRASER, I. S. 2009. Diagnosis of endometriosis by detection of 
nerve fibres in an endometrial biopsy: A double blind study. Human Reproduction, 24, 3019-
3024. 
ALBEE, R. B., JR., SINERVO, K. & FISHER, D. T. 2008. Laparoscopic excision of lesions 
suggestive of endometriosis or otherwise atypical in appearance: Relationship between visual 
findings and final histologic diagnosis. Journal of Minimally Invasive Gynecology, 15, 32-7. 
AMER, S. 2008. Endometriosis. Obstetrics, Gynaecology & Reproductive Medicine, 18, 
126-133. 
ANAF, V., CHAPRON, C., EL NAKADI, I., DE MOOR, V., SIMONART, T. & NOËL, J.-
C. 2006. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating 
endometriosis. Fertility and Sterility, 86, 1336-1343. 
ANAF, V., SIMON, P., EL NAKADI, I., FAYT, I., BUXANT, F., SIMONART, T., PENY, 
M. O. & NOEL, J. C. 2000. Relationship between endometriotic foci and nerves in 
rectovaginal endometriotic nodules. Human Reproduction, 15, 1744-1750. 
ANAF, V., SIMON, P., EL NAKADI, I., FAYT, I., SIMONART, T., BUXANT, F. & 
NOEL, J. C. 2002. Hyperalgesia, nerve infiltration and nerve growth factor expression in 
deep adenomyotic nodules, peritoneal and ovarian endometriosis. Human Reproduction, 17, 
1895-1900. 
 113 
 
ANDERSEN, M. H., SCHRAMA, D., THOR STRATEN, P. & BECKER, J. C. 2006. 
Cytotoxic t cells. Journal of Investigative Dermatology, 126, 32-41. 
ANNA-SOFIA, M., CECILIA, L., NINOA, M., MARJA-LIISA, S., PÄR, S. & AGNETA, 
B. 2013. Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian 
cancer. Acta Obstetricia Et Gynecologica Scandinavica, 92, 546. 
ANTSIFEROVA, Y. S., SOTNIKOVA, N. Y., POSISEEVA, L. V. & SHOR, A. L. 2005. 
Changes in the t-helper cytokine profile and in lymphocyte activation at the systemic and 
local levels in women with endometriosis. Fertility and Sterility, 84, 1705-1711. 
ARICI, A. 2002. Local cytokines in endometrial tissue: The role of interleukin‐8 in the 
pathogenesis of endometriosis. Annals of the New York Academy of Sciences, 955, 101-109. 
ARICI, A., ORAL, E., ATTAR, E., TAZUKE, S. I. & OLIVE, D. L. 1997. Monocyte 
chemotactic protein-1 concentration in peritoneal fluid of women with endometriosis and its 
modulation of expression in mesothelial cells. Fertility and Sterility, 67, 1065-72. 
ARICI, A., ORAL, E., BUKULMEZ, O., DULEBA, A., OLIVE, D. L. & JONES, E. E. 
1996. The effect of endometriosis on implantation: Results from the yale university in vitro 
fertilization and embryo transfer program. Fertility and Sterility, 65, 603-7. 
ASRM 1997. Classification of endometriosis: 1996. Fertility and Sterility, 67, 817-821. 
AYERS, J. W. 1982. Hormonal therapy for tubal occlusion: Danazol and tubal 
endometriosis. Fertility and Sterility, 38, 748-50. 
BADAWY, S. Z., CUENCA, V., STITZEL, A., JACOBS, R. D. & TOMAR, R. H. 1984. 
Autoimmune phenomena in infertile patients with endometriosis. Obstetrics and Gynecology, 
63, 271-5. 
BADAWY, S. Z., CUENCA, V., STITZEL, A. & TICE, D. 1987. Immune rosettes of t and b 
lymphocytes in infertile women with endometriosis. Journal of Reproductive Medicine, 32, 
194-7. 
BALLARD, K., LOWTON, K. & WRIGHT, J. 2006. What's the delay? A qualitative study 
of women's experiences of reaching a diagnosis of endometriosis. Fertility and Sterility, 86, 
1296-1301. 
BALLARD, K. D., SEAMAN, H. E., DE VRIES, C. S. & WRIGHT, J. T. 2008. Can 
symptomatology help in the diagnosis of endometriosis? Findings from a national case-
control study--part 1. Bjog: An International Journal of Obstetrics & Gynaecology, 115, 
1382-91. 
 114 
 
BANCHEREAU, J. & STEINMAN, R. M. 1998. Dendritic cells and the control of 
immunity. Nature, 392, 245-252. 
BANERJEE, S., BALLARD, K. D., LOVELL, D. P. & WRIGHT, J. 2006. Deep and 
superficial endometriotic disease: The response to radical laparoscopic excision in the 
treatment of chronic pelvic pain. Gynecological Surgery, 3, 199-205. 
BECKER, J. C., DUMMER, R., HARTMANN, A. A., BURG, G. & SCHMIDT, R. E. 1991. 
Shedding of icam-1 from human melanoma cell lines induced by ifn-gamma and tumor 
necrosis factor-alpha. Functional consequences on cell- mediated cytotoxicity. The Journal of 
Immunology, 147, 4398. 
BECKER, J. C., TERMEER, C., SCHMIDT, R. E. & BROCKER, E. B. 1993. Soluble 
intercellular adhesion molecule-1 inhibits mhc-restricted specific t cell/tumor interaction. The 
Journal of Immunology, 151, 7224. 
BEDAIWY, M. A. & FALCONE, T. 2003. Peritoneal fluid environment in endometriosis. 
Minerva Ginecologica, 55, 45-333. 
BEDAIWY, M. A. & FALCONE, T. 2004. Laboratory testing for endometriosis. 
Netherlands: Elsevier B.V. 
BEDAIWY, M. A., FALCONE, T., SHARMA, R. K., GOLDBERG, J. M., ATTARAN, M., 
NELSON, D. R. & AGARWAL, A. 2002. Prediction of endometriosis with serum and 
peritoneal fluid markers: A prospective controlled trial. Human Reproduction, 17, 426-31. 
BERBIC, M., HEY-CUNNINGHAM, A. J., NG, C., TOKUSHIGE, N., GANEWATTA, S., 
MARKHAM, R., RUSSELL, P. & FRASER, I. S. 2010. The role of foxp3+ regulatory t-cells 
in endometriosis: A potential controlling mechanism for a complex, chronic immunological 
condition. Human Reproduction, 25, 900-907. 
BERBIC, M., SCHULKE, L., MARKHAM, R., TOKUSHIGE, N., RUSSELL, P. & 
FRASER, I. S. 2009. Macrophage expression in endometrium of women with and without 
endometriosis. Human Reproduction, 24, 325-332. 
BERKLEY, K. J., DMITRIEVA, N., CURTIS, K. S., PAPKA, R. E. & BARTOSHUK, L. 
M. 2004. Innervation of ectopic endometrium in a rat model of endometriosis. Proceedings 
of the National Academy of Sciences of the United States of America, 101, 11094-11098. 
BIRT, J. A., NABLI, H., STILLEY, J. A., WINDHAM, E. A., FRAZIER, S. R. & SHARPE-
TIMMS, K. L. 2013. Elevated peritoneal fluid tnf-α incites ovarian early growth response 
factor 1 expression and downstream protease mediators: A correlation with ovulatory 
dysfunction in endometriosis. Reproductive Sciences, 20, 514-523. 
 115 
 
BLOOM, W. F., DN. (ed.) 1978. A textbook of histology. 
BOENISCH, T. 2001. Formalin-fixed and heat-retrieved tissue antigens: A comparison of 
their immunoreactivity in experimental antibody diluents. Appl Immunohistochem Mol 
Morphol, 9, 176-9. 
BOKOR, A., KYAMA, C. M., VERCRUYSSE, L., FASSBENDER, A., GEVAERT, O., 
VODOLAZKAIA, A., DE MOOR, B., FÜLÖP, V. & D'HOOGHE, T. 2009. Density of 
small diameter sensory nerve fibres in endometrium: A semi-invasive diagnostic test for 
minimal to mild endometriosis. Human Reproduction, 24, 3025-3032. 
BOURLEV, V., VOLKOV, N., PAVLOVITCH, S., LETS, N., LARSSON, A. & 
OLOVSSON, M. 2006. The relationship between microvessel density, proliferative activity 
and expression of vascular endothelial growth factor-a and its receptors in eutopic 
endometrium and endometriotic lesions. Reproduction, 132, 501-9. 
BROOKS, P. C., KLEMKE, R. L., SCHÖN, S., LEWIS, J. M., SCHWARTZ, M. A. & 
CHERESH, D. A. 1997. Insulin-like growth factor receptor cooperates with integrin αvβ5 to 
promote tumor cell dissemination in vivo. Journal of Clinical Investigation, 99, 1390-1398. 
BROOKS, P. C., STRÖMBLAD, S., SANDERS, L. C., VON SCHALSCHA, T. L., AIMES, 
R. T., STETLER-STEVENSON, W. G., QUIGLEY, J. P. & CHERESH, D. A. 1996. 
Localization of matrix metalloproteinase mmp-2 to the surface of invasive cells by 
interaction with integrin alpha v beta 3. Cell, 85, 683. 
BROSENS, I., PUTTEMANS, P. & DEPREST, J. 1993. Appearances of endometriosis. 
Bailliere's Clinical Obstetrics and Gynaecology, 7, 741-757. 
BROSENS, I. A. 1997. Endometriosis--a disease because it is characterized by bleeding. 
American Journal of Obstetrics & Gynecology, 176, 263-7. 
BROWN, J., PAN, A. & HART, R. J. 2010. Gonadotrophin-releasing hormone analogues for 
pain associated with endometriosis. The Cochrane Database of Systematic Reviews, 
CD008475. 
BRUNER, K. L., MATRISIAN, L. M., RODGERS, W. H., GORSTEIN, F. & OSTEEN, K. 
G. 1997. Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions 
by human endometrium in nude mice. The Journal of Clinical Investigation, 99, 2851-2857. 
BUCHWALOW, I. B. & EBRARY, I. 2010. Immunohistochemistry: Basics and methods, 
New York; Heidelberg, Springer. 
BURKMAN, R. T. 1991. Intrauterine devices. Current Opinion in Obstetrics and 
Gynecology, 3, 482-485. 
 116 
 
BURLEV, V. A., PAVLOVICH, S. V. & IL'YASOVA, N. A. 2006. Apoptosis and 
proliferative activity in endometrium during peritoneal endometriosis. Bulletin of 
Experimental Biology and Medicine, 141, 204-207. 
CAHILL, D. J., WARDLE, P. G., MAILE, L. A., HARLOW, C. R. & HULL, M. G. 1997. 
Ovarian dysfunction in endometriosis-associated and unexplained infertility. Journal of 
Assisted Reproduction and Genetics, 14, 554-557. 
CASTELLINO, F. & GERMAIN, R. N. 2006. Cooperation between cd4+ and cd8+ t cells: 
When, where, and how. Annual Review of Immunology, 24, 519-540. 
CATALANO, G. F., MARANA, R., CARUANA, P., MUZII, L. & MANCUSO, S. 1996. 
Laparoscopy versus microsurgery by laparotomy for excision of ovarian cysts in patients 
with moderate or severe endometriosis. Journal of the American Association of Gynecologic 
Laparoscopists, 3, 267-270. 
CHAMIE, L. P., BLASBALG, R., PEREIRA, R. M., WARMBRAND, G. & SERAFINI, P. 
C. 2011. Findings of pelvic endometriosis at transvaginal US, MR imaging, and laparoscopy. 
Radiographics, 31, E77-100. 
CHAPRON, C., BOUCHER, E., FAUCONNIER, A., VIEIRA, M., DUBUISSON, J.-B. & 
VACHER-LAVENU, M.-C. 2002. Anatomopathological lesions of bladder endometriosis 
are heterogeneous. Fertility and Sterility, 78, 740-742. 
CHUNG, H. W., LEE, J. Y., MOON, H.-S., HUR, S. E., PARK, M. H., WEN, Y. & POLAN, 
M. L. 2002. Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and 
tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. 
Fertility and Sterility, 78, 787-795. 
CHWALISZ, K., PEREZ, M. C., DEMANNO, D., WINKEL, C., SCHUBERT, G. & 
ELGER, W. 2005. Selective progesterone receptor modulator development and use in the 
treatment of leiomyomata and endometriosis. Endocrine Reviews, 26, 423-438. 
COHEN, T., NAHARI, D., CEREM, L. W., NEUFELD, G. & LEVI, B.-Z. 1996. Interleukin 
6 induces the expression of vascular endothelial growth factor. Journal of Biological 
Chemistry, 271, 736-741. 
COLLETTE, T., BELLEHUMEUR, C., KATS, R., MAHEUX, R., MAILLOUX, J., 
VILLENEUVE, M. & AKOUM, A. 2004. Evidence for an increased release of proteolytic 
activity by the eutopic endometrial tissue in women with endometriosis and for involvement 
of matrix metalloproteinase-9. Human Reproduction, 19, 1257-1264. 
CRAMER, D. W. & MISSMER, S. A. 2002. The epidemiology of endometriosis. Annals of 
the New York Academy of Sciences, 955, 11-22. 
 117 
 
CROSIGNANI, P., OLIVE, D., BERGQVIST, A. & LUCIANO, A. 2006. Advances in the 
management of endometriosis: An update for clinicians. Human Reproduction Update, 12, 
179-189. 
CULLEN, T. S. 1920. The distribution of adenomyomas containing uterine mucosa, United 
States  
D'HOOGHE, T. M., BAMBRA, C. S., RAEYMAEKERS, B. M., DE JONGE, I., 
LAUWERYNS, J. M. & KONINCKX, P. R. 1995. Intrapelvic injection of menstrual 
endometrium causes endometriosis in baboons (papio cynocephalus and papio anubis). 
American Journal of Obstetrics and Gynecology, 173, 125-134. 
D'HOOGHE, T. M., KYAMA, C. M., CHAI, D., FASSBENDER, A., VODOLAZKAIA, A., 
BOKOR, A. & MWENDA, J. M. 2009. Nonhuman primate models for translational research 
in endometriosis. Reproductive Sciences, 16, 152-161. 
D'HOOGHE, T. M., MIHALYI, A. M., SIMSA, P., KYAMA, C. K., PEERAER, K., DE 
LOECKER, P., MEEUWIS, L., SEGAL, L. & MEULEMAN, C. 2006. Why we need a 
noninvasive diagnostic test for minimal to mild endometriosis with a high sensitivity. 
Gynecologic and Obstetric Investigation, 62, 136-138. 
D’HOOGHE, T. M., BAMBRA, C. S., XIAO, L., PEIXE, K. & HILL, J. A. 2001a. Effect of 
menstruation and intrapelvic injection of endometrium on inflammatory parameters of 
peritoneal fluid in the baboon ( papio anubis and papio cynocephalus). American Journal of 
Obstetrics and Gynecology, 184, 917-925. 
D’HOOGHE, T. M., CUNEO, S., NUGENT, N., CHAI, D., DEER, F. & MWENDA, J. 
2001b. Recombinant human tnf binding protein-1 (r-htbp-1) inhibits the development of 
endometriosis in baboons: A prospective, randomized, placebo- and drug-controlled study. 
Fertility and Sterility, 76, S1-S1. 
DAN, C. M. 1990. Laparoscopic appearance of endometriosis. Color atlas. Memphis: 
Resurge Press. 
DANCET, E. A. F., APERS, S., KLUIVERS, K. B., KREMER, J. A. M., SERMEUS, W., 
DEVRIENDT, C., NELEN, W. L. D. M. & D'HOOGHE, T. M. 2012. The endocare 
questionnaire guides: European endometriosis clinics to improve the patient-centeredness of 
their care. Human Reproduction 27, 3168. 
DE SAINT-VIS, B., VINCENT, J., VANDENABEELE, S., VANBERVLIET, B., PIN, J. J., 
AÏT-YAHIA, S., PATEL, S., MATTEI, M. G., BANCHEREAU, J., ZURAWSKI, S., 
DAVOUST, J., CAUX, C. & LEBECQUE, S. 1998. A novel lysosome-associated membrane 
glycoprotein, dc-lamp, induced upon dc maturation, is transiently expressed in mhc class ii 
compartment. Immunity, 9, 325-336. 
 118 
 
DENNY, E. 2004. Women's experience of endometriosis. Journal of Advanced Nursing, 46, 
641-648. 
DEOLA, S., PANELLI, M. C., MARIC, D., SELLERI, S., DMITRIEVA, N. I., VOSS, C. 
Y., KLEIN, H., STRONCEK, D., WANG, E. & MARINCOLA, F. M. 2008. Helper b cells 
promote cytotoxic t cell survival and proliferation independently of antigen presentation 
through cd27/cd70 interactions. The Journal of Immunology, 180, 1362. 
DESANCHO, M. T. 2014. Risk of venous thrombosis varies with different types of 
combined oral contraceptives. Evidence-Based Medicine, 19, e11. 
DMOWSKI, W. P., DING, J., SHEN, J., RANA, N., FERNANDEZ, B. B. & BRAUN, D. P. 
2001. Apoptosis in endometrial glandular and stromal cells in women with and without 
endometriosis. Human Reproduction, 16, 1802-1808. 
DMOWSKI, W. P., GEBEL, H. & BRAUN, D. P. 1998. Decreased apoptosis and sensitivity 
to macrophage mediated cytolysis of endometrial cells in endometriosis. Human 
Reproduction Update, 4, 696-701. 
DMOWSKI, W. P., GEBEL, H. M. & BRAUN, D. P. 1994. The role of cell-mediated 
immunity in pathogenesis of endometriosis. Acta Obstetricia Et Gynecologica Scandinavica, 
Supplement, 73, 7-14. 
DONNEZ, J., NISOLLE, M., CASANAS-ROUX, F., BASSIL, S. & ANAF, V. 1995. 
Rectovaginal septum, endometriosis or adenomyosis: Laparoscopic management in a series 
of 231 patients. Human Reproduction, 10, 630-635. 
DONNEZ, J., NISOLLE, M., SMOES, P., GILLET, N., BEGUIN, S. & CASANAS-ROUX, 
F. 1996. Peritoneal endometriosis and "endometriotic" nodules of the rectovaginal septum 
are two different entities. Fertility and Sterility, 66, 362-8. 
DONNEZ, J., SMETS, M., JADOUL, P., PIRARD, C. & SQUIFFLET, J. 2003. 
Laparoscopic management of peritoneal endometriosis, endometriotic cysts, and rectovaginal 
adenomyosis. Annals of the New York Academy of Sciences, 997, 274-81. 
DONNEZ, J., SMOES, P., GILLEROT, S., CASANAS-ROUX, F. & NISOLLE, M. 1998. 
Vascular endothelial growth factor (vegf) in endometriosis. Human Reproduction, 13, 1686-
1690. 
DONNEZ, J. & THOMAS, K. 1982. Incidence of the luteinized unruptured follicle 
syndrome in fertile women and in women with endometriosis. European Journal of 
Obstetrics, Gynecology, and Reproductive Biology, 14, 187-190. 
 119 
 
DUNSELMAN, G. A., GROOTHUIS, P. G., DE GOEIJ, A. F. & EVERS, J. L. 2001. The 
mesothelium, teflon or velcro? Mesothelium in endometriosis pathogenesis. Human 
Reproduction, 16, 605-7. 
DUNSELMAN, G. A. J., NAP, A., PRENTICE, A., SARIDOGAN, E., SORIANO, D., 
NELEN, W., VERMEULEN, N., BECKER, C., CALHAZ-JORGE, C., D'HOOGHE, T., DE 
BIE, B., HEIKINHEIMO, O., HORNE, A. W. & KIESEL, L. 2014. Eshre guideline: 
Management of women with endometriosis. Human Reproduction, 29, 400. 
ESKENAZI, B. & WARNER, M. L. 1997. Epidemiology of endometriosis. Obstetrics and 
Gynecology Clinics of North America, 24, 235-258. 
FAINARU, O., ADINI, A., BENNY, O., ADINI, I., SHORT, S., BAZINET, L., NAKAI, K., 
PRAVDA, E., HORNSTEIN, M. D., D'AMATO, R. J. & FOLKMAN, J. 2008. Dendritic 
cells support angiogenesis and promote lesion growth in a murine model of endometriosis. 
Official Publication of the Federation of American Societies for Experimental Biology, 22, 
522-529. 
FAUCONNIER, A. & CHAPRON, C. 2005. Endometriosis and pelvic pain: Epidemiological 
evidence of the relationship and implications. Human Reproduction Update, 11, 595-606. 
FAUCONNIER, A., CHAPRON, C., DUBUISSON, J.-B., VIEIRA, M., DOUSSET, B. & 
BRÉART, G. 2002. Relation between pain symptoms and the anatomic location of deep 
infiltrating endometriosis. Fertility and Sterility, 78, 719-726. 
FAUSER, B. C. J. M., EZCURRA, D., HOWLES, C. M., DIEDRICH, K., BOUCHARD, P., 
DOMÍNGUEZ, F., MATZUK, M., FRANKS, S., HAMAMAH, S., SIMÓN, C., DEVROEY, 
P. & EVIAN ANNUAL REPRODUCTION WORKSHOP, G. 2011. Contemporary genetic 
technologies and female reproduction. Human Reproduction Update, 17, 829-847. 
FEHERVARI, Z. & SAKAGUCHI, S. 2004. Cd4(+) tregs and immune control. Journal of 
Clinical Investigation, 114, 1209-1217. 
FERNANDO, S., SOH, P. Q., COOPER, M., EVANS, S., REID, G., TSALTAS, J. & 
ROMBAUTS, L. 2013. Reliability of visual diagnosis of endometriosis. Journal of 
Minimally Invasive Gynecology, 20, 783. 
FERRARO, A., D’ALISE, A. M., RAJ, T., ASINOVSKI, N., PHILLIPS, R., ERGUN, A., 
REPLOGLE, J. M., BERNIER, A., LAFFEL, L., STRANGER, B. E., PHILIP, L. D. J., 
MATHIS, D. & BENOIST, C. 2014. Interindividual variation in human t regulatory cells. 
Proceedings of the National Academy of Sciences, 111, E1111-E1120. 
FERRERO, S., REMORGIDA, V. & VENTURINI, P. L. 2010. Current pharmacotherapy for 
endometriosis. Expert Opin Pharmacother, 11, 1123-34. 
 120 
 
FRASER, I. S. 2008. Recognising, understanding and managing endometriosis. Journal of 
Human Reproductive Sciences, 1, 56-64. 
FRASER, I. S. 2010a. Mysteries of endometriosis pain: Chien-tien hsu memorial lecture 
2009. Journal of Obstetrics and Gynaecology Research, 36, 1-10. 
FRASER, I. S. 2010b. Non-contraceptive health benefits of intrauterine hormonal systems. 
Contraception, 82, 396-403. 
FUKAYA, T., SUGAWARA, J., YOSHIDA, H. & YAJIMA, A. 1994. The role of 
macrophage colony stimulating factor in the peritoneal fluid in infertile patients with 
endometriosis. Tohoku Journal of Experimental Medicine, 172, 221-6. 
GALLINELLI, A., CHIOSSI, G., GIANNELLA, L., MARSELLA, T., GENAZZANI, A. D. 
& VOLPE, A. 2004. Different concentrations of interleukins in the peritoneal fluid of women 
with endometriosis: Relationships with lymphocyte subsets. Gynecological Endocrinology, 
18, 144-151. 
GANEWATTA, S. P., BERBIC, M., LUSCOMBE, G., MARKHAM, R. & FRASER, I. S. 
2010. The characteristic expression of cd3+ t cells, cd8+ t cells and cd57+ nk cells in distinct 
zones of peritoneal endometriotic lesions. Journal of Endometriosis, 2, 189-196. 
GAO, C., WANG, A. Y. & HAN, Y. J. 2008. Microwave antigen retrieval blocks 
endogenous peroxidase activity in immunohistochemistry. Appl Immunohistochem Mol 
Morphol, 16, 393-9. 
GARCIA-VALLEJO, J. J., KONING, N., AMBROSINI, M., KALAY, H., VUIST, I., 
SARRAMI-FOROOSHANI, R., GEIJTENBEEK, T. B. H. & VAN KOOYK, Y. 2013. 
Glycodendrimers prevent hiv transmission via dc-sign on dendritic cells. International 
Immunology, 25, 221. 
GARRIDO, N., NAVARRO, J., REMOHÍ, J., SIMÓN, C. & PELLICER, A. 2000. Follicular 
hormonal environment and embryo quality in women with endometriosis. Human 
Reproduction Update, 6, 67-74. 
GAZVANI, R. & TEMPLETON, A. 2002. Peritoneal environment, cytokines and 
angiogenesis in the pathophysiology of endometriosis. Reproduction, 123, 217-226. 
GEBEL, H. M., BRAUN, D. P., TAMBUR, A., FRAME, D., RANA, N. & DMOWSKI, W. 
P. 1998. Spontaneous apoptosis of endometrial tissue is impaired in women with 
endometriosis. Fertility and Sterility, 69, 1042-1047. 
GEIJTENBEEK, T. B. H., KWON, D. S., TORENSMA, R., VAN VLIET, S. J., VAN 
DUIJNHOVEN, G. C. F., MIDDEL, J., CORNELISSEN, I. L. M. H. A., NOTTET, H. S. L. 
 121 
 
M., KEWALRAMANI, V. N., LITTMAN, D. R., FIGDOR, C. G. & VAN KOOYK, Y. 
2000. Dc-sign, a dendritic cell–specific hiv-1-binding protein that enhances trans-infection of 
t cells. Cell, 100, 587-597. 
GIATROMANOLAKI, A., BATES, G. J., KOUKOURAKIS, M. I., SIVRIDIS, E., 
GATTER, K. C., HARRIS, A. L. & BANHAM, A. H. 2008. The presence of tumor-
infiltrating foxp3 + lymphocytes correlates with intratumoral angiogenesis in endometrial 
cancer. Gynecologic Oncology, 110, 216-221. 
GILABERT-ESTELLES, J., RAMON, L. A., ESPANA, F., GILABERT, J., VILA, V., 
REGANON, E., CASTELLO, R. & CHIRIVELLA, M. E., A. 2007. Expression of 
angiogenic factors in endometriosis: Relationship to fibrinolytic and metalloproteinase 
systems. Human Reproduction, , 22, 2120-2127. 
GIUDICE, L. C. 1994. Growth factors and growth modulators in human uterine 
endometrium: Their potential relevance to reproductive medicine. Fertility and Sterility, 61, 
1-17. 
GIUDICE, L. C. 2010. Endometriosis. The New England Journal of Medicine, 362, 2389-
2398. 
GIUDICE, L. C. & KAO, L. C. 2004. Endometriosis. The Lancet, 364, 1789-1799. 
GIUDICE, L. C., TELLES, T. L., LOBO, S. & KAO, L. E. E. 2002. The molecular basis for 
implantation failure in endometriosis. Annals of the New York Academy of Sciences, 955, 
252-264. 
GIULIANI, E., PARKIN, K. L., LESSEY, B. A., YOUNG, S. L. & FAZLEABAS, A. T. 
2014. Characterization of uterine nk cells in women with infertility or recurrent pregnancy 
loss and associated endometriosis. American Journal of Reproductive Immunology, 72, 262-
269. 
GRAHAM, J., FRANKS, S. & BONNEY, R. C. 1994. In vivo and in vitro effects of gamma-
linolenic acid and eicosapentaenoic acid on prostaglandin production and arachidonic acid 
uptake by human endometrium. Prostaglandins Leukotrienes and Essential Fatty Acids, 50, 
321-9. 
GUO, S.-W. 2009. Recurrence of endometriosis and its control. Human Reproduction 
Update, 15, 441-461. 
GUZICK, D. S., SILLIMAN, N. P., ADAMSON, G. D., BUTTRAM, V. C., JR., CANIS, 
M., MALINAK, L. R. & SCHENKEN, R. S. 1997. Prediction of pregnancy in infertile 
women based on the american society for reproductive medicine's revised classification of 
endometriosis. Fertility and Sterility, 67, 822-9. 
 122 
 
HALBAN, J. 1924. Metastatic hysteroadenosis. Wiener Klinische Wochenschrift, 37, 1205-
1206. 
HALIS, G. & ARICI, A. 2004. Endometriosis and inflammation in infertility. Annals of the 
New York Academy of Sciences, 1034, 300-315. 
HALME J, BECKER S, HAMMOND MG & RAJ MH, R. S. 1983. Increased activation of 
pelvic macrophages in infertile women with mild endometriosis. Am J Obstet Gynecol Int, 
145:333–337. 
HALME, J., HAMMOND, M. G., HULKA, J. F., RAJ, S. G. & TALBERT, L. M. 1984. 
Retrograde menstruation in healthy women and in patients with endometriosis. Obstetrics 
and Gynecology, 64, 151-154. 
HARADA, T., IWABE, T. & TERAKAWA, N. 2001. Role of cytokines in endometriosis. 
Fertility and Sterility, 76, 1-10. 
HARADA, T., YOSHIOKA, H., YOSHIDA, S., IWABE, T., ONOHARA, Y., TANIKAWA, 
M. & TERAKAWA, N. 1997. Increased interleukin-6 levels in peritoneal fluid of infertile 
patients with active endometriosis. American Journal of Obstetrics & Gynecology, 176, 593-
7. 
HASSA, H., TANIR, H. M., TEKIN, B., KIRILMAZ, S. D. & SAHIN MUTLU, F. 2009. 
Cytokine and immune cell levels in peritoneal fluid and peripheral blood of women with 
early- and late-staged endometriosis. Archives of Gynecology and Obstetrics, 279, 891-895. 
HAYRABEDYAN, S. & KYURKCHIEV, S. K., I. 2005. Endoglin (cd105) and s100a13 as 
markers of active angiogenesis in endometriosis. Reproductive Biology, 5, 51-67. 
HEALY, D. L., ROGERS, P. A., HII, L. & WINGFIELD, M. 1998. Angiogenesis: A new 
theory for endometriosis. Human Reproduction Update, 4, 736-40. 
HERSHLAG, A. & MARKOVITZ, J. 2005. Is laparoscopy back? Fertility and Sterility, 84, 
1585-1586. 
HEY-CUNNINGHAM, A. J., BERBIC, M., NG, C. H. M., MARKHAM, R. & FRASER, I. 
S. 2011. Lymphatic vessels in peritoneal endometriotic lesions. Journal of Endometriosis, 3, 
59-66. 
HEY-CUNNINGHAM, A. J., NG, F. W., BUSARD, M. P. H., BERBIC, M., MANCONI, F., 
YOUNG, L., ZEVALLOS, H. B. V., RUSSELL, P., MARKHAM, R. & FRASER, I. S. 
2010. Uterine lymphatic and blood micro-vessels in women with endometriosis through the 
menstrual cycle. Journal of Endometriosis, 2, 197-204. 
 123 
 
HICKEY, M., BALLARD, K. & FARQUHAR, C. 2014. Endometriosis. Bmj (Clinical 
Research Ed.), 348, g1752. 
HIGASHI-KUWATA, N., MAKINO, T., INOUE, Y., TAKEYA, M. & IHN, H. 2009. 
Alternatively activated macrophages (m2 macrophages) in the skin of patient with localized 
scleroderma. Experimental Dermatology, 18, 727. 
HILL, J. A., FARIS, H. M., SCHIFF, I. & ANDERSON, D. J. 1988. Characterization of 
leukocyte subpopulations in the peritoneal fluid of women with endometriosis. Fertility and 
Sterility, 50, 216-22. 
HO, H. N., CHAO, K. H., CHEN, H. F., WU, M. Y., YANG, Y. S. & LEE, T. Y. 1995. 
Peritoneal natural killer cytotoxicity and cd25+ cd3+ lymphocyte subpopulation are 
decreased in women with stage iii-iv endometriosis. Human Reproduction, 10, 2671. 
HO, H. N., WU, M. Y., CHAO, K. H., CHEN, C. D., CHEN, S. U. & YANG, Y. S. 1997a. 
Peritoneal interleukin-10 increases with decrease in activated cd4+ t lymphocytes in women 
with endometriosis. Human Reproduction, 12, 2528-2533. 
HO, H. N., WU, M. Y. & YANG, Y. S. 1997b. Peritoneal cellular immunity and 
endometriosis. American Journal of Reproductive Immunology, 38, 400-12. 
HODES, G. E., PFAU, M. L., LEBOEUF, M., GOLDEN, S. A., CHRISTOFFEL, D. J., 
BREGMAN, D., REBUSI, N., HESHMATI, M., ALEYASIN, H., WARREN, B. L., 
LEBONTÉ, B., HORN, S., LAPIDUS, K. A., STELZHAMMER, V., ERIK, H. F. W., 
BAHN, S., KRISHNAN, V., BOLAÑOS-GUZMAN, C. A., MURROUGH, J. W., MERAD, 
M. & RUSSO, S. J. 2014. Individual differences in the peripheral immune system promote 
resilience versus susceptibility to social stress. Proceedings of the National Academy of 
Sciences, 111, 16136-16141. 
HORI, S., NOMURA, T. & SAKAGUCHI, S. 2003. Control of regulatory t cell development 
by the transcription factor foxp3. Science, 299, 1057-1061. 
HOWARD, F. M. 2009. Endometriosis and mechanisms of pelvic pain. Journal of Minimally 
Invasive Gynecology, 16, 540-550. 
HSU, C. C., YANG, B. C., WU, M. H. & HUANG, K. E. 1997. Enhanced interleukin-4 
expression in patients with endometriosis. Fertility and Sterility, 67, 1059-64. 
HUDELIST, G., LASS, H., KECKSTEIN, J., WALTER, I., WIESER, F., WENZL, R., 
MUELLER, R., CZERWENKA, K., KUBISTA, E. & SINGER, C. F. 2005. Interleukin 
1alpha and tissue-lytic matrix metalloproteinase-1 are elevated in ectopic endometrium of 
patients with endometriosis. Human Reproduction, 20, 1695. 
 124 
 
HUR, S. E., LEE, J. Y. & MOON, H. S. C., H. W. 2006. Angiopoietin-1, angiopoietin-2 and 
tie-2 expression in eutopic endometrium in advanced endometriosis. . Molecular Human 
Reproduction,, 12, 421-426. 
HURD, W. W. 1998. Criteria that indicate endometriosis is the cause of chronic pelvic pain. 
Obstetrics and Gynecology, 92, 1029-1032. 
IWABE, T., HARADA, T. & TERAKAWA, N. 2002. Role of cytokines in endometriosis-
associated infertility. Gynecologic and obstetric investigation, 53, 19-25. 
IWABE, T., HARADA, T., TSUDO, T., NAGANO, Y., YOSHIDA, S., TANIKAWA, M. & 
TERAKAWA, N. 2000. Tumor necrosis factor-alpha promotes proliferation of endometriotic 
stromal cells by inducing interleukin-8 gene and protein expression. Journal of Clinical 
Endocrinology and Metabolism, 85, 824-829. 
IWABE, T., HARADA, T., TSUDO, T., TANIKAWA, M., ONOHARA, Y. & 
TERAKAWA, N. 1998. Pathogenetic significance of increased levels of interleukin-8 in the 
peritoneal fluid of patients with endometriosis. Fertility and Sterility, 69, 924-30. 
JAMIESON, D. J. & STEEGE, J. F. 1996. The prevalence of dysmenorrhea, dyspareunia, 
pelvic pain, and irritable bowel syndrome in primary care practices. Obstetrics and 
Gynecology, 87, 55-58. 
JANSEN, R. P. 1993. Endometriosis symptoms and the limitations of pathology-based 
classification of severity. International Journal of Gynaecology and Obstetrics, 40 Suppl, 
S3-7. 
JANSEN, R. P. S. & RUSSEL, P. 1987. Nonpigmented endometriosis; clinical, laparoscopic, 
and pathologic definition. International Journal of Gynecology and Obstetrics, 25, 428. 
JANSEN, R. P. S. & RUSSELL, P. 1986. Nonpigmented endometriosis: Clinical, 
laparoscopic, and pathologic definition. American Journal of Obstetrics and Gynecology, 
155, 1154-1159. 
JAVERT, C. T. 1949. Pathogenesis of endometriosis based on endometrial homeoplasia, 
direct extension, exfoliation and implantation, lymphatic and hematogenous metastasis. 
Including five case reports of endometrial tissue in pelvic lymph nodes. Cancer, 2, 399-410. 
JAVERT, C. T. 1951. Observations on the pathology and spread of endometriosis based on 
the theory of benign metastasis. American Journal of Obstetrics and Gynecology, 62, 477-
487. 
JENKINS, S., OLIVE, D. L. & HANEY, A. F. 1986. Endometriosis: Pathogenetic 
implications of the anatomic distribution. Obstetrics and Gynecology, 67, 335-338. 
 125 
 
JIN, J. 2014. Oral contraceptives. Jama - Journal of the American Medical Association, 311, 
321. 
JOLICOEUR, C., BOUTOUIL, M., DROUIN, R., PARADIS, I., LEMAY, A. & AKOUM, 
A. 1998. Increased expression of monocyte chemotactic protein-1 in the endometrium of 
women with endometriosis. American Journal of Pathology, 152, 125-133. 
JONES, R. K., BULMER, J. N. & SEARLE, R. F. 1998. Phenotypic and functional studies 
of leukocytes in human endometrium and endometriosis. Human Reproduction Update, 4, 
702-709. 
JURGENSEN, A., L. METTLER, N. & VOLKOV, E. A. 1996. Proliferative activity of the 
endometrium throughout the menstrual cycle in infertile women with and without 
endometriosis. Fertility and Sterility, 66: 369–375. 
KALU, E., SUMAR, N., GIANNOPOULOS, T., PATEL, P., CROUCHER, C., SHERRIFF, 
E. & BANSAL, A. 2007. Cytokine profiles in serum and peritoneal fluid from infertile 
women with and without endometriosis. Journal of Obstetrics and Gynaecology Research, 
33, 490-495. 
KARCK, U., REISTER, F., SCHAFER, W., ZAHRADNIK, H. P. & BRECKWOLDT, M. 
1996. Pge2 and pgf2 alpha release by human peritoneal macrophages in endometriosis. 
Prostaglandins, 51, 49-60. 
KEICHEL, S., BARCENA DE ARELLANO, M. L., REICHELT, U., RIEDLINGER, W. F. 
J., SCHNEIDER, A., KÖHLER, C. & MECHSNER, S. 2011. Lymphangiogenesis in deep 
infiltrating endometriosis. Human Reproduction, 26, 2713-2720. 
KENNEDY, S., BERGQVIST, A., CHAPRON, C., D'HOOGHE, T., DUNSELMAN, G., 
GREB, R., HUMMELSHOJ, L., PRENTICE, A., SARIDOGAN, E., ENDOMETRIOSIS, E. 
S. I. G. F. & ENDOMETRIUM GUIDELINE DEVELOPMENT, G. 2005. Eshre guideline 
for the diagnosis and treatment of endometriosis. Human Reproduction, 20, 2698-2704. 
KERSCHENSTEINER, M., BARTKE, I., STADELMANN, C., LASSMANN, H., 
WEKERLE, H., HOHLFELD, R., GALLMEIER, E., BEHRENS, L., LEAL, V. V., 
MISGELD, T., KLINKERT, W. E., KOLBECK, R., HOPPE, E. & OROPEZA-WEKERLE, 
R. L. 1999. Activated human t cells, b cells, and monocytes produce brain-derived 
neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of 
inflammation? The Journal of Experimental Medicine, 189, 865-870. 
KHAN, K. N., MASUZAKI, H., FUJISHITA, A., KITAJIMA, M., SEKINE, I. & 
ISHIMARU, T. 2003. Immunoexpression of hepatocyte growth factor and c-met receptor in 
 126 
 
the eutopic endometrium predicts the activity of ectopic endometrium. Fertility and Sterility, 
79, 173-181. 
KHAN, K. N., MASUZAKI, H., FUJISHITA, A., KITAJIMA, M., SEKINE, I. & 
ISHIMARU, T. 2004a. Differential macrophage infiltration in early and advanced 
endometriosis and adjacent peritoneum. Fertility and Sterility, 81, 652-661. 
KHAN, K. N., MASUZAKI, H., FUJISHITA, A., KITAJIMA, M., SEKINE, I. & 
ISHIMARU, T. 2004b. Higher activity by opaque endometriotic lesions than nonopaque 
lesions. Acta Obstetricia Et Gynecologica Scandinavica, 83, 375-375. 
KHORRAM, O., TAYLOR, R. N., RYAN, I. P., SCHALL, T. J. & LANDERS, D. V. 1993. 
Peritoneal fluid concentrations of the cytokine rantes correlate with the severity of 
endometriosis. American Journal of Obstetrics and Gynecology, 169, 1545-1549. 
KIM, S. H., CHOI, Y. M., CHAE, H. D., KIM, K. R., KIM, C. H. & KANG, B. M. 2001. 
Increased expression of endoglin in the eutopic endometrium of women with endometriosis. 
Fertility and Sterility, 76, 918-22. 
KINKEL, K., FREI, K. A., BALLEYGUIER, C. & CHAPRON, C. 2006. Diagnosis of 
endometriosis with imaging: A review. European Radiology, 16, 285-298. 
KISSELEVA, T. & BRENNER, D. A. 2008. Mechanisms of fibrogenesis. Experimental 
Biology and Medicine, 233, 109-122. 
KISTNER, R. W. 1979. Endometriosis and infertility. Clinical Obstetrics and Gynecology, 
22, 101-120. 
KOH, C. E., JUSZCZYK, K., COOPER, M. J. W. & SOLOMON, M. J. 2012. Management 
of deeply infiltrating endometriosis involving the rectum. Diseases of the Colon & Rectum, 
55, 925-931. 
KOKS, C. A., DUNSELMAN, G. A., DE GOEIJ, A. F., ARENDS, J. W. & EVERS, J. L. 
1997. Evaluation of a menstrual cup to collect shed endometrium for in vitro studies. Fertility 
and Sterility, 68, 560-564. 
KONINCKX, P. R., KENNEDY, S. H. & BARLOW, D. H. 1998. Endometriotic disease: 
The role of peritoneal fluid. Human Reproduction Update, 4, 741-751. 
KONINCKX, P. R. & MARTIN, D. C. 1992. Deep endometriosis: A consequence of 
infiltration or retraction or possibly adenomyosis externa? Fertility and sterility, 58, 924-928. 
KONNO, R., YAMADA-OKABE, H., FUJIWARA, H., UCHIIDE, I., SHIBAHARA, H., 
OKWADA, M., IHARA, T., SUGAMATA, M. & SUZUKI, M. 2003. Role of 
 127 
 
immunoreactions and mast cells in pathogenesis of human endometriosis-morphologic study 
and gene expression analysis. Human Cell, 16, 141-149. 
KOYAMA, N., MATSUURA, K. & OKAMURA, H. 1993. Cytokines in the peritoneal fluid 
of patients with endometriosis. International Journal of Gynaecology and Obstetrics, 43, 45-
50. 
KRENÁCS, L., TISZALVICZ, L., KRENÁCS, T. & BOUMSELL, L. 1993. 
Immunohistochemical detection of cd1a antigen in formalin-fixed and paraffin-embedded 
tissue sections with monoclonal antibody 010. The Journal of Pathology, 171, 99. 
KUOHUNG, W., JONES, G. L., VITONIS, A. F., CRAMER, D. W., KENNEDY, S. H., 
THOMAS, D. & HORNSTEIN, M. D. 2002. Characteristics of patients with endometriosis 
in the united states and the united kingdom. Fertility and Sterility, 78, 767-772. 
LACHAPELLE, M. H., HEMMINGS, R., ROY, D. C., FALCONE, T. & MIRON, P. 1996. 
Flow cytometric evaluation of leukocyte subpopulations in the follicular fluids of infertile 
patients. Fertility and Sterility, 65, 1135-40. 
LASKIN, D. L., SUNIL, V. R., GARDNER, C. R. & LASKIN, J. D. 2011. Macrophages and 
tissue injury: Agents of defense or destruction? Annual Review of Pharmacology and 
Toxicology, 51, 267-288. 
LEBOVIC, D. I., MUELLER, M. D. & TAYLOR, R. N. 2001. Immunobiology of 
endometriosis. Fertility and Sterility, 75, 1-10. 
LEE, M. N., YE, C., VILLANI, A.-C., RAJ, T., LI, W., EISENHAURE, T. M., IMBOYWA, 
S. H., CHIPENDO, P. I., RAN, F. A., SLOWIKOWSKI, K., WARD, L. D., RADDASSI, K., 
MCCABE, C., LEE, M. H. & FROHLICH, I. Y. 2014. Common genetic variants modulate 
pathogen-sensing responses in human dendritic cells. Science, 343, 1246980-1246980. 
LEVANDER, G. & NORMANN, P. 1955. The pathogenesis of endometriosis; an 
experimental study. Acta Obstetricia Et Gynecologica Scandinavica, 34, 366. 
LIN, Y.-J., LAI, M.-D., LEI, H.-Y. & WING, L.-Y. C. 2006. Neutrophils and macrophages 
promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology, 
147, 1278-1286. 
LIU, D. T. & HITCHCOCK, A. 1986. Endometriosis: Its association with retrograde 
menstruation, dysmenorrhoea and tubal pathology. British Journal of Obstetrics and 
Gynaecology, 93, 859. 
 128 
 
LUSCOMBE, G. M., MARKHAM, R., JUDIO, M., GRIGORIU, A. & FRASER, I. S. 2009. 
Abdominal bloating: An under-recognized endometriosis symptom. . Journal of Obstetrics 
and Gynaecology Canada, 31. 
MACHADO, D. E., ABRAO, M. S., BERARDO, P. T., TAKIYA, C. M. & NASCIUTTI, L. 
E. 2008. Vascular density and distribution of vascular endothelial growth factor (vegf) and its 
receptor vegfr-2 (flk-1) are significantly higher in patients with deeply infiltrating 
endometriosis affecting the rectum. Fertility and Sterility, 90, 148-155. 
MAEDA, N., IZUMIYA, C., YAMAMOTO, Y., OGURI, H., KUSUME, T. & FUKAYA, T. 
2002. Increased killer inhibitory receptor KIR2DL1 expression among natural killer cells in 
women with pelvic endometriosis. Fertility and sterility, 77, 297-302. 
MAHMOOD, T. A., TEMPLETON, A. A., THOMSON, L. & FRASER, C. 1991. Menstrual 
symptoms in women with pelvic endometriosis. British Journal of Obstetrics and 
Gynaecology, 98, 558. 
MAHNKE, J. L., YUSOFF DAWOOD, M. & HUANG, J.-C. 2000. Vascular endothelial 
growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertility 
and Sterility, 73, 166-170. 
MANUCK, S. B., COHEN, S., RABIN, B. S., MULDOON, M. F. & BACHEN, E. A. 1991. 
Individual differences in dellular immune response to stress. Psychological Science, 2, 111-
115. 
MARCOUX, S., MAHEUX, R., BÉRUBÉ, S. & THE CANADIAN COLLABORATIVE 
GROUP ON, E. 1997. Laparoscopic surgery in infertile women with minimal or mild 
endometriosis. The New England Journal of Medicine, 337, 217-222. 
MARSHALL, R. J. & JONES, D. B. 1988. An i\immunohistochemical study of lymphoid 
tissue in human endometrium. International Journal of Gynecological Pathology, 7, 225-
235. 
MATSUURA, K., OHTAKE, H., KATABUCHI, H. & OKAMURA, H. 1999. Coelomic 
metaplasia theory of endometriosis: Evidence from in vivo studies and an in vitro 
experimental model. Gynecologic and Obstetric Investigation, 47, 18-22. 
MATSUZAKI, S., CANIS, M., DARCHA, C., DECHELOTTE, P., POULY, J.-L. & 
BRUHAT, MAURICE A. 1999. Fibrogenesis in peritoneal endometriosis. Gynecologic and 
Obstetric Investigation, 47, 197-199. 
MAZZEO, D., VIGANO, P., DI BLASIO, A. M., SINIGAGLIA, F., VIGNALI, M. & 
PANINA-BORDIGNON, P. 1998. Interleukin-12 and its free p40 subunit regulate immune 
 129 
 
recognition of endometrial cells: Potential role in endometriosis. Journal of Clinical 
Endocrinology & Metabolism, 83, 911-6. 
MCLAREN, J. 2000. Vascular endothelial growth factor and endometriotic angiogenesis. 
Human Reproduction Update, 6, 45-55. 
MCLAREN, J., DEALTRY, G., PRENTICE, A., CHARNOCK-JONES, D. S. & SMITH, S. 
K. 1997. Decreased levels of the potent regulator of monocyte/macrophage activation, 
interleukin-13, in the peritoneal fluid of patients with endometriosis. Human Reproduction, 
12, 1307-10. 
MCLAREN, J., PRENTICE, A., CHARNOCK-JONES, D. S., MILLICAN, S. A., 
MÜLLER, K. H., SHARKEY, A. M. & SMITH, S. K. 1996a. Vascular endothelial growth 
factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by 
ovarian steroids. The Journal of Clinical Investigation, 98, 482-489. 
MCLAREN, J., PRENTICE, A., CHARNOCK-JONES, D. S. & SMITH, S. K. 1996b. 
Vascular endothelial growth factor (vegf) concentrations are elevated in peritoneal fluid of 
women with endometriosis. Human Reproduction 11, 220. 
MECHSNER, S., SCHWARZ, J., THODE, J., LODDENKEMPER, C., SALOMON, D. S. & 
EBERT, A. D. 2007. Growth-associated protein 43-positive sensory nerve fibers 
accompanied by immature vessels are located in or near peritoneal endometriotic lesions. 
Fertility and Sterility, 88, 581-7. 
MECHSNER, S., WEICHBRODT, M., RIEDLINGER, W. F. J., KAUFMANN, A. M., 
SCHNEIDER, A. & KÖHLER, C. 2010. Immunohistochemical evaluation of endometriotic 
lesions and disseminated endometriosis-like cells in incidental lymph nodes of patients with 
endometriosis. Fertility and Sterility, 94, 457-463. 
MERESMAN, G. F., VIGHI, S., BUQUET, R. A., CONTRERAS-ORTIZ, O., TESONE, M. 
& RUMI, L. S. 2000. Apoptosis and expression of bcl-2 and bax in eutopic endometrium 
from women with endometriosis. Fertility and Sterility, 74, 760-766. 
MILINGOS, D., KATOPODIS, H., MILINGOS, S., PROTOPAPAS, A., CREATSAS, G., 
MICHALAS, S., ANTSAKLIS, A. & KOUTSILIERIS, M. 2006. Insulin-like growth factor-
1 isoform mrna expression in women with endometriosis: Eutopic endometrium versus 
endometriotic cyst. Annals of the New York Academy of Sciences, 1092, 434-439. 
MILINGOS, D. S., KOUTSILIERIS, M., PHILIPPOU, A., ARMAKOLAS, A., 
PAPAGEORGIOU, E., SOURLA, A., PROTOPAPAS, A., LIAPI, A., ANTSAKLIS, A. & 
MASTROMINAS, M. 2011. Insulin like growth factor-1ec (mgf) expression in eutopic and 
ectopic endometrium: Characterization of the mgf e-peptide actions in vitro. Molecular 
Medicine 17, 21. 
 130 
 
MILLER, M. K., UNGER, P. D. & BLEIWEISS, I. J. 2001. Immunohistochemical analysis 
of prostate specific antigen in breast cancer. Breast Cancer Res Treat, 68, 111-6. 
MOUNSEY, A. L., WILGUS, A. & SLAWSON, D. C. 2006. Diagnosis and management of 
endometriosis. American Family Physician, 74, 594. 
MURPHY, A. A. 2002. Clinical aspects of endometriosis. Annals of the New York Academy 
of Sciences, 955, 1-10. 
MUSE, K. 1988. Clinical manifestations and classification of endometriosis. Clinical 
Obstetrics and Gynecology, 31, 813-822. 
NAGORSEN, D., MARINCOLA, F. M. & PANELLI, M. C. 2004. Cytokine and chemokine 
expression profiles of maturing dendritic cells using multiprotein platform arrays. Cytokine, 
25, 31-35. 
NAIR, A. S., NAIR, H. B., LUCIDI, R. S., KIRCHNER, A. J., SCHENKEN, R. S., 
TEKMAL, R. R. & WITZ, C. A. 2008. Modeling the early endometriotic lesion: 
Mesothelium-endometrial cell co-culture increases endometrial invasion and alters 
mesothelial and endometrial gene transcription. Fertility and Sterility, 90, 1487-1495. 
NANDAKUMAR, S., MILLER, C. W. & KUMARAGURU, U. 2009. T regulatory cells: An 
overview and intervention techniques to modulate allergy outcome. Clinical and Molecular 
Allergy, 7, 5-5. 
NELSON, B. H. 2010. Cd20+ b cells: The other tumor-infiltrating lymphocytes. Journal of 
Immunology, 185, 4977. 
NETTER, F. H. 1954. The ciba collection of medical illustrations. Vol 2: Reproductive 
system. In: Oppenheimer, E. (ed.). Summit, N.J.: CIBA Pharmaceuticals. 
NISOLLE, M., CASANAS-ROUX, F., ANAF, V., MINE, J. M. & DONNEZ, J. 1993. 
Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertility and 
Sterility, 59, 681-4. 
NISOLLE, M., CASANAS-ROUX, F., WYNS, C., DE MENTEN, Y., MATHIEU, P. E. & 
DONNEZ, J. 1994. Immunohistochemical analysis of estrogen and progesterone receptors in 
endometrium and peritoneal endometriosis: A new quantitative method. Fertility and 
Sterility, 62, 751-9. 
NISOLLE, M. & DONNEZ, J. 1997. Peritoneal endometriosis, ovarian endometriosis, and 
adenomyotic nodules of the rectovaginal septum are three different entities. Fertility and 
Sterility, 68, 585-596. 
 131 
 
NOBLE, L. S., BULUN, S. E., TAKAYAMA, K., ZEITOUN, K. M., PUTMAN, J. M., 
JOHNS, D. A., HINSHELWOOD, M. M., AGARWAL, V. R., ZHAO, Y. & CARR, B. R. 
1997. Prostaglandin e2 stimulates aromatase expression in endometriosis-derived stromal 
cells. The Journal of Clinical Endocrinology and Metabolism, 82, 600-606. 
NOGA, O., PEISER, M., ALTENÄHR, M., KNIELING, H., WANNER, R., HANF, G., 
GROSSE, R. & SUTTORP, N. 2007. Differential activation of dendritic cells by nerve 
growth factor and brain-derived neurotrophic factor. Clinical and Experimental Allergy, 37, 
1701-1701. 
NOTHNICK, W. B. 2001. Treating endometriosis as an autoimmune disease. Fertility and 
Sterility, 76, 223-231. 
ODAGIRI, K., KONNO, R., FUJIWARA, H., NETSU, S., YANG, C. & SUZUKI, M. 2009. 
Smooth muscle metaplasia and innervation in interstitium of endometriotic lesions related to 
pain. Fertility and Sterility, 92, 1525-1531. 
OLIVE, D. L. 2005. Endometriosis in clinical practice, London, Taylor & Francis. 
OLIVE, D. L., LINDHEIM, S. R. & PRITTS, E. A. 2004. New medical treatments for 
endometriosis. Best Practice and Research in Clinical Obstetrics and Gynaecology, 18, 319. 
OOSTERLYNCK, D. J., CORNILLIE, F. J., WAER, M. & KONINCKX, P. R. 1993a. 
Immunohistochemical characterization of leukocyte subpopulations in endometriotic lesions. 
Archives of Gynecology and Obstetrics, 253, 197-206. 
OOSTERLYNCK, D. J., CORNILLIE, F. J., WAER, M., VANDEPUTTE, M. & 
KONINCKX, P. R. 1991. Women with endometriosis show a defect in natural killer activity 
resulting in a decreased cytotoxicity to autologous endometrium. Fertility and Sterility, 56, 
45-51. 
OOSTERLYNCK, D. J., MEULEMAN, C., SOBIS, H., VANDEPUTTE, M. & 
KONINCKX, P. R. 1993b. Angiogenic activity of peritoneal fluid from women with 
endometriosis. Fertility and Sterility, 59, 778-82. 
OOSTERLYNCK, D. J., MEULEMAN, C., WAER, M. & KONINCKX, P. R. 1994. 
Transforming growth factor-beta activity is increased in peritoneal fluid from women with 
endometriosis. Obstetrics and Gynecology, 83, 287-92. 
OOSTERLYNCK, D. J., MEULEMAN, C., WAER, M., VANDEPUTTE, M. & 
KONINCKX, P. R. 1992. The natural killer activity of peritoneal fluid lymphocytes is 
decreased in women with endometriosis. Fertility and Sterility, 58, 290-5. 
 132 
 
ORAL, E. & ARICI, A. 1996. Peritoneal growth factors and endometriosis. Seminars in 
Reproductive Endocrinology, 14, 257. 
ORAL, E., OLIVE, D. L. & ARICI, A. 1996. The peritoneal environment in endometriosis. 
Human Reproduction Update, 2, 385-398. 
ORLICKY, D. J., SILIO, M., WILLIAMS, C., GORDON, J. & GERSCHENSON, L. E. 
1986. Regulation of inositol phosphate levels by prostaglandins in cultured endometrial cells. 
Journal of Cellular Physiology, 128, 105-112. 
ORTIZ, B. D., KRENSKY, A. M. & NELSON, P. J. 1996. Kinetics of transcription factors 
regulating the rantes chemokine gene reveal a developmental switch in nuclear events during 
t-lymphocyte maturation. Molecular and Cellular Biology, 16, 202-10. 
OTA, H., IGARASHI, S. & TANAKA, T. 1996. Expression of γδt cells and adhesion 
molecules in endometriotic tissue in patients with endometriosis and adenomyosis. American 
Journal of Reproductive Immunology, 35, 477-482. 
OVERTON, C. 2007. An atlas of endometriosis, London, Informa Healthcare. 
ÖZKAN, S. & ARICI, A. 2009. Advances in treatment options of endometriosis. 
Gynecologic and Obstetric Investigation, 67, 81-91. 
OZKAN, S., MURK, W. & ARICI, A. 2008. Endometriosis and infertility: Epidemiology 
and evidence-based treatments. Annals of the New York Academy of Sciences, 1127, 92-92. 
PAHLAJANI, G. & FALCONE, T. 2010. Laparoscopic surgery for endometriosis-associated 
infertility: A pathophysiologic approach. Gynecological Surgery, 7, 319-328. 
PALMISANO, G. P., ADAMSON, G. D. & LAMB, E. J. 1993. Can staging systems for 
endometriosis based on anatomic location and lesion type predict pregnancy rates? 
International Journal of Fertility and Menopausal Studies, 38, 241-9. 
PARK, J. S., LEE, J. H., KIM, M., CHANG, K. H., CHANG, H. J. & HWANG, K. J. 2009. 
Endometrium from women with endometriosis shows increased proliferation activity. 
Fertility and Sterility, 92, 1246-1249. 
PAUL DMOWSKI, W. & BRAUN, D. P. 2004. Immunology of endometriosis. Best Practice 
and Research in Clinical Obstetrics and Gynaecology, 18, 245-263. 
PICCINNI, M.-P. 2005. T cells in pregnancy. Chemical Immunology and Allergy, 89, 3. 
 133 
 
PILLAI, S., RUST, P. F. & HOWARD, L. 1998. Effects of antibodies to transferrin and 
alpha 2-hs glycoprotein on in vitro sperm motion: Implications in infertility associated with 
endometriosis. American Journal of Reproductive Immunology, 39, 235-242. 
PRACTICE COMMITTEE OF AMERICAN SOCIETY FOR REPRODUCTIVE 
MEDICINE 2008. Definitions of infertility and recurrent pregnancy loss. Fertility and 
Sterility, 90, S60-S60. 
PRINT, C., VALTOLA, R., EVANS, A., LESSAN, K., MALIK, S. & SMITH, S. 2004. 
Soluble factors from human endometrium promote angiogenesis and regulate the endothelial 
cell transcriptome. Human Reproduction, 19, 2356-2366. 
PROKOP, S., HEPPNER, F. L., GOEBEL, H. H. & STENZEL, W. 2011. M2 polarized 
macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. The 
American Journal of Pathology, 178, 1279-1286. 
PULENDRAN, B., WILLIAMS, I. R., DENNING, T. L., PATEL, S. R. & WANG, Y.-C. 
2007. Lamina propria macrophages and dendritic cells differentially induce regulatory and 
interleukin 17-producing t cell responses. Nature Immunology, 8, 1086-1094. 
PUPO-NOGUEIRA, A., DE OLIVEIRA, R. M., PETTA, C. A., PODGAEC, S., DIAS, J. A., 
JR. & ABRAO, M. S. 2007. Vascular endothelial growth factor concentrations in the serum 
and peritoneal fluid of women with endometriosis. International Journal of Gynaecology & 
Obstetrics, 99, 33-7. 
QIN, Z., RICHTER, G., BLANKENSTEIN, T., CAO, X., IBE, S. & SCHÜLER, T. 1998. B 
cells inhibit induction of t cell-dependent tumor immunity. Nature Medicine, 4, 627-630. 
RAFET GAZVANI, M., CHRISTMAS, S., QUENBY, S., KIRWAN, J., JOHNSON, P. M. 
& KINGSLAND, C. R. 1998. Peritoneal fluid concentrations of interleukin-8 in women with 
endometriosis: Relationship to stage of disease. Human Reproduction, 13, 1957-1961. 
RAMOS-VARA, J. A. 2005. Technical aspects of immunohistochemistry. Vet Pathol, 42, 
405-26. 
REDWINE, D. B. 1987. Age-related evolution in color appearance of endometriosis. 
Fertility and Sterility, 48, 1062-3. 
REICHELT, U., KEICHEL, S., BARCENA DE ARELLANO, M. L., CHIANTERA, V., 
SCHNEIDER, A. & MECHSNER, S. 2012. High lymph vessel density and expression of 
lymphatic growth factors in peritoneal endometriosis. Reproductive Sciences, 19, 876-82. 
RIDLEY, J. H. & EDWARDS, I. K. 1959. Experimental endometriosis in the human 
Obstetrical and Gynecological Survey, 14, 130-133. 
 134 
 
ROKITANSKY, C. 1860. Über uterusdrüsen-neubildung in uterus- und ovarial-sarcomen. Z 
Ges Aerzte Wien, 16:577–81. 
SAKAGUCHI, S., YAMAGUCHI, T., NOMURA, T. & ONO, M. 2008. Regulatory t cells 
and immune tolerance. Cell, 133, 775-787. 
SALAMONSEN, L. A. & LATHBURY, L. J. 2000. Endometrial leukocytes and 
menstruation. Human Reproduction Update, 6, 16-27. 
SALAMONSEN, L. A., ZHANG, J. & BRASTED, M. 2002. Leukocyte networks and 
human endometrial remodelling. Journal of Reproductive Immunology, 57, 95-108. 
SALAMONSEN, L. A., ZHANG, J., HAMPTON, A. & LATHBURY, L. 2000. Regulation 
of matrix metalloproteinases in human endometrium. Human Reproduction, 15 Suppl 3, 112. 
SAMPSON, J. A. 1922. Intestinal adenomas of endometrial type: Their importance and their 
relation to ovarian hematomas of endometrial type (perforating hemorrhagic cysts of the 
ovary). Archives of Surgery 5, 217. 
SAMPSON, J. A. 1927a. Metastatic or embolic endometriosis, due to the menstrual 
dissemination of endometrial tissue into the venous circulation. The American Journal of 
Pathology, 3, 93-110.43. 
SAMPSON, J. A. 1927b. Peritoneal endometriosis due to the menstrual dissemination of 
endometrial tissue into the peritoneal cavity. American Journal of Obstetrics Gynecology 14, 
422-469. 
SASSON, I. E. & TAYLOR, H. S. 2009. Aromatase inhibitor for treatment of a recurrent 
abdominal wall endometrioma in a postmenopausal woman. Fertility and Sterility, 92, 
1170.e1-1170.e4. 
SBRACIA, M., ZUPI, E., ALO, P., MANNA, C., MARCONI, D., SCARPELLINI, F., 
GRASSO, J. A., DI TONDO, U. & ROMANINI, C. 1997. Differential expression of igf-i 
and igf-ii in eutopic and ectopic endometria of women with endometriosis and in women 
without endometriosis. American Journal of Reproductive Immunology (New York, N.Y. : 
1989), 37, 326-329. 
SCHENKEN, R. S. 1996. Treatment of human infertility: The special case of endometriosis. 
In: ADASHI EY, R. J., ROSENWAKS Z,  (ed.) Reproductive Endocrinology, Surgery, and 
Technology. Philadelphia: Lippincott-Raven. 
SCHINDLER, A. E. 2004. Pathophysiology, diagnosis and treatment of endometriosis. 
Minerva Ginecologica, 56, 419-35. 
 135 
 
SCHULKE, L., BERBIC, M., MANCONI, F., TOKUSHIGE, N., MARKHAM, R. & 
FRASER, I. S. 2009. Dendritic cell populations in the eutopic and ectopic endometrium of 
women with endometriosis. Human Reproduction, 24, 1695-703. 
SCOTT, R. B. & TELINDE, R. W. 1950. External endometriosis--the scourge of the private 
patient. Annals of Surgery, 131, 697-720. 
SEAMAN, H. E., BALLARD, K. D., WRIGHT, J. T. & DE VRIES, C. S. 2008. 
Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory 
disease: Findings from a national case-control study - part 2. . Bjog: An International Journal 
of Obstetrics and Gynaecology, 115, 1392-1396. 
SEELEY, R. R., STEPHENS, T. D. & TATE, P. 2005. Essentials of anatomy & physiology, 
Boston, McGraw-Hill. 
SELI, E., BERKKANOGLU, M. & ARICI, A. 2003. Pathogenesis of endometriosis. 
Obstetrics and Gynecology Clinics of North America, 30, 41-61. 
SENTURK, L. M. & ARICI, A. 1999. Immunology of endometriosis. Journal of 
Reproductive Immunology, 43, 67-83. 
SEO, S. S., HWANG, K. J., KIM, M. R., KIM, Y. A., PARK, D. W. & RYU, H. S. 2004. 
Increased proliferative activity in endometrium with endometriosis. Fertility and Sterility, 82, 
S160-S160. 
SHARPE‐TIMMS, K. L. 2001. Endometrial anomalies in women with endometriosis. Annals 
of the New York Academy of Sciences, 943, 131-147. 
SILLEM, M., PRIFTI, S., NEHER, M. & RUNNEBAUM, B. 1998. Extracellular matrix 
remodelling in the endometrium and its possible relevance to the pathogenesis of 
endometriosis. Human Reproduction Update, 4, 730-735. 
SINAII, N., PLUMB, K., COTTON, L., LAMBERT, A., KENNEDY, S., ZONDERVAN, K. 
& STRATTON, P. 2008. Differences in characteristics among 1,000 women with 
endometriosis based on extent of disease. Fertility and Sterility, 89, 538-545. 
SOKOLOV, D. I., SOLODOVNIKOVA, N. G., PAVLOV, O. V., NIAURI, D. A., 
VOLKOV, N. N. & SEL'KOV, S. A. 2005. Study of cytokine profile and angiogenic 
potential of peritoneal fluid in patients with external genital endometriosis. Bulletin of 
Experimental Biology and Medicine, 140, 541-544. 
SOMIGLIANA, E., VIGANÒ, P., GAFFURI, B., GUARNERI, D., BUSACCA, M. & 
VIGNALI, M. 1996. Human endometrial stromal cells as a source of soluble intercellular 
adhesion molecule (icam)-1 molecules. Human Reproduction, 11, 1190. 
 136 
 
SONDELL, M., LUNDBORG, G. & KANJE, M. 1999. Vascular endothelial growth factor 
has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and 
schwann cell proliferation in the peripheral nervous system. Journal of Neuroscience, 19, 
5731. 
SONDELL, M., SUNDLER, F. & KANJE, M. 2000. Vascular endothelial growth factor is a 
neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. The 
European Journal of Neuroscience, 12, 4243. 
STEELE, R. W., DMOWSKI, W. P. & MARMER, D. J. 1984. Immunologic aspects of 
human endometriosis. American Journal of Reproductive Immunology, 6, 33-6. 
STEGEMAN, B. H., DE BASTOS, M., ROSENDAAL, F. R., VAN HYLCKAMA VLIEG, 
A., HELMERHORST, F. M., STIJNEN, T. & DEKKERS, O. M. 2013. Different combined 
oral contraceptives and the risk of venous thrombosis: Systematic review and network meta-
analysis. British Medical Journal, 347, f5298. 
STRATTON, P., SINAII, N., SEGARS, J., KOZIOL, D., WESLEY, R., ZIMMER, C., 
WINKEL, C. & NIEMAN, L. K. 2008. Return of chronic pelvic pain from endometriosis 
after raloxifene treatment: A randomized controlled trial. Obstetrics and Gynecology, 111, 
88-96. 
SUNDERKÖTTER, C., STEINBRINK, K., GOEBELER, M., BHARDWAJ, R. & SORG, C. 
1994. Macrophages and angiogenesis. Journal of Leukocyte Biology, 55, 410. 
SUTTON, C. J., POOLEY, A. S., EWEN, S. P. & HAINES, P. 1997. Follow-up report on a 
randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated 
with minimal to moderate endometriosis. Fertility and Sterility, 68, 1070-1074. 
SYROP, C. H. & HALME, J. 1987. Cyclic changes of peritoneal fluid parameters in normal 
and infertile patients. Obstetrics and Gynecology, 69, 416-418. 
SZYLLO, K., TCHORZEWSKI, H., BANASIK, M., GLOWACKA, E., LEWKOWICZ, P. 
& KAMER-BARTOSINSKA, A. 2003. The involvement of T lymphocytes in the 
pathogenesis of endometriotic tissues overgrowth in women with endometriosis. Mediators 
of inflammation, 12, 131-138. 
SZYMANOWSKI, K. 2007. Apoptosis pattern in human endometrium in women with pelvic 
endometriosis. European Journal of Obstetrics and Gynecology, 132, 107-110. 
TAKAYAMA, K., ZEITOUN, K., GUNBY, R. T., SASANO, H., CARR, B. R. & BULUN, 
S. E. 1998. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. 
Fertility and Sterility, 69, 709-713. 
 137 
 
TAKEHARA, M., UEDA, M., YAMASHITA, Y., TERAI, Y., HUNG, Y.-C. & UEKI, M. 
2004. Vascular endothelial growth factor a and c gene expression in endometriosis. Human 
Pathology, 35, 1369-1375. 
TAMBURRO, S., CANIS, M., ALBUISSON, E., DECHELOTTE, P., DARCHA, C. & 
MAGE, G. 2003. Expression of transforming growth factor β1 in nerve fibers is related to 
dysmenorrhea and laparoscopic appearance of endometriotic implants. Fertility and Sterility, 
80, 1131-1136. 
TAN, X.-J., LANG, J.-H., LIU, D.-Y., SHEN, K., LENG, J.-H. & ZHU, L. 2002. Expression 
of vascular endothelial growth factor and thrombospondin-1 mrna in patients with 
endometriosis. Fertility and Sterility, 78, 148-153. 
TAYLOR, R. N., LEBOVIC, D. I. & MUELLER, M. D. 2002. Angiogenic factors in 
endometriosis. Annals of the New York Academy of Sciences, 955, 89-100. 
TELSER, A. 2002. Helper t cells and lymphocyte activation. Molecular Biology of the Cell. 
4th edition ed. 
TEUNIS, B. H. G., ENGERING, A. & KOOYK, Y. V. 2002. Dc-sign, a c-type lectin on 
dendritic cells that unveils many aspects of dendritic cell biology. Journal of Leukocyte 
Biology, 71, 921. 
THORNTON, A. M. 2005. T regulatory cells. Current Biology, 15, R582-R582. 
TOKUSHIGE, N., MARKHAM, R., RUSSELL, P. & FRASER, I. S. 2006a. High density of 
small nerve fibres in the functional layer of the endometrium in women with endometriosis. 
Human Reproduction, 21, 782. 
TOKUSHIGE, N., MARKHAM, R., RUSSELL, P. & FRASER, I. S. 2006b. Nerve fibres in 
peritoneal endometriosis. Human Reproduction, 21, 3001-7. 
TOKUSHIGE, N., MARKHAM, R., RUSSELL, P. & FRASER, I. S. 2007. Different types 
of small nerve fibers in eutopic endometrium and myometrium in women with 
endometriosis. Fertility and Sterility, 88, 795-803. 
TOKUSHIGE, N., MARKHAM, R., RUSSELL, P. & FRASER, I. S. 2008. Effects of 
hormonal treatment on nerve fibers in endometrium and myometrium in women with 
endometriosis. Fertility and Sterility, 90, 1589-1598. 
TOKUSHIGE, N., RUSSELL, P., BLACK, K., BARRERA, H., DUBINOVSKY, S., 
MARKHAM, R. & FRASER, I. S. 2010. Nerve fibers in ovarian endometriomas. Fertility 
and Sterility, 94, 1944-1947. 
 138 
 
TORCIA, M., BRACCI-LAUDIERO, L., LUCIBELLO, M., NENCIONI, L., LABARDI, D., 
RUBARTELLI, A., COZZOLINO, F., ALOE, L. & GARACI, E. 1996. Nerve growth factor 
is an autocrine survival factor for memory b lymphocytes. Cell, 85, 345-356. 
TOYA, M., SAITO, H., SAITO, T., OHTA, N., KANEKO, T. & HIROI, M. 2000. Moderate 
and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in 
patients undergoing in vitro fertilization and embryo transfer. Fertility and Sterility, 73, 344-
350. 
TRAN, L. V., TOKUSHIGE, N., BERBIC, M., MARKHAM, R. & FRASER, I. S. 2009. 
Macrophages and nerve fibres in peritoneal endometriosis. Human Reproduction, 24, 835-41. 
TUCKER, B. A. & MEAROW, K. M. 2008. Peripheral sensory axon growth: From receptor 
binding to cellular signaling. Can J Neurol Sci, 35, 551-566. 
TULANDI, T., FELEMBAN, A. & CHEN, M. F. 2001. Nerve fibers and histopathology of 
endometriosis-harboring peritoneum. Journal of the American Association of Gynecologic 
Laparoscopists, 8, 95-8. 
UEKI, M. 1991. Histologic study of endometriosis and examination of lymphatic drainage in 
and from the uterus. American Journal of Obstetrics and Gynecology, 165, 201-209. 
ULUKUS, M., CAKMAK, H. & ARICI, A. 2006. The role of endometrium in endometriosis. 
Journal of the Society for Gynecologic Investigation, 13, 467-476. 
UMARIA, N. & OLLIFF, J. F. 2001. Imaging features of pelvic endometriosis. The British 
Journal of Radiology, 74, 556. 
VAN LANGENDONCKT, A., EGGERMONT, J., CASANAS-ROUX, F., SCHOLTES, H. 
E. & DONNEZ, J. 2004. Expression of platelet endothelial cell adhesion molecule-1 in red 
and black endometriotic lesions. Fertility and Sterility, 82, 984-5. 
VELASCO, I., RUEDA, J. & ACIÉN, P. 2006. Aromatase expression in endometriotic 
tissues and cell cultures of patients with endometriosis. Molecular Human Reproduction, 12, 
377-381. 
VERCELLINI, P., CROSIGNANI, P. G., ABBIATI, A., SOMIGLIANA, E., VIGANÒ, P. & 
FEDELE, L. 2009. The effect of surgery for symptomatic endometriosis: The other side of 
the story. Human Reproduction Update, 15, 177-188. 
VERCELLINI, P., DE GIORGI, O., AIMI, G., PANAZZA, S., UGLIETTI, A. & 
CROSIGNANI, P. G. 1997. Menstrual characteristics in women with and without 
endometriosis. Obstetrics and Gynecology, 90, 264-8. 
 139 
 
VERCELLINI, P., FEDELE, L., AIMI, G., DE GIORGI, O., CONSONNI, D. & 
CROSIGNANI, P. G. 2006. Reproductive performance, pain recurrence and disease relapse 
after conservative surgical treatment for endometriosis: The predictive value of the current 
classification system. Human Reproduction, 21, 2679-2685. 
VERCELLINI, P., FEDELE, L., AIMI, G., PIETROPAOLO, G., CONSONNI, D. & 
CROSIGNANI, P. G. 2007. Association between endometriosis stage, lesion type, patient 
characteristics and severity of pelvic pain symptoms: A multivariate analysis of over 1000 
patients. Human Reproduction, 22, 266-271. 
VERCELLINI, P., SOMIGLIANA, E., VIGANÒ, P., ABBIATI, A., DAGUATI, R. & 
CROSIGNANI, P. G. 2008. Endometriosis: Current and future medical therapies. Best 
Practice and Research. Clinical Obstetrics and Gynaecology, 22, 275-306. 
VERCELLINI, P., TRESPIDI, L., DE GIORGI, O., CORTESI, I., PARAZZINI, F. & 
CROSIGNANI, P. G. 1996. Endometriosis and pelvic pain: Relation to disease stage and 
localization vercellini p.; trespidi l.; de giorgi o.; cortesi i.; parazzini f.; crosignani p.G. Ita 
fertil steril 1996 65/2 (299–304). International Journal of Gynecology & Obstetrics, 54, 210. 
VIGANÒ, P., SOMIGLIANA, E., GAFFURI, B., SANTORSOLA, R., BUSACCA, M. & 
VIGNALI, M. 2000. Endometrial release of soluble intercellular adhesion molecule 1 and 
endometriosis: Relationship to the extent of the disease. Obstetrics and Gynecology, 95, 115-
118. 
VIVIER, E., WALZER, T., TOMASELLO, E., BARATIN, M. & UGOLINI, S. 2008. 
Functions of natural killer cells. Nature immunology, 9, 503-510. 
VON, R., F. 1896. Adenomyomas and cystadenomas of the wall of the uterus and tube: Their 
origin as remnants of the wolffian body. Wien Klin Wochenschr, 8. 
VORONOV, E., SHOUVAL, D. S., KRELIN, Y., CAGNANO, E., BENHARROCH, D., 
IWAKURA, Y., DINARELLO, C. A. & APTE, R. N. 2003. Il-1 is required for tumor 
invasiveness and angiogenesis. Proceedings of the National Academy of Sciences of the 
United States of America, 100, 2645-2650. 
WAISMAN, A. & BECHER, B. 2014. T-helper cells: Methods and protocols, New York, 
Humana Press. 
WALLER, D. K., SPEARS, W. D., GU, Y. & CUNNINGHAM, G. C. 2000. Assessing 
number‐specific error in the recall of onset of last menstrual period. Paediatric and Perinatal 
Epidemiology, 14, 263-267. 
WANG, G., TOKUSHIGE, N., MARKHAM, R. & FRASER, I. S. 2009a. Rich innervation 
of deep infiltrating endometriosis. Human Reproduction, 24, 827-834. 
 140 
 
WANG, G., TOKUSHIGE, N., RUSSELL, P., DUBINOVSKY, S., MARKHAM, R. & 
FRASER, I. S. 2009b. Hyperinnervation in intestinal deep infiltrating endometriosis. Journal 
of Minimally Invasive Gynecology, 16, 713-719. 
WARDLE, P. G., MITCHELL, J. D., MCLAUGHLIN, E. A., RAY, B. D., MCDERMOTT, 
A. & HULL, M. G. 1985. Endometriosis and ovulatory disorder: Reduced fertilisation in 
vitro compared with tubal and unexplained infertility. Lancet, 2, 236. 
WEGIENKA, G. & BAIRD, D. D. 2005. A comparison of recalled date of last menstrual 
period with prospectively recorded dates. Journal of Women's Health, 14, 248-252. 
WELLBERY, C. 1999. Diagnosis and treatment of endometriosis. American Family 
Physician, 60, 1753-1762. 
WIDEMAN, L., MONTGOMERY, M. M., LEVINE, B. J., BEYNNON, B. D. & SHULTZ, 
S. J. 2013. Accuracy of calendar-based methods for assigning menstrual cycle phase in 
women. Sports Health: A Multidisciplinary Approach, 5, 143-149. 
WILSON, T. J., HERTZOG, P. J., ANGUS, D., MUNNERY, L., WOOD, E. C. & KOLA, I. 
1994. Decreased natural killer cell activity in endometriosis patients: Relationship to disease 
pathogenesis. Fertility and Sterility, 62, 1086-8. 
WINER EP, HUDIS C, B. H., CHLEBOWSKI RT, INGLE JN, EDGE SB & AL., E. 2002. 
American society of clinical oncology technology assessment on the use of aromatase 
inhibitors as adjuvant therapy for women with hormone receptor–positive breast cancer: 
Status report. Journal of Clinical Oncology, 20, 3317–27. 
WINGFIELD, M., MACPHERSON, A., HEALY, D. L. & ROGERS, P. A. 1995. Cell 
proliferation is increased in the endometrium of women with endometriosis. Fertility and 
Sterility, 64, 340-6. 
WINKEL, C. A. 2003. Evaluation and management of women with endometriosis. Obstetrics 
and Gynecology, 102, 397-408. 
WITZ, C. A., MONOTOYA-RODRIGUEZ, I. A. & SCHENKEN, R. S. 1999. Whole 
explants of peritoneum and endometrium: A novel model of the early endometriosis lesion. 
Fertility and Sterility, 71, 56-60. 
WITZ, C. A., MONTOYA-RODRIGUEZ, I. A., CENTONZE, V. E. & SCHENKEN, R. S. 
2002. Menstrual endometrium and individual endometrial stromal and epithelial cells are 
unique in their ability to adhere to and invade peritoneal mesothelium. Fertility and Sterility, 
78, S199-S199. 
 141 
 
WITZ, C. A., MONTOYA, I. A., DEY, T. D. & SCHENKEN, R. S. 1994. Characterization 
of lymphocyte subpopulations and t cell activation in endometriosis. American Journal of 
Reproductive Immunology, 32, 173-9. 
WOOD, C., KUHN, R. & TSALTAS, J. 2002. Laparoscopic diagnosis of endometriosis. The 
Australian and New Zealand Journal of Obstetrics and Gynaecology, 42, 277-281. 
WU, M. Y. & HO, H. N. 2003. The role of cytokines in endometriosis. American Journal of 
Reproductive Immunology, 49, 285-296. 
WW., R. 1899. Aberrant portions of the mu¨ llerian duct found in an ovary: Ovarian cysts of 
mu¨llerian origin. Bull John Hopkins Hospital, 10, 8-10. 
WYKES, M. & MACPHERSON, G. 2000. Dendritic cell–b‐cell interaction: Dendritic cells 
provide b cells with cd40‐independent proliferation signals and cd40‐dependent survival 
signals. Immunology, 100, 1-3. 
WYNN, T. A. 2004. Fibrotic disease and the th1/th2 paradigm. Nature Reviews Immunology, 
4, 583-594. 
YEAMAN, G. R., GUYRE, P. M., FANGER, M. W., COLLINS, J. E., WHITE, H. D., 
RATHBUN, W., ORNDORFF, K. A., GONZALEZ, J., STERN, J. E. & WIRA, C. R. 1997. 
Unique cd8+ t cell-rich lymphoid aggregates in human uterine endometrium. Journal of 
Leukocyte Biology, 61, 427. 
YOUNG, V. J., BROWN, J. K., SAUNDERS, P. T. K. & HORNE, A. W. 2013. The role of 
the peritoneum in the pathogenesis of endometriosis. Human Reproduction Update, 19, 558. 
YOUSSRY, M., ORIEF, Y., PALAPELAS, V. & AL-HASANI, S. 2008. Embryo 
cryopreservation: Is vitrification ready to replace slow freezing? Expert Rev. Obstet. 
Gynecol, 3, 455-463. 
ZHANG, X., LU, B., HUANG, X., XU, H., ZHOU, C. & LIN, J. 2009. Endometrial nerve 
fibers in women with endometriosis, adenomyosis, and uterine fibroids. Fertility and 
Sterility, 92, 1799-1801. 
ZHANG, X., YAO, H., HUANG, X., LU, B., XU, H. & ZHOU, C. 2010. Nerve fibres in 
ovarian endometriotic lesions in women with ovarian endometriosis. Human Reproduction, 
25, 392-397. 
ZHANG, Y., CHIRMULE, N., GAO, G.-P., QIAN, R., CROYLE, M., JOSHI, B., 
TAZELAAR, J. & WILSON, J. M. 2001. Acute cytokine response to systemic adenoviral 
vectors in mice is mediated by dendritic cells and macrophages. Molecular Therapy, 3, 697-
697. 
 142 
 
ZHOU, T., CHEN, Y., HAO, L. & ZHANG, Y. 2006. Dc-sign and immunoregulation. 
Cellular and Molecular Immunology, 3, 279. 
ZHU, J., GUO, L., MIN, B., WATSON, C. J., HU-LI, J., YOUNG, H. A., TSICHLIS, P. N. 
& PAUL, W. E. 2002. Growth factor independent-1 induced by il-4 regulates th2 cell 
proliferation. Immunity, 16, 733-744. 
ZONDERVAN, K. T., YUDKIN, P. L., VESSEY, M. P., DAWES, M. G., BARLOW, D. H. 
& KENNEDY, S. H. 1999. Patterns of diagnosis and referral in women consulting for 
chronic pelvic pain in uk primary care. Bjog: An International Journal of Obstetrics & 
Gynaecology, 106, 1156-1161. 
 
